{"docstore/data": {"65cf5448-5f43-4262-82c8-ae4fb45cc069": {"__data__": {"id_": "65cf5448-5f43-4262-82c8-ae4fb45cc069", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n", "original_text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d6f6d88-24c1-4c28-827b-1f1dcbb69e45", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65. ", "original_text": "On the basis of U.S. "}, "hash": "180faab596e9a611d9dd55d726742ee07ec54a29fd6b4e3f478c877d1229c7eb", "class_name": "RelatedNodeInfo"}}, "text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion. ", "start_char_idx": 0, "end_char_idx": 569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d6f6d88-24c1-4c28-827b-1f1dcbb69e45": {"__data__": {"id_": "7d6f6d88-24c1-4c28-827b-1f1dcbb69e45", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65cf5448-5f43-4262-82c8-ae4fb45cc069", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n", "original_text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de92d6fda10a99e18ee44d2bd19b7d782ba51ea334c0b531e14ed3f4a8d7ca1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f43f9f0a-d150-4016-a04a-27a207abf0f3", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter. "}, "hash": "1212cdb12438191c1c3efa45db61fcc1033db9c855807679af2750084b1b8b91", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 569, "end_char_idx": 590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f43f9f0a-d150-4016-a04a-27a207abf0f3": {"__data__": {"id_": "f43f9f0a-d150-4016-a04a-27a207abf0f3", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d6f6d88-24c1-4c28-827b-1f1dcbb69e45", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77bef1b152abf9ee099f9a6c967e6ccf1bd24cc4c63143e5597829c1f47acc2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3de3e5c-4716-4a2c-9788-ae8bc87f1a14", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access. ", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n"}, "hash": "46d93be3ab561ea290a191e32663c3090806b74a55af45a67857a77ececdc39c", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter. ", "start_char_idx": 590, "end_char_idx": 764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3de3e5c-4716-4a2c-9788-ae8bc87f1a14": {"__data__": {"id_": "a3de3e5c-4716-4a2c-9788-ae8bc87f1a14", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access. ", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f43f9f0a-d150-4016-a04a-27a207abf0f3", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebc9753be7bc1a05cb7bc4ce964b180ab2e3be164301cac6a34188695751bca4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b8e0094-c182-4e78-b0fa-0ac0721c1281", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n", "original_text": "The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65. "}, "hash": "5c3b93231578b9688358460ea7569c70af006dbbda92fcf073cd969c2674676d", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n", "start_char_idx": 764, "end_char_idx": 911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b8e0094-c182-4e78-b0fa-0ac0721c1281": {"__data__": {"id_": "0b8e0094-c182-4e78-b0fa-0ac0721c1281", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n", "original_text": "The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3de3e5c-4716-4a2c-9788-ae8bc87f1a14", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access. ", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07da3a134c0ee7c618f7a530b87777d55d87422ae913aa723e6b3330659a7f04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be2d12e1-26f7-4dec-b96f-8aa3e5d3fe98", "node_type": "1", "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr. ", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n"}, "hash": "244a6641ddbf3ead0ac360f4c5c32ae94a6b72311c8cc10904a713fb030b20a9", "class_name": "RelatedNodeInfo"}}, "text": "The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65. ", "start_char_idx": 911, "end_char_idx": 1052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be2d12e1-26f7-4dec-b96f-8aa3e5d3fe98": {"__data__": {"id_": "be2d12e1-26f7-4dec-b96f-8aa3e5d3fe98", "embedding": null, "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr. ", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b8e0094-c182-4e78-b0fa-0ac0721c1281", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n", "original_text": "The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77d1759db4ba81f716a3b8a3c6bc92acbffd4caf607a4a9d9a2cf572e72614de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92986c5e-74e8-4354-ae6b-adb13da6ad54", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued. ", "original_text": "\"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access. "}, "hash": "747d0e743f6e69ac79d3abe5aee427d1779cd56b9a668328f4d2dea985d2d923", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n", "start_char_idx": 1052, "end_char_idx": 1176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92986c5e-74e8-4354-ae6b-adb13da6ad54": {"__data__": {"id_": "92986c5e-74e8-4354-ae6b-adb13da6ad54", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued. ", "original_text": "\"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be2d12e1-26f7-4dec-b96f-8aa3e5d3fe98", "node_type": "1", "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr. ", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "666829f5440a926f3f037a8ab222086b109dcfe575bc21e9e1efd74a494a3ef4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cf7f7d2-63f7-4893-9d65-c6855806b44a", "node_type": "1", "metadata": {"window": "The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n", "original_text": "Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n"}, "hash": "eed88a34222804f91f1fa6ecbfaad6fd7a65dc711662c9c4d2914f193a3d0daf", "class_name": "RelatedNodeInfo"}}, "text": "\"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access. ", "start_char_idx": 1176, "end_char_idx": 1328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cf7f7d2-63f7-4893-9d65-c6855806b44a": {"__data__": {"id_": "9cf7f7d2-63f7-4893-9d65-c6855806b44a", "embedding": null, "metadata": {"window": "The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n", "original_text": "Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92986c5e-74e8-4354-ae6b-adb13da6ad54", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued. ", "original_text": "\"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6122eaab9d1e11b55384c3d5c3c1d9aa45cf3e99a58c25d1de8811508268e8c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b9dd5f6-98d4-4ade-ba05-a2b175751483", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "original_text": "\"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr. "}, "hash": "09154921f00d32440dfde42cda57aaec851a39c1c512982f38b5780ca7aeb6c9", "class_name": "RelatedNodeInfo"}}, "text": "Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n", "start_char_idx": 1328, "end_char_idx": 1608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b9dd5f6-98d4-4ade-ba05-a2b175751483": {"__data__": {"id_": "9b9dd5f6-98d4-4ade-ba05-a2b175751483", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "original_text": "\"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cf7f7d2-63f7-4893-9d65-c6855806b44a", "node_type": "1", "metadata": {"window": "The Company raised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.80 to $7.95 from the previous range of $7.35\nto $7.65.  The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n", "original_text": "Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4527e03e7bab04265ef457e336373241ad4828a76562eadc6fd6e89c6fe93f51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0034bf60-6477-45e3-98f9-623168b91951", "node_type": "1", "metadata": {"window": "\"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "original_text": "Collis continued. "}, "hash": "9b8a91db0307ca4dcd8c4ed3518744eff2038e81eae762ae236df6c553023e84", "class_name": "RelatedNodeInfo"}}, "text": "\"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr. ", "start_char_idx": 1608, "end_char_idx": 1820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0034bf60-6477-45e3-98f9-623168b91951": {"__data__": {"id_": "0034bf60-6477-45e3-98f9-623168b91951", "embedding": null, "metadata": {"window": "\"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b9dd5f6-98d4-4ade-ba05-a2b175751483", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020\nExpectations.\n \"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "original_text": "\"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3cad07f43e4db2402d858ae8dd540a4f5e57b97735afbf163904f92505c0c4b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4750d4fc-2788-4a51-adec-7b0f770caf59", "node_type": "1", "metadata": {"window": "Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "original_text": "\"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n"}, "hash": "27e1a9d37d904001c73fb1f41cfb3e456bebc63b0e9c3b3074dc7b896cf0e022", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued. ", "start_char_idx": 1820, "end_char_idx": 1838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4750d4fc-2788-4a51-adec-7b0f770caf59": {"__data__": {"id_": "4750d4fc-2788-4a51-adec-7b0f770caf59", "embedding": null, "metadata": {"window": "Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "original_text": "\"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0034bf60-6477-45e3-98f9-623168b91951", "node_type": "1", "metadata": {"window": "\"In the third quarter of the fiscal year, we saw the resilience of our business as our associates worked diligently to ensure continued\npatient access.  Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a933b3d3be493bddb7074af53b54707d8da3c9c839d06e3d6cd6f20fa8022be3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ca8ccc3-e5a7-4070-9fd6-d237ae957bee", "node_type": "1", "metadata": {"window": "\"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n", "original_text": "Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. "}, "hash": "4c5273830bb6951ca611da074529046860694222b53238751d43a8ccac33277c", "class_name": "RelatedNodeInfo"}}, "text": "\"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n", "start_char_idx": 1838, "end_char_idx": 2126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ca8ccc3-e5a7-4070-9fd6-d237ae957bee": {"__data__": {"id_": "3ca8ccc3-e5a7-4070-9fd6-d237ae957bee", "embedding": null, "metadata": {"window": "\"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n", "original_text": "Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4750d4fc-2788-4a51-adec-7b0f770caf59", "node_type": "1", "metadata": {"window": "Our updated outlook for fiscal 2020 reflects the continued execution by our teams and the strength of\nAmerisourceBergen's value proposition, deep partnerships and strategic positioning,\" said Steven H. Collis, Chairman, President and\nChief Executive Officer of AmerisourceBergen.\n \"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "original_text": "\"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1cd195f61063f99a7a54f05856c6bf2eae35fb162c7b56b872c3ed68cf05b40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52fb37b8-e761-43b2-9cad-eb0f16a69491", "node_type": "1", "metadata": {"window": "Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "b5402d49165d810109e4f2a272ae79111163eb54f152cd28103ce157ceac5ca2", "class_name": "RelatedNodeInfo"}}, "text": "Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "start_char_idx": 2126, "end_char_idx": 2691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52fb37b8-e761-43b2-9cad-eb0f16a69491": {"__data__": {"id_": "52fb37b8-e761-43b2-9cad-eb0f16a69491", "embedding": null, "metadata": {"window": "Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ca8ccc3-e5a7-4070-9fd6-d237ae957bee", "node_type": "1", "metadata": {"window": "\"Our teams are leveraging the power of AmerisourceBergen's culture to deliver collaborative and innovative services and solutions\nfor our partners as they navigate the complexity of the current environment,\" Mr.  Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n", "original_text": "Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "324d0ad3996f9ab1ae5aaa56a16bb6db250d11de38d352055da3304c37387d9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f1c0d3f-f615-4d86-a3e6-63e4d989e122", "node_type": "1", "metadata": {"window": "\"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n"}, "hash": "a74a08df45924208a0d91453200165d67664c8e2a3c311dfbb7935bd45d80cb0", "class_name": "RelatedNodeInfo"}}, "text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 2691, "end_char_idx": 2783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f1c0d3f-f615-4d86-a3e6-63e4d989e122": {"__data__": {"id_": "2f1c0d3f-f615-4d86-a3e6-63e4d989e122", "embedding": null, "metadata": {"window": "\"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52fb37b8-e761-43b2-9cad-eb0f16a69491", "node_type": "1", "metadata": {"window": "Collis continued.  \"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41029a7b14f494be793abb0956a3c0b2c2ec6e7a7cd3aa4a52b755feb18b9d05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76e609f2-c9be-4ab9-9704-51676ff6f80b", "node_type": "1", "metadata": {"window": "Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "original_text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n"}, "hash": "3b2158658e9227fef357b2a66aa163d9770349d2def76cedfe1425af8968160a", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "start_char_idx": 2783, "end_char_idx": 3005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76e609f2-c9be-4ab9-9704-51676ff6f80b": {"__data__": {"id_": "76e609f2-c9be-4ab9-9704-51676ff6f80b", "embedding": null, "metadata": {"window": "Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "original_text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f1c0d3f-f615-4d86-a3e6-63e4d989e122", "node_type": "1", "metadata": {"window": "\"AmerisourceBergen is living our\npurpose of being united in our responsibility to create healthier futures as we continue to focus on protecting our associates,\nexecution across our company and advancing our talent and culture, driving long-term value creation for all our stakeholders.\"\n Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93e8b01e0214ea14c271c34baf7c9fb2ed2e47666780713a7ec1400a91f1d681", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2921b4b-04ec-4106-b38a-47980ea3667a", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "original_text": "Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year. "}, "hash": "be19fa2c00f97df46337e8fc99b4fbb204589704bc8178fb7a2711a5225bbf8e", "class_name": "RelatedNodeInfo"}}, "text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n", "start_char_idx": 3005, "end_char_idx": 3315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2921b4b-04ec-4106-b38a-47980ea3667a": {"__data__": {"id_": "f2921b4b-04ec-4106-b38a-47980ea3667a", "embedding": null, "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "original_text": "Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76e609f2-c9be-4ab9-9704-51676ff6f80b", "node_type": "1", "metadata": {"window": "Third Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0\u00a0\u00a0\u00a0\u00a0 GAAP Adjust ed (Non-GAAP)\n\u00a0\u00a0\u00a0\u00a0Revenue \u00a0$45.4B \u00a0\u00a0$45.4B\n\u00a0\u00a0\u00a0\u00a0Gross Pr ofit \u00a0$1.2B \u00a0\u00a0$1.2B\n\u00a0\u00a0\u00a0\u00a0Operating Expenses \u00a0$821M \u00a0\u00a0$725M\n\u00a0\u00a0\u00a0\u00a0Operating Income \u00a0$405M \u00a0\u00a0$508M\n\u00a0\u00a0\u00a0\u00a0Interest Expense, Net \u00a0$38M \u00a0\u00a0$38M\n\u00a0\u00a0\u00a0\u00a0Effectiv e Tax Rat e \u00a016.5% \u00a0\u00a018.8%\n\u00a0\u00a0\u00a0\u00a0Net Income A ttributable t o ABC \u00a0$289M \u00a0\u00a0$380M\n\u00a0\u00a0\u00a0\u00a0Dilut ed Earnings P er Shar e \u00a0$1.41 \u00a0\u00a0$1.85\n\u00a0\u00a0\u00a0\u00a0Dilut ed Shar es Outstanding \u00a0206M \u00a0\u00a0206M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "original_text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31f6383622e1e96f82a476da42949a9d36732958d151f089831666415c8bdba1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "555c8fb4-805d-4dcc-bf8c-a6471b086555", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "original_text": "Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1"}, "hash": "6109cabd1f2a4b9d0dbd9ae351ec1f3a826566b5bcbc335439d6edac8bf9ed82", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year. ", "start_char_idx": 3315, "end_char_idx": 3474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "555c8fb4-805d-4dcc-bf8c-a6471b086555": {"__data__": {"id_": "555c8fb4-805d-4dcc-bf8c-a6471b086555", "embedding": null, "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "original_text": "Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70fbebac-ea31-4518-b251-cb6129d6e68f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2529cd78c9736b9f4faf5ebd3070149191fe39631c91333f4a30fd4ac3033278", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2921b4b-04ec-4106-b38a-47980ea3667a", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "original_text": "Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97adfdce0901c9f639fed74d4b27e0e7b0deac36b4f4bbe7059e2bfcb36ac03b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c61b07fc-e085-46a5-bbd9-5c868f05b95f", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs.  Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs. ", "original_text": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs. "}, "hash": "f6d90fdf6a5a58b52b3f118ece68a62f945e198c7655226d703d2501c358074f", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "start_char_idx": 3474, "end_char_idx": 3700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c61b07fc-e085-46a5-bbd9-5c868f05b95f": {"__data__": {"id_": "c61b07fc-e085-46a5-bbd9-5c868f05b95f", "embedding": null, "metadata": {"window": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs.  Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs. ", "original_text": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "555c8fb4-805d-4dcc-bf8c-a6471b086555", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2020, revenue was $45.4 billion, up 0.3 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 0.1 percent increase in Pharmaceutical Distribution Services revenue and a 4.4 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 third quarter was $1.2 billion, a 0.4 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "original_text": "Gross profit was unfavorably impacted by lower gains from antitrust litigation settlements and a\nLIFO expense in comparison to a LIFO credit in the prior year period, which were offset in part by increases in gross profit in\n1", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7bb0e599aef39e0c503703b0161dde35994ce4b4bd8f244949864c746b8dac1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2edbebf9-5b55-48d4-b7a0-142f9277a8ba", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs.  Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n", "original_text": "Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n"}, "hash": "c8d74c4a555e6b4af17cdd8c170d958215717b2596e0e2aea6e826db0d63ade7", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs. ", "start_char_idx": 0, "end_char_idx": 100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2edbebf9-5b55-48d4-b7a0-142f9277a8ba": {"__data__": {"id_": "2edbebf9-5b55-48d4-b7a0-142f9277a8ba", "embedding": null, "metadata": {"window": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs.  Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n", "original_text": "Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c61b07fc-e085-46a5-bbd9-5c868f05b95f", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs.  Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs. ", "original_text": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38b1903f48cb32de794d2a1b413c74de81c1d484c88fa7cd1094bcfe42bf0dbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c6a0519-3c7b-4edf-a5ff-ec2c75f65ab3", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs.  Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter. ", "original_text": "Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year. "}, "hash": "c672469156127d769f987146f2d3c4c7e8f8c642a70eb30ab16580a0c6d74a3e", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n", "start_char_idx": 100, "end_char_idx": 216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c6a0519-3c7b-4edf-a5ff-ec2c75f65ab3": {"__data__": {"id_": "2c6a0519-3c7b-4edf-a5ff-ec2c75f65ab3", "embedding": null, "metadata": {"window": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs.  Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter. ", "original_text": "Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2edbebf9-5b55-48d4-b7a0-142f9277a8ba", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs.  Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n", "original_text": "Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1da4e3e7f6bfdada522e6761d1eec4b0e5a70ddc3faf2837c2f60ae4c567f75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb4cf860-3433-4096-a93e-ca96629437fe", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs.  Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n", "original_text": "The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs. "}, "hash": "da1ba1d7fb503e00bf2a1a62ccd12efb481077a2252d2db86f31b3ebe5ff9bdc", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year. ", "start_char_idx": 216, "end_char_idx": 378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb4cf860-3433-4096-a93e-ca96629437fe": {"__data__": {"id_": "fb4cf860-3433-4096-a93e-ca96629437fe", "embedding": null, "metadata": {"window": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs.  Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n", "original_text": "The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c6a0519-3c7b-4edf-a5ff-ec2c75f65ab3", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs.  Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter. ", "original_text": "Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ef3e5298435cf3ed4d1809a1ad30b7dff29131e6b66da56c8ed15b3d0fe1af5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07886e14-7582-419a-8a5b-0fba740cd28b", "node_type": "1", "metadata": {"window": "Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n", "original_text": "Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n"}, "hash": "1c564ccc7f77ac509a9aaa09236936e55bb643c5862b931a6928c088efafa849", "class_name": "RelatedNodeInfo"}}, "text": "The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs. ", "start_char_idx": 378, "end_char_idx": 560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07886e14-7582-419a-8a5b-0fba740cd28b": {"__data__": {"id_": "07886e14-7582-419a-8a5b-0fba740cd28b", "embedding": null, "metadata": {"window": "Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n", "original_text": "Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb4cf860-3433-4096-a93e-ca96629437fe", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs.  Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n", "original_text": "The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41fdf521d43fc979f5788bfc8771fb4b98e8f9048dcfbf91dfca36950c5ceea7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b347cd0-667f-4a79-9230-e23e6b78ce21", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n", "original_text": "Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter. "}, "hash": "8db0a555cf5cd841e387e9c313dc501af197cb3a0af17d53a29dcb070dedd767", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n", "start_char_idx": 560, "end_char_idx": 731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b347cd0-667f-4a79-9230-e23e6b78ce21": {"__data__": {"id_": "9b347cd0-667f-4a79-9230-e23e6b78ce21", "embedding": null, "metadata": {"window": "Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n", "original_text": "Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07886e14-7582-419a-8a5b-0fba740cd28b", "node_type": "1", "metadata": {"window": "Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n", "original_text": "Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdd307e7534aac27c6d10feddc0a32c68d96ec35c7a03c28181e76951d893ea6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70febc7e-2f9c-4741-9381-a6e192d395e8", "node_type": "1", "metadata": {"window": "The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n", "original_text": "Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n"}, "hash": "ef4dfcb14d0a447c27b9045e3e26555d2a2527013118e667b464af56662534cf", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter. ", "start_char_idx": 731, "end_char_idx": 876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70febc7e-2f9c-4741-9381-a6e192d395e8": {"__data__": {"id_": "70febc7e-2f9c-4741-9381-a6e192d395e8", "embedding": null, "metadata": {"window": "The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n", "original_text": "Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b347cd0-667f-4a79-9230-e23e6b78ce21", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n", "original_text": "Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a211f668a6d46032fdcb4884667c3cca7628b7a47e9ef8e1ff93e79bc198d943", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2096a2ec-ca2d-479a-a530-fbf61d1efc21", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n", "original_text": "Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n"}, "hash": "b0b3f7be33f6413d7a3198bf484ea38badfac2b197e1958584dcb75343f86b64", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n", "start_char_idx": 876, "end_char_idx": 1048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2096a2ec-ca2d-479a-a530-fbf61d1efc21": {"__data__": {"id_": "2096a2ec-ca2d-479a-a530-fbf61d1efc21", "embedding": null, "metadata": {"window": "Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n", "original_text": "Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70febc7e-2f9c-4741-9381-a6e192d395e8", "node_type": "1", "metadata": {"window": "The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs.  Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n", "original_text": "Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d129ff1b5d4165a5218bea4999da0afc2447f95898f34db7791bae1f13d8f259", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10067524-4a83-481b-8428-d60924b1b4e2", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n"}, "hash": "3efb6a55f512ebd357bc21c438fc31180d8a6424f04278c92f0b16a427b3c900", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n", "start_char_idx": 1048, "end_char_idx": 1358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10067524-4a83-481b-8428-d60924b1b4e2": {"__data__": {"id_": "10067524-4a83-481b-8428-d60924b1b4e2", "embedding": null, "metadata": {"window": "Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2096a2ec-ca2d-479a-a530-fbf61d1efc21", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.81 percent, compared to 1.82 percent for the same period in the previous fiscal\nyear.\n Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n", "original_text": "Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e8cce02527f8b15189ec3b73a0713a9cd4778eb22bfbb89e118b75b0b3bb9f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d36e7527-72a0-4751-a0b8-76f9e7d8b18b", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n"}, "hash": "b20d57649185ada9ddb0067ef310a6f0c19c094084fb795a55f5799f350b38cc", "class_name": "RelatedNodeInfo"}}, "text": "Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n", "start_char_idx": 1358, "end_char_idx": 1557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d36e7527-72a0-4751-a0b8-76f9e7d8b18b": {"__data__": {"id_": "d36e7527-72a0-4751-a0b8-76f9e7d8b18b", "embedding": null, "metadata": {"window": "Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10067524-4a83-481b-8428-d60924b1b4e2", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2020 third quarter, operating income decreased to $404.8 million from $406.7 million in the\nprior year quarter.  Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b04abf59506d18c34eec6260df9b91952e98f8099e369234fdf9e0e09806909", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbfd74f3-e6cb-4608-9110-850f7776f554", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n"}, "hash": "8e44dac2b1799b264e3fcaa38658c7a9b5837a40482a14e56e43154ac4c32339", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n", "start_char_idx": 1557, "end_char_idx": 1722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbfd74f3-e6cb-4608-9110-850f7776f554": {"__data__": {"id_": "bbfd74f3-e6cb-4608-9110-850f7776f554", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d36e7527-72a0-4751-a0b8-76f9e7d8b18b", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 0.89 percent in the third quarter of fiscal 2020,\ncompared to 0.90 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1505bdeb5fed3813bf18dc50b7e95b286b03e4a6b7d1677b0e1f33200a32f295", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7c31c6d-ee05-42c9-bd4b-8a4239ba2f96", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other. ", "original_text": "Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n"}, "hash": "17040a020544e9fe596d699064730fcc3d479d87906ae790c6662c510defe114", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n", "start_char_idx": 1722, "end_char_idx": 1984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7c31c6d-ee05-42c9-bd4b-8a4239ba2f96": {"__data__": {"id_": "f7c31c6d-ee05-42c9-bd4b-8a4239ba2f96", "embedding": null, "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other. ", "original_text": "Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbfd74f3-e6cb-4608-9110-850f7776f554", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2020 third quarter, net interest expense of $37.7 million was up 5.1 percent versus the prior\nyear quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates and was\nsubstantially offset by a decrease in interest expense.\n Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3251c8833596c969837c05494a4880fff1161e634578d9df051af55fa3056333", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2f15511-665e-4dec-902c-d3359433ab00", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n", "original_text": "Revenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "77ffdff0024afe849e413a1d1d7629ea34b3f9866b287fc6aff0b35eec93b4d5", "class_name": "RelatedNodeInfo"}}, "text": "Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n", "start_char_idx": 1984, "end_char_idx": 2522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2f15511-665e-4dec-902c-d3359433ab00": {"__data__": {"id_": "d2f15511-665e-4dec-902c-d3359433ab00", "embedding": null, "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n", "original_text": "Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7c31c6d-ee05-42c9-bd4b-8a4239ba2f96", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 16.5 percent for the third quarter of fiscal 2020 and 18.6 percent in the prior year\nquarter, reflecting a benefit resulting from a discrete tax item.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other. ", "original_text": "Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b106900bd18676c5817ac0c723d9382411394ac02423234041b52d3f8735396", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60870ee5-963e-4507-a924-f1bb00ca573b", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year. ", "original_text": "In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n"}, "hash": "30112427c88d888ebb9fc31dc7977c79996498a5a03d77ef8c624b48cf00e36a", "class_name": "RelatedNodeInfo"}}, "text": "Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 2522, "end_char_idx": 2594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60870ee5-963e-4507-a924-f1bb00ca573b": {"__data__": {"id_": "60870ee5-963e-4507-a924-f1bb00ca573b", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year. ", "original_text": "In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2f15511-665e-4dec-902c-d3359433ab00", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.41 in the third quarter of fiscal 2020 compared to $1.43 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n", "original_text": "Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f06e9fee323dbd25a0f980eb0791de1abcc3a0c753f796a3876c2ef142c26958", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7615bba1-4d83-46db-8753-3be042780b26", "node_type": "1", "metadata": {"window": "Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other. "}, "hash": "c2f6cc27933f4b35ab587caf2de92493b894cc24d915d1534fb9602cf5be6acd", "class_name": "RelatedNodeInfo"}}, "text": "In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n", "start_char_idx": 2594, "end_char_idx": 2865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7615bba1-4d83-46db-8753-3be042780b26": {"__data__": {"id_": "7615bba1-4d83-46db-8753-3be042780b26", "embedding": null, "metadata": {"window": "Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60870ee5-963e-4507-a924-f1bb00ca573b", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2020 were 205.5\nmillion, a 2.7 percent decline versus the prior fiscal year third quarter primarily due to share repurchases, net of stock option\nexercises.\n Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year. ", "original_text": "In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b82fd81f21d4e0fed26134e219df6f2c61ce8eeaf8be060f64c9ff1388e7654", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcde7a54-33b6-4019-af55-5da6faca1e30", "node_type": "1", "metadata": {"window": "Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n"}, "hash": "c7227be34ce22ca903bc93f87f5548c0212c19aed76685be4a78e13cbf13c0b2", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other. ", "start_char_idx": 2865, "end_char_idx": 3125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcde7a54-33b6-4019-af55-5da6faca1e30": {"__data__": {"id_": "bcde7a54-33b6-4019-af55-5da6faca1e30", "embedding": null, "metadata": {"window": "Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7615bba1-4d83-46db-8753-3be042780b26", "node_type": "1", "metadata": {"window": "Third Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets; a loss on\nearly retirement of debt; a gain on the sale of an equity investment; certain discrete tax benefits; and tax reform.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2f4915b553eb0d10302fce8a9fee61224a31da43e5f8c74954921f3bd3a7261", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d997cf5a-719d-49cb-80f6-0bf62b31eb70", "node_type": "1", "metadata": {"window": "In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n", "original_text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year. "}, "hash": "6b144b31fc3af0807435bfe11b5fe2a043512e35a86e2686ca8c3b71557e677e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n", "start_char_idx": 3125, "end_char_idx": 3271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d997cf5a-719d-49cb-80f6-0bf62b31eb70": {"__data__": {"id_": "d997cf5a-719d-49cb-80f6-0bf62b31eb70", "embedding": null, "metadata": {"window": "In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n", "original_text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcde7a54-33b6-4019-af55-5da6faca1e30", "node_type": "1", "metadata": {"window": "Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c0adb1862af098a5fdfd5d870dcac2fa950eac7580b7b6a89db8ac632a7f155", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e562088d-bfb4-4f89-986e-8d532f02227c", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n"}, "hash": "68d985b7a79de690a23e77c91263c39bd03204a2460014882817d6c000a74e3e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year. ", "start_char_idx": 3271, "end_char_idx": 3471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e562088d-bfb4-4f89-986e-8d532f02227c": {"__data__": {"id_": "e562088d-bfb4-4f89-986e-8d532f02227c", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d997cf5a-719d-49cb-80f6-0bf62b31eb70", "node_type": "1", "metadata": {"window": "In the third quarter of fiscal 2020, revenue was\n$45.4 billion, up 0.3 percent compared to the same quarter in the previous fiscal year, reflecting a 0.1 percent increase in\nPharmaceutical Distribution Services revenue and a 4.4 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n", "original_text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca1609e08fd5668b0bceae49acc7b6d6c16fd065b6d8d650216638c64d1e0a34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1398d408-af67-41aa-a990-5761b746b38c", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other. "}, "hash": "07714ac3ce19f747de4e16bc39329c0c6f3bf54cb84712da6bb9f3bd09c5f784", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n", "start_char_idx": 3471, "end_char_idx": 3623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1398d408-af67-41aa-a990-5761b746b38c": {"__data__": {"id_": "1398d408-af67-41aa-a990-5761b746b38c", "embedding": null, "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e562088d-bfb4-4f89-986e-8d532f02227c", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 third quarter was $1.2 billion, which was up 0.2 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e1aa15f4b9027f1ff40850ed36b110eca2ee7391880e8d93728efaeb39e7615", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52a0b661-7151-4af7-8742-0e05a3783bda", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n", "original_text": "Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n"}, "hash": "76ea8bb70925e404d59cf19271e0ca5bc69db8318401ee371ffe2ca40c526e52", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other. ", "start_char_idx": 3623, "end_char_idx": 3948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52a0b661-7151-4af7-8742-0e05a3783bda": {"__data__": {"id_": "52a0b661-7151-4af7-8742-0e05a3783bda", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n", "original_text": "Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1398d408-af67-41aa-a990-5761b746b38c", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 2.72 percent in the fiscal 2020 third quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9fe833773f983bc760dbd6e26d94db2af878a7d2c778c7769d7c9cf8e7120b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c737dfdd-6a16-45dc-b0a8-0fc674b28795", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "79b2e0ba00f2eb094578a6026de2f2a650a474c943d76bd1ee279174e6c045e2", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n", "start_char_idx": 3948, "end_char_idx": 4098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c737dfdd-6a16-45dc-b0a8-0fc674b28795": {"__data__": {"id_": "c737dfdd-6a16-45dc-b0a8-0fc674b28795", "embedding": null, "metadata": {"window": "Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52a0b661-7151-4af7-8742-0e05a3783bda", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the third quarter of fiscal 2020, adjusted operating expenses were $724.7 million, an increase\nof 0.3 percent compared to the same period in the previous fiscal year.  Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n", "original_text": "Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d85413330ae3213aa161c3653fff578600973f105e865f900a31906de313473", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d74de821-9354-40e2-bc8b-4c09101b12d8", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n"}, "hash": "112da1ce5096c545c4229c6a9c0263e3987a60ca45ebef1c93efa2e73e8a8b6d", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 4098, "end_char_idx": 4197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d74de821-9354-40e2-bc8b-4c09101b12d8": {"__data__": {"id_": "d74de821-9354-40e2-bc8b-4c09101b12d8", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c737dfdd-6a16-45dc-b0a8-0fc674b28795", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of\nrevenue in the fiscal 2020 third quarter was 1.60 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c936d903ad6e51946a37d1a54730056acec85e8fce7ede1c944708234ccb50c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a498470-3430-4f48-bfb2-fc58d41dcd68", "node_type": "1", "metadata": {"window": "Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n"}, "hash": "93f46a66eb744a871d20a5b930e9f4cc081c1b59535241444970cd5b996ac433", "class_name": "RelatedNodeInfo"}}, "text": "In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n", "start_char_idx": 4197, "end_char_idx": 4483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a498470-3430-4f48-bfb2-fc58d41dcd68": {"__data__": {"id_": "7a498470-3430-4f48-bfb2-fc58d41dcd68", "embedding": null, "metadata": {"window": "Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d74de821-9354-40e2-bc8b-4c09101b12d8", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2020 third quarter, adjusted operating income of $507.5 million increased 0.2\npercent from the prior year period due to a 3.6 percent increase in operating income within Pharmaceutical Distribution\nServices, offset in part by a 12.9 percent decline in operating income within Other.  Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "280d5c430efc7bc552de6abc162e0f6822217abc10fc76b578b32ba95406445a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43486c2c-b2f7-40f9-8c47-9aed9ca0582c", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n"}, "hash": "5af8dd850a6be32e239215850a8e47de0995e937cb221d0774ebac5207904ed4", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n", "start_char_idx": 4483, "end_char_idx": 4708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43486c2c-b2f7-40f9-8c47-9aed9ca0582c": {"__data__": {"id_": "43486c2c-b2f7-40f9-8c47-9aed9ca0582c", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a498470-3430-4f48-bfb2-fc58d41dcd68", "node_type": "1", "metadata": {"window": "Adjusted operating income as a\npercentage of revenue was 1.12 percent in the fiscal 2020 third quarter, flat when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05caf2d44ba2557a8f4a5867bc7d9a2bc6d1be994376ec9b69ec846b51ae9538", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8df2db55-703d-4081-89eb-135755a7455c", "node_type": "1", "metadata": {"window": "In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "48a3dec3b41e83fbbabfc0ce06d7a6b39748da41a0c69d55d58f67e34fd21db7", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n", "start_char_idx": 4708, "end_char_idx": 5017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8df2db55-703d-4081-89eb-135755a7455c": {"__data__": {"id_": "8df2db55-703d-4081-89eb-135755a7455c", "embedding": null, "metadata": {"window": "In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43486c2c-b2f7-40f9-8c47-9aed9ca0582c", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "128e1f8ef49dbbc6b827270cba73e270453346d57aafdab445cee03cdd454744", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03866011-1c44-4e7c-a203-3de645853070", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "original_text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n"}, "hash": "6af4f0f5a64c613a6cb0841423c8c4306edfaf10b5fa96aa862cf1fb34ee2638", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 5017, "end_char_idx": 5127, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03866011-1c44-4e7c-a203-3de645853070": {"__data__": {"id_": "03866011-1c44-4e7c-a203-3de645853070", "embedding": null, "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "original_text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8df2db55-703d-4081-89eb-135755a7455c", "node_type": "1", "metadata": {"window": "In the fiscal 2020 third\nquarter, net interest expense of $37.7 million was up 5.1 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates and was substantially offset by a decrease in interest\nexpense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "025c14d7bdd2ca48c28cc687dfec5bf90fae57c3531ff9132453834d6a50046a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17ded132-431a-4f15-80a0-3c021c5312a6", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. "}, "hash": "03cb2c63330bb111f698645d39d03eb378b754c1dcfee0939de6790933945b0d", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n", "start_char_idx": 5127, "end_char_idx": 5360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17ded132-431a-4f15-80a0-3c021c5312a6": {"__data__": {"id_": "17ded132-431a-4f15-80a0-3c021c5312a6", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03866011-1c44-4e7c-a203-3de645853070", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 18.8 percent for the third quarter of fiscal 2020 compared to\n21.0 percent in the prior year quarter, reflecting a benefit resulting from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "original_text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0de5ef5a2203226d81bb593b9ac75c18f4957c42d2f99b1c22078b409f36c866", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c4b96ef-e5c4-4cdd-8a38-d18d14a3b9aa", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n"}, "hash": "86a0f3c970b6596d340b61a7c28d9cd5cc0aec0ff93e7abea64c3a57761cdac6", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "start_char_idx": 5360, "end_char_idx": 5692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c4b96ef-e5c4-4cdd-8a38-d18d14a3b9aa": {"__data__": {"id_": "7c4b96ef-e5c4-4cdd-8a38-d18d14a3b9aa", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17ded132-431a-4f15-80a0-3c021c5312a6", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.1 percent to $1.85 in the third quarter of\nfiscal 2020 compared to $1.76 in the previous fiscal year\u2019s third quarter, driven primarily by the lower adjusted effective tax\nrate and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a55e28ba8d2f2c2eb31193a40276b3837b8282d9055032aade9945648ddb361f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68219e55-d717-42f9-9236-89f24fe8aca6", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2"}, "hash": "2d427653a1058be88ebe917400e131659c86865b2b9f8b788c18dd3e38494fd6", "class_name": "RelatedNodeInfo"}}, "text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "start_char_idx": 5692, "end_char_idx": 5897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68219e55-d717-42f9-9236-89f24fe8aca6": {"__data__": {"id_": "68219e55-d717-42f9-9236-89f24fe8aca6", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4204106-c462-4112-a022-54a77599d681", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10e1001fef0f540239f2d6d3c8e696fcaa19a59cddc415f9caa8ecb09531372", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c4b96ef-e5c4-4cdd-8a38-d18d14a3b9aa", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87ba17408e2d4e80281a854848efd69af374da426f7be4dd74e0f160b749b310", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dd829af-18ca-49ab-bc5a-41852ec4039d", "node_type": "1", "metadata": {"window": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020.  Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020. ", "original_text": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020. "}, "hash": "0868044b8729e6ee41f9af99e13a82161c664a05bbcd248d6f822b5c0baeff5b", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "start_char_idx": 5897, "end_char_idx": 6076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dd829af-18ca-49ab-bc5a-41852ec4039d": {"__data__": {"id_": "2dd829af-18ca-49ab-bc5a-41852ec4039d", "embedding": null, "metadata": {"window": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020.  Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020. ", "original_text": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68219e55-d717-42f9-9236-89f24fe8aca6", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2020 were 205.5 million, a 2.7 percent decline versus the\nprior fiscal year third quarter primarily due to share repurchases, net of stock option exercises.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $43.6 billion, an increase of 0.1 percent compared to the same quarter in the prior\n2", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "750d25886642aff2c1fab1882fca34c6882657592d36b361bababe196570e8ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bb8e118-5f41-4b36-8562-b5cb2093f8a4", "node_type": "1", "metadata": {"window": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020.  Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n", "original_text": "Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n"}, "hash": "c5e619bba084935acb8999fd42211ce6a699e100c4206eefadda179a04e95d9d", "class_name": "RelatedNodeInfo"}}, "text": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020. ", "start_char_idx": 0, "end_char_idx": 240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bb8e118-5f41-4b36-8562-b5cb2093f8a4": {"__data__": {"id_": "2bb8e118-5f41-4b36-8562-b5cb2093f8a4", "embedding": null, "metadata": {"window": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020.  Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n", "original_text": "Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dd829af-18ca-49ab-bc5a-41852ec4039d", "node_type": "1", "metadata": {"window": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020.  Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020. ", "original_text": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c35882eae032530390d18bc496dedbff4d509062609f3a96a200ddb8b55ffb41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b20584c-1fd8-46d4-8f95-8074f9173572", "node_type": "1", "metadata": {"window": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020.  Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "original_text": "Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier. "}, "hash": "97029fe43fac686f2b1ef08ec6c6231453cd440d18f623e88a8f07e0058ef5bb", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n", "start_char_idx": 240, "end_char_idx": 452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b20584c-1fd8-46d4-8f95-8074f9173572": {"__data__": {"id_": "3b20584c-1fd8-46d4-8f95-8074f9173572", "embedding": null, "metadata": {"window": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020.  Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "original_text": "Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bb8e118-5f41-4b36-8562-b5cb2093f8a4", "node_type": "1", "metadata": {"window": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020.  Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n", "original_text": "Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93ca8a2112840cee3a5219fb007920a5526e00b2147f8f7146e56a79988e18c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d95cf284-192d-4136-88ba-0a196bfcbe7e", "node_type": "1", "metadata": {"window": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020.  Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S. ", "original_text": "Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020. "}, "hash": "53c6e8188c4e8c93b8d42d039ce67466d68346b5c130cdf5ed964d41bccc16d1", "class_name": "RelatedNodeInfo"}}, "text": "Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier. ", "start_char_idx": 452, "end_char_idx": 650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d95cf284-192d-4136-88ba-0a196bfcbe7e": {"__data__": {"id_": "d95cf284-192d-4136-88ba-0a196bfcbe7e", "embedding": null, "metadata": {"window": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020.  Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S. ", "original_text": "Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b20584c-1fd8-46d4-8f95-8074f9173572", "node_type": "1", "metadata": {"window": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020.  Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "original_text": "Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a957fdb211aa975ba970b2fd456448d90c135628a43afc7cf024e645afe622f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2bca132-7af7-4fa6-b525-16801b980051", "node_type": "1", "metadata": {"window": "Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study. ", "original_text": "This decrease was primarily due to impacts of COVID-19 at MWI.\n"}, "hash": "d66c863abe711f401f5efc9b99202e2fccabb17c51d701d441d5783bac1cdfc7", "class_name": "RelatedNodeInfo"}}, "text": "Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020. ", "start_char_idx": 650, "end_char_idx": 753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2bca132-7af7-4fa6-b525-16801b980051": {"__data__": {"id_": "f2bca132-7af7-4fa6-b525-16801b980051", "embedding": null, "metadata": {"window": "Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study. ", "original_text": "This decrease was primarily due to impacts of COVID-19 at MWI.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d95cf284-192d-4136-88ba-0a196bfcbe7e", "node_type": "1", "metadata": {"window": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020.  Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S. ", "original_text": "Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6326c0ff80de54f6a7872f8bc755f41569e2dbc197849498c3ef6d94c34cf40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e870d7ed-2626-478e-8344-068fab05121c", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n", "original_text": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. "}, "hash": "11fb5794bbe093c51a4d6f02b1c338a92b8a642d01632c1b2a62f0aed4ae433f", "class_name": "RelatedNodeInfo"}}, "text": "This decrease was primarily due to impacts of COVID-19 at MWI.\n", "start_char_idx": 753, "end_char_idx": 816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e870d7ed-2626-478e-8344-068fab05121c": {"__data__": {"id_": "e870d7ed-2626-478e-8344-068fab05121c", "embedding": null, "metadata": {"window": "Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n", "original_text": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2bca132-7af7-4fa6-b525-16801b980051", "node_type": "1", "metadata": {"window": "Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study. ", "original_text": "This decrease was primarily due to impacts of COVID-19 at MWI.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9a7d867de30c67146e29f2275c2260e10b382d72ad24eadeb2b33eb2b6912bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07160d94-78e2-451b-ae72-9610b098deba", "node_type": "1", "metadata": {"window": "Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n", "original_text": "Power 2020 U.S. "}, "hash": "aec5a8ffabd19dcb7a754cfdb1239cecae71ce39f185306784523a9ba1a2fcd9", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "start_char_idx": 816, "end_char_idx": 1054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07160d94-78e2-451b-ae72-9610b098deba": {"__data__": {"id_": "07160d94-78e2-451b-ae72-9610b098deba", "embedding": null, "metadata": {"window": "Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n", "original_text": "Power 2020 U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e870d7ed-2626-478e-8344-068fab05121c", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n", "original_text": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e353c66a7216a2e74cdb1b7a28843163a1b0ca7a0c64cb9dd936c87c562072a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bc0e261-5929-4f36-a597-5805536cf65a", "node_type": "1", "metadata": {"window": "This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n", "original_text": "Pharmacy Study. "}, "hash": "81681940643bec3e405372975b7ad3d95fdf11dd96960e3fc661b202e9483697", "class_name": "RelatedNodeInfo"}}, "text": "Power 2020 U.S. ", "start_char_idx": 1054, "end_char_idx": 1070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bc0e261-5929-4f36-a597-5805536cf65a": {"__data__": {"id_": "3bc0e261-5929-4f36-a597-5805536cf65a", "embedding": null, "metadata": {"window": "This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n", "original_text": "Pharmacy Study. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07160d94-78e2-451b-ae72-9610b098deba", "node_type": "1", "metadata": {"window": "Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020.  This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n", "original_text": "Power 2020 U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e5fd220a185c3a2d43edf30a9c38297d0e1cb074dc22e3b7104e895e2c47534", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ed4ea10-3d63-4f11-92ff-944e50ba780b", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n"}, "hash": "8b4fbb75a9f9d8688a9872aec20edf1982e2d3a19ef6702d66622b696aa8fd57", "class_name": "RelatedNodeInfo"}}, "text": "Pharmacy Study. ", "start_char_idx": 1070, "end_char_idx": 1086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ed4ea10-3d63-4f11-92ff-944e50ba780b": {"__data__": {"id_": "1ed4ea10-3d63-4f11-92ff-944e50ba780b", "embedding": null, "metadata": {"window": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bc0e261-5929-4f36-a597-5805536cf65a", "node_type": "1", "metadata": {"window": "This decrease was primarily due to impacts of COVID-19 at MWI.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n", "original_text": "Pharmacy Study. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f866aaf6fb3f1b0c4ea23abc775d76cc486fcba8708933d4668ac97771a60b08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c033763-c7fe-497c-b901-fe940d6a29f1", "node_type": "1", "metadata": {"window": "Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n"}, "hash": "11201727397fb442eb82fb6a07ef8025ab561be36faa558e88a01bf2cd3932cf", "class_name": "RelatedNodeInfo"}}, "text": "This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n", "start_char_idx": 1086, "end_char_idx": 1189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c033763-c7fe-497c-b901-fe940d6a29f1": {"__data__": {"id_": "1c033763-c7fe-497c-b901-fe940d6a29f1", "embedding": null, "metadata": {"window": "Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ed4ea10-3d63-4f11-92ff-944e50ba780b", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ee15b837f3434ed1b6558f0884454b05c6978f991dca1a18dc28deae114d601", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bf23e80-efce-4844-9ecb-ffd8190f46f2", "node_type": "1", "metadata": {"window": "Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. ", "original_text": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n"}, "hash": "6c2e4b481927259f96cbc823c646587ddfe5acc67e83539d4efc4349be5f3684", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n", "start_char_idx": 1189, "end_char_idx": 1406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bf23e80-efce-4844-9ecb-ffd8190f46f2": {"__data__": {"id_": "7bf23e80-efce-4844-9ecb-ffd8190f46f2", "embedding": null, "metadata": {"window": "Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. ", "original_text": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c033763-c7fe-497c-b901-fe940d6a29f1", "node_type": "1", "metadata": {"window": "Power 2020 U.S.  Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70f89fa42b75b8b91bf10e9738c9114ce2790b23b936bda099d8370fd37cfb58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb10e42b-97c9-436e-a179-7dafb546f876", "node_type": "1", "metadata": {"window": "This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n", "original_text": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. "}, "hash": "0be41effaddfc45d0670423d54cc55d0c4d185df8881fb914de3ed71ac4a1ed1", "class_name": "RelatedNodeInfo"}}, "text": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n", "start_char_idx": 1406, "end_char_idx": 1679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb10e42b-97c9-436e-a179-7dafb546f876": {"__data__": {"id_": "bb10e42b-97c9-436e-a179-7dafb546f876", "embedding": null, "metadata": {"window": "This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n", "original_text": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bf23e80-efce-4844-9ecb-ffd8190f46f2", "node_type": "1", "metadata": {"window": "Pharmacy Study.  This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. ", "original_text": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8648775585c82d9fdc1c9affd1ef59a386c54103e5624e3ec36c196ca1067724", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63b5bf62-8b0b-4041-bbfd-733c382d4bdb", "node_type": "1", "metadata": {"window": "AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "93d105e9f2e2488e2bedddec7016cf6a8fd8a11bb03039da3d2838b8747722fc", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "start_char_idx": 1679, "end_char_idx": 1923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63b5bf62-8b0b-4041-bbfd-733c382d4bdb": {"__data__": {"id_": "63b5bf62-8b0b-4041-bbfd-733c382d4bdb", "embedding": null, "metadata": {"window": "AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb10e42b-97c9-436e-a179-7dafb546f876", "node_type": "1", "metadata": {"window": "This marks\nthe ninth time that Good Neighbor Pharmacy has earned the achievement in the last 11 years.\n AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n", "original_text": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d58143736fbde77c84ca6a723ea6ad2f251b54b4a46d9064f20b549a66c4c300", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04642c91-5028-416a-bf53-00bf20c51836", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "original_text": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. "}, "hash": "fc5fed842090dc98f953aada94d618386904ab3e769c81e568637f51f1bfc105", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 1923, "end_char_idx": 2055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04642c91-5028-416a-bf53-00bf20c51836": {"__data__": {"id_": "04642c91-5028-416a-bf53-00bf20c51836", "embedding": null, "metadata": {"window": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "original_text": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63b5bf62-8b0b-4041-bbfd-733c382d4bdb", "node_type": "1", "metadata": {"window": "AmerisourceBergen has been named a 2020 DiversityInc  \u2018Noteworthy\u2019 company for the fourth year in a row, based on its\nhiring, retention and promotion of women, minorities, people with disabilities, LGBT and veterans.\n The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6dbb63b5d9effbd73df14dbc747e8fb1ebb7da773f8bf1848b9a57861556d9ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6811513d-cb7f-4fef-98fa-12aca72014f7", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n", "original_text": "The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n"}, "hash": "31b8c781ccd149be05f2c5ec1ee63db759373e59b073cf0e94b33fbb82d59f18", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. ", "start_char_idx": 2055, "end_char_idx": 2264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6811513d-cb7f-4fef-98fa-12aca72014f7": {"__data__": {"id_": "6811513d-cb7f-4fef-98fa-12aca72014f7", "embedding": null, "metadata": {"window": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n", "original_text": "The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04642c91-5028-416a-bf53-00bf20c51836", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation, a separate not-for-profit charitable giving organization, hosted its second annual\nconference, bringing together over sixty non-profit partners to address challenging issues society is facing today and share\nstrategies and best practices.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "original_text": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4402e534267023b1de7e32221461902d33b48d7ef073e9a6349ea6342c21f849", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd0e457a-04ce-4fc3-9252-836501691d12", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n"}, "hash": "ee327e5585398048f2012597df5dd17138ce4176d5d6d4b17ceb5df258b3c4bd", "class_name": "RelatedNodeInfo"}}, "text": "The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n", "start_char_idx": 2264, "end_char_idx": 2505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd0e457a-04ce-4fc3-9252-836501691d12": {"__data__": {"id_": "bd0e457a-04ce-4fc3-9252-836501691d12", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6811513d-cb7f-4fef-98fa-12aca72014f7", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n", "original_text": "The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f2755bd5ae1f22ace196111f302a52a243cf195751fc7c0082218f05d8c3666", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f81b76a2-876e-40aa-b288-711c3bf0bf5f", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020. ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n"}, "hash": "470f2d55ea747c082c8cd58b40523c3d547b535ebd798f72811f88bb147925fc", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n", "start_char_idx": 2505, "end_char_idx": 3289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f81b76a2-876e-40aa-b288-711c3bf0bf5f": {"__data__": {"id_": "f81b76a2-876e-40aa-b288-711c3bf0bf5f", "embedding": null, "metadata": {"window": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020. ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd0e457a-04ce-4fc3-9252-836501691d12", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "028180908afbe00e1a001e4fc12cdbba37fcc5ca9e5a99c9d5d347a07fc308f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbb4de3d-c64c-4b78-b7a3-eb2cc4eddcbc", "node_type": "1", "metadata": {"window": "The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n"}, "hash": "67c81c99b17e283d4812e328c374a0e4a88d3e86db7ad13cd48bcc47f609ac21", "class_name": "RelatedNodeInfo"}}, "text": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "start_char_idx": 3289, "end_char_idx": 3417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbb4de3d-c64c-4b78-b7a3-eb2cc4eddcbc": {"__data__": {"id_": "bbb4de3d-c64c-4b78-b7a3-eb2cc4eddcbc", "embedding": null, "metadata": {"window": "The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f81b76a2-876e-40aa-b288-711c3bf0bf5f", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nsolid execution.  The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020. ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54453a16a9807588f77314e227a3c22c248d4a7766499c35cf7e58dd9aff7e0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a85d0ad3-9925-4b24-ae2c-4df19bbdcb29", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "c7db888e5b6071a1436004bb392b2e9bc166a6ee3250b75e27b6ec7e5986c5b1", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n", "start_char_idx": 3417, "end_char_idx": 3631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a85d0ad3-9925-4b24-ae2c-4df19bbdcb29": {"__data__": {"id_": "a85d0ad3-9925-4b24-ae2c-4df19bbdcb29", "embedding": null, "metadata": {"window": "Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbb4de3d-c64c-4b78-b7a3-eb2cc4eddcbc", "node_type": "1", "metadata": {"window": "The Company now expects:\nRevenue growth in the mid-single digit percent range, up from the low- to mid- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.80 to $7.95, up from the previous range of $7.35 to $7.65.\n Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3df1c01f6c0939cd6720dc6e2bc642a8474b6a8ba35a0de1c2092363a9f707bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9a1e6a6-4961-477d-866d-24d684666623", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282. ", "original_text": "ET on August 5, 2020. "}, "hash": "dfe9eec02a52411ed1ea7d69a5c129a9cc69dba0ba11fb0fe1c6216d24b923cc", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 3631, "end_char_idx": 3746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9a1e6a6-4961-477d-866d-24d684666623": {"__data__": {"id_": "c9a1e6a6-4961-477d-866d-24d684666623", "embedding": null, "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282. ", "original_text": "ET on August 5, 2020. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a85d0ad3-9925-4b24-ae2c-4df19bbdcb29", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted operating income growth in the mid- to high-single digit percent range, up from the low- to mid-single digit\npercent range;\nPharmaceutical Distribution Services segment operating income growth in the mid- to high-single digit percent range,\nup from the low- to mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome growth in the low-single digit percent range, up from operating income decline in the low-single digit percent\nrage; and\nAdjusted effective tax rate of approximately 21 percent, down from the previous range of 21 percent to 22 percent; and\nCapital expenditures of approximately $375 million, down from the $400 million range.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "896956fc17978e3d35ebafa760150c96c04218c75f9f4d6598343cd4c43a1646", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff625ce1-47d6-4d7d-894e-ca4b5e8f7f66", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . "}, "hash": "f82cc7b660a293ad1d1bc3bd855cdc1b13fe4e8cb705213fbbff454235de9a29", "class_name": "RelatedNodeInfo"}}, "text": "ET on August 5, 2020. ", "start_char_idx": 3746, "end_char_idx": 3768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff625ce1-47d6-4d7d-894e-ca4b5e8f7f66": {"__data__": {"id_": "ff625ce1-47d6-4d7d-894e-ca4b5e8f7f66", "embedding": null, "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9a1e6a6-4961-477d-866d-24d684666623", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282. ", "original_text": "ET on August 5, 2020. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1b680c2c3e866dbb34876cbe6aed401c2e9d8e399b36f986c09e62689eaf0b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e75d999-6ff5-445d-bc52-dca61a47cba1", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. "}, "hash": "a3fa2ecff46b4987def67e4fcdcfdb77ea6f3103c22894f62ea685151008d4bc", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "start_char_idx": 3768, "end_char_idx": 3885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e75d999-6ff5-445d-bc52-dca61a47cba1": {"__data__": {"id_": "6e75d999-6ff5-445d-bc52-dca61a47cba1", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff625ce1-47d6-4d7d-894e-ca4b5e8f7f66", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable September 1, 2020, to\nstockholders of record at the close of business on August 17, 2020.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84bec078329088321c012aba91ac12b605fc22bae4c8da0aafa1eaf3e590c551", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "808c28b0-e82e-4404-bb7f-1b29186eb969", "node_type": "1", "metadata": {"window": "ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial (412) 317-5282. "}, "hash": "f38513a094195d1c7adcf14fb92996850952647f75ee231e9f4e9b49d1ff04d4", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "start_char_idx": 3885, "end_char_idx": 4124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "808c28b0-e82e-4404-bb7f-1b29186eb969": {"__data__": {"id_": "808c28b0-e82e-4404-bb7f-1b29186eb969", "embedding": null, "metadata": {"window": "ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial (412) 317-5282. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e75d999-6ff5-445d-bc52-dca61a47cba1", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0b4b5908870995b2a4da331f6fd5f9b6622362545899452a733dfa679b4e84c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e84990b-f8f5-42ec-a7b6-97002c129ee5", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. "}, "hash": "0c7989a2b1b2ce8905cb13df7ecd8929b2a028dbc69a1fa1b326a794e6de22d2", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States, dial (412) 317-5282. ", "start_char_idx": 4124, "end_char_idx": 4177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e84990b-f8f5-42ec-a7b6-97002c129ee5": {"__data__": {"id_": "3e84990b-f8f5-42ec-a7b6-97002c129ee5", "embedding": null, "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "808c28b0-e82e-4404-bb7f-1b29186eb969", "node_type": "1", "metadata": {"window": "ET on August 5, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial (412) 317-5282. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aaf2423d4bb14c69d8fd1af7dd057e3b4500b670a9270b730af49a4845e1320a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bc6c30c-a2f6-4371-a5d8-0d7cb88f9b37", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . "}, "hash": "cb10f26492d5373a276421a8b5d323bb1edf7224b60ca48311b314ead4acf838", "class_name": "RelatedNodeInfo"}}, "text": "No access code is\nrequired. ", "start_char_idx": 4177, "end_char_idx": 4205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bc6c30c-a2f6-4371-a5d8-0d7cb88f9b37": {"__data__": {"id_": "8bc6c30c-a2f6-4371-a5d8-0d7cb88f9b37", "embedding": null, "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e84990b-f8f5-42ec-a7b6-97002c129ee5", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e62f25594ea5ef0b224c0582b930b7d7fa4c7643d5eb863b192e3133faf7ccd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5befb07-a5c8-469e-b31d-485663131926", "node_type": "1", "metadata": {"window": "From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n"}, "hash": "7e657ebd3b0efb45af0c3871812334bb28274badefe8dee1e69da89753e6eba6", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "start_char_idx": 4205, "end_char_idx": 4302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5befb07-a5c8-469e-b31d-485663131926": {"__data__": {"id_": "f5befb07-a5c8-469e-b31d-485663131926", "embedding": null, "metadata": {"window": "From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bc6c30c-a2f6-4371-a5d8-0d7cb88f9b37", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0601cf86e0e650e3e31101d5126395d8918a4cbc974eeaf8f3b626cdb2392957", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0c15b16-1c43-4ca2-aa52-24bf5fc8eb1d", "node_type": "1", "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "a785338c29e966735e941039c52688d2834afbc610b23b145bbdf354a4b80e19", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "start_char_idx": 4302, "end_char_idx": 4425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0c15b16-1c43-4ca2-aa52-24bf5fc8eb1d": {"__data__": {"id_": "c0c15b16-1c43-4ca2-aa52-24bf5fc8eb1d", "embedding": null, "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5befb07-a5c8-469e-b31d-485663131926", "node_type": "1", "metadata": {"window": "From outside the United States, dial (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3f34b0a49d81deff67a565378d765ccc756701cd36661dbba93051f925cbe5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1b297ad-ddf5-4437-b8ed-c276397227e3", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. "}, "hash": "80b230657dea1b2f679665d2b0aff2710493136c1e1e423ccbded544c67949c2", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 4425, "end_char_idx": 4495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1b297ad-ddf5-4437-b8ed-c276397227e3": {"__data__": {"id_": "d1b297ad-ddf5-4437-b8ed-c276397227e3", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0c15b16-1c43-4ca2-aa52-24bf5fc8eb1d", "node_type": "1", "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "669f5345a6720b8ec596874fad851de94a2be45f5741355f849089c682f6354e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aea15a83-6f51-4b3e-80bc-3140149d4cdb", "node_type": "1", "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. "}, "hash": "0b885c158d26a5b360f201cea0d8affe463970880a02f11eaf905e31bf97d58c", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 4495, "end_char_idx": 4665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aea15a83-6f51-4b3e-80bc-3140149d4cdb": {"__data__": {"id_": "aea15a83-6f51-4b3e-80bc-3140149d4cdb", "embedding": null, "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1b297ad-ddf5-4437-b8ed-c276397227e3", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a98a0270fcb5c82e91e6e64cb16d0cd27bca53b4abce10338023edfdbd4a5787", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4acd4213-e5bf-46c5-ba0d-4078e84347cc", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. "}, "hash": "5fb3db4ac5fe0093ebffa1a38ee1621a504d20d44fadeed181056e0e40887f40", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 4665, "end_char_idx": 4807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4acd4213-e5bf-46c5-ba0d-4078e84347cc": {"__data__": {"id_": "4acd4213-e5bf-46c5-ba0d-4078e84347cc", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aea15a83-6f51-4b3e-80bc-3140149d4cdb", "node_type": "1", "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec16c826309d78e4d47901ca5a11deb294e364126d04b905f79613171125c763", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbf0dbfb-b0f2-4af1-a04b-7cefcce6c8b6", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n 3", "original_text": "From Canada, dial (855) 669-9658. "}, "hash": "f01efb5d84012fe975673f64ddcce9adab329cc05e1e24f1c9da1772cf5d0cce", "class_name": "RelatedNodeInfo"}}, "text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "start_char_idx": 4807, "end_char_idx": 4881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbf0dbfb-b0f2-4af1-a04b-7cefcce6c8b6": {"__data__": {"id_": "bbf0dbfb-b0f2-4af1-a04b-7cefcce6c8b6", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n 3", "original_text": "From Canada, dial (855) 669-9658. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4acd4213-e5bf-46c5-ba0d-4078e84347cc", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1ef178707254469e23d7b3c105162bdc6e011959574285cdd6588e1c3c747b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38a63f77-0eac-4e12-9fd1-565dcca30368", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n 3", "original_text": "From outside the\nUnited States and Canada, dial (412) 317-0088. "}, "hash": "cf2a73b405d2e92df0f11eef2fdbf1fd91b554fde138f7789fd88205de7f5c77", "class_name": "RelatedNodeInfo"}}, "text": "From Canada, dial (855) 669-9658. ", "start_char_idx": 4881, "end_char_idx": 4915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38a63f77-0eac-4e12-9fd1-565dcca30368": {"__data__": {"id_": "38a63f77-0eac-4e12-9fd1-565dcca30368", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n 3", "original_text": "From outside the\nUnited States and Canada, dial (412) 317-0088. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbf0dbfb-b0f2-4af1-a04b-7cefcce6c8b6", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n 3", "original_text": "From Canada, dial (855) 669-9658. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c56ffa0d8d6e5957b6f6270a495b5b50324f22d4ceb127f51c518ed9a20f38e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e99052be-0815-488e-b3b7-822cf5b1a100", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n 3", "original_text": "The access code for the replay is 10145670.\n"}, "hash": "9ca7b22cff789d3bf8b134bbd942511eccda44584737713ea248bcd240b8daa1", "class_name": "RelatedNodeInfo"}}, "text": "From outside the\nUnited States and Canada, dial (412) 317-0088. ", "start_char_idx": 4915, "end_char_idx": 4979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e99052be-0815-488e-b3b7-822cf5b1a100": {"__data__": {"id_": "e99052be-0815-488e-b3b7-822cf5b1a100", "embedding": null, "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n 3", "original_text": "The access code for the replay is 10145670.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38a63f77-0eac-4e12-9fd1-565dcca30368", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n 3", "original_text": "From outside the\nUnited States and Canada, dial (412) 317-0088. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d75c7cc1dab256710a50a39bfb86d831d0c414907a78b9bed1cf6fd33478564", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ab5417d-0af0-4e19-8ab3-5b2c52e1fbf5", "node_type": "1", "metadata": {"window": "From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n 3", "original_text": "3"}, "hash": "d02f04eb6dea3ecdc6b9b9bfd252f78aecbcf9e991c1bb94536082b55be0853f", "class_name": "RelatedNodeInfo"}}, "text": "The access code for the replay is 10145670.\n", "start_char_idx": 4979, "end_char_idx": 5023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ab5417d-0af0-4e19-8ab3-5b2c52e1fbf5": {"__data__": {"id_": "8ab5417d-0af0-4e19-8ab3-5b2c52e1fbf5", "embedding": null, "metadata": {"window": "From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n 3", "original_text": "3", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec2e6c3eb650baade110f1b0facbb2c2c2e94f503139d6b11735f7f433c73b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e99052be-0815-488e-b3b7-822cf5b1a100", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n 3", "original_text": "The access code for the replay is 10145670.\n", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8bc2ae8bf59e9ff23a9d74716e49e66dd1545379e2328c0dbfc25f2cb9a25d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9e5dd88-2a14-42b4-b32f-1b36551f621f", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n"}, "hash": "d1edca772aea9025464114f8816b89b0daad4a7be365d552a133952fc8b120fd", "class_name": "RelatedNodeInfo"}}, "text": "3", "start_char_idx": 153, "end_char_idx": 154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9e5dd88-2a14-42b4-b32f-1b36551f621f": {"__data__": {"id_": "a9e5dd88-2a14-42b4-b32f-1b36551f621f", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ab5417d-0af0-4e19-8ab3-5b2c52e1fbf5", "node_type": "1", "metadata": {"window": "From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10145670.\n 3", "original_text": "3", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34571ed837dd8646fa8f784ca3e679df5e7aff0748a5392422d6e58c542b47bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60431961-ac23-489e-b587-53fa02c36d62", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n"}, "hash": "2f14ce874504132b96a050bd8fe3989736807b218487e66a47c7960663c23071", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n", "start_char_idx": 0, "end_char_idx": 206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60431961-ac23-489e-b587-53fa02c36d62": {"__data__": {"id_": "60431961-ac23-489e-b587-53fa02c36d62", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9e5dd88-2a14-42b4-b32f-1b36551f621f", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd0c98dd7ca803c58cdc8d61e21cef8e57ad5896f5f06e6dc1846dde935872cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "058b7293-baa3-4875-a2a9-23776e73cd71", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n"}, "hash": "69b33afb1999cc12f8607103987fe3ff6ba60242c0c1efbb900fae37a0a1fb87", "class_name": "RelatedNodeInfo"}}, "text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "start_char_idx": 206, "end_char_idx": 335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "058b7293-baa3-4875-a2a9-23776e73cd71": {"__data__": {"id_": "058b7293-baa3-4875-a2a9-23776e73cd71", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60431961-ac23-489e-b587-53fa02c36d62", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05c7773012f5be7aaa957cd58b26a8e858fd3ae9bd3941ab477bf8034e4b5ed9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49ed8040-65fa-435c-82fa-b6ae1e8d9745", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "original_text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. "}, "hash": "b913b233edee95b3fae1598144d898f16828c74e6b5d0c605cc220b54b66f1d9", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "start_char_idx": 335, "end_char_idx": 488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49ed8040-65fa-435c-82fa-b6ae1e8d9745": {"__data__": {"id_": "49ed8040-65fa-435c-82fa-b6ae1e8d9745", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "original_text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "058b7293-baa3-4875-a2a9-23776e73cd71", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44040eb09c5934052079518ddd1e73d1509475f429f52226a5ec70d444130405", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95ff92e8-a198-44fa-bb19-212a26d4b000", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa. ", "original_text": "Global manufacturers depend on us for services that drive commercial success for their products.\n"}, "hash": "bd586078b4e7769262cab84e00182d725bef235a19cba68de89e066be1d6037e", "class_name": "RelatedNodeInfo"}}, "text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "start_char_idx": 488, "end_char_idx": 638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95ff92e8-a198-44fa-bb19-212a26d4b000": {"__data__": {"id_": "95ff92e8-a198-44fa-bb19-212a26d4b000", "embedding": null, "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa. ", "original_text": "Global manufacturers depend on us for services that drive commercial success for their products.\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49ed8040-65fa-435c-82fa-b6ae1e8d9745", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "original_text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7dc0ef453eb975c37b278c235a2954039f00606450b7cf972b3929da850bde3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50e6c2d8-0b17-4a48-8a8c-878c8f822527", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries. ", "original_text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n"}, "hash": "aebc4c2cfb51b28ba3015cd4a38cf53c4b5aeee8a71e16e30724ee8c562851a1", "class_name": "RelatedNodeInfo"}}, "text": "Global manufacturers depend on us for services that drive commercial success for their products.\n", "start_char_idx": 638, "end_char_idx": 735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50e6c2d8-0b17-4a48-8a8c-878c8f822527": {"__data__": {"id_": "50e6c2d8-0b17-4a48-8a8c-878c8f822527", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries. ", "original_text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95ff92e8-a198-44fa-bb19-212a26d4b000", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa. ", "original_text": "Global manufacturers depend on us for services that drive commercial success for their products.\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390a6f96641a04f2dac33ee748f6b96958c6cf788fcbed3a270dcad548cf0624", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3466ebfc-759a-4ef1-9d05-9b825ae4b7eb", "node_type": "1", "metadata": {"window": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. "}, "hash": "0dcc30e6190a7f58768b4bc52bcd6f37b4cd49c3fb5dfc0f32a6fb7ecf07d241", "class_name": "RelatedNodeInfo"}}, "text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "start_char_idx": 735, "end_char_idx": 860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3466ebfc-759a-4ef1-9d05-9b825ae4b7eb": {"__data__": {"id_": "3466ebfc-759a-4ef1-9d05-9b825ae4b7eb", "embedding": null, "metadata": {"window": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50e6c2d8-0b17-4a48-8a8c-878c8f822527", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries. ", "original_text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db54878784dbb379a5a3da72e7448f556714255043bb8b8bc33d1df51196dcd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6db64365-be1d-47bd-8732-c1ffd8041dc9", "node_type": "1", "metadata": {"window": "Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "original_text": "The company is\nheadquartered in Valley Forge, Pa. "}, "hash": "0d32ad6cc2d7e3d2ae932f4ce7188ac7243adfce983c796bde6af64e93dbab33", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "start_char_idx": 860, "end_char_idx": 959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6db64365-be1d-47bd-8732-c1ffd8041dc9": {"__data__": {"id_": "6db64365-be1d-47bd-8732-c1ffd8041dc9", "embedding": null, "metadata": {"window": "Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "original_text": "The company is\nheadquartered in Valley Forge, Pa. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3466ebfc-759a-4ef1-9d05-9b825ae4b7eb", "node_type": "1", "metadata": {"window": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4caa07f525ef9179755929555e7ebc6d12c1727254a979ec4493527fa4f7ce40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa29ce30-8b9b-4fbe-ae19-87d85a09efa8", "node_type": "1", "metadata": {"window": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "original_text": "and has a presence in 50+ countries. "}, "hash": "2e47e76656207a66e5acd002c225504b043b0143ef1feb5800accf488ac77c88", "class_name": "RelatedNodeInfo"}}, "text": "The company is\nheadquartered in Valley Forge, Pa. ", "start_char_idx": 959, "end_char_idx": 1009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa29ce30-8b9b-4fbe-ae19-87d85a09efa8": {"__data__": {"id_": "fa29ce30-8b9b-4fbe-ae19-87d85a09efa8", "embedding": null, "metadata": {"window": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "original_text": "and has a presence in 50+ countries. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6db64365-be1d-47bd-8732-c1ffd8041dc9", "node_type": "1", "metadata": {"window": "Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "original_text": "The company is\nheadquartered in Valley Forge, Pa. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ae74b2fcedfe4ce2c82b7824450e3d540b19226a8cd129bc4258651f86993a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21af7843-87fe-4c07-b658-d9124465f39c", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n"}, "hash": "5631b8bab61118657afb6e07902ca1591f73e0cdb475904445649b1a2286c3cf", "class_name": "RelatedNodeInfo"}}, "text": "and has a presence in 50+ countries. ", "start_char_idx": 1009, "end_char_idx": 1046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21af7843-87fe-4c07-b658-d9124465f39c": {"__data__": {"id_": "21af7843-87fe-4c07-b658-d9124465f39c", "embedding": null, "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa29ce30-8b9b-4fbe-ae19-87d85a09efa8", "node_type": "1", "metadata": {"window": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "original_text": "and has a presence in 50+ countries. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52418b5de58eb34f31385a2f8ff272c94b10ba5a0ca05bc09081eadb10e10e94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "904f6680-ef74-4dfb-a157-e44d4820fc47", "node_type": "1", "metadata": {"window": "The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. "}, "hash": "fe71244f6b2c67e469ddd315eaac25f556f330c506ea28300e3eb2f7e15e93ac", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com .\n", "start_char_idx": 1046, "end_char_idx": 1093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "904f6680-ef74-4dfb-a157-e44d4820fc47": {"__data__": {"id_": "904f6680-ef74-4dfb-a157-e44d4820fc47", "embedding": null, "metadata": {"window": "The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21af7843-87fe-4c07-b658-d9124465f39c", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca41913baf6eb85e33662230b40b21a23d97c1b7146ce65b85f7224f7b68cd3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86c1be64-bc3d-4ca1-becc-afd5d160910e", "node_type": "1", "metadata": {"window": "and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. "}, "hash": "fbbaa0f123dc7ca161fd33be8e05a7259db87a7b1c4aad3692eabcb61b8ce131", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "start_char_idx": 1093, "end_char_idx": 1383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86c1be64-bc3d-4ca1-becc-afd5d160910e": {"__data__": {"id_": "86c1be64-bc3d-4ca1-becc-afd5d160910e", "embedding": null, "metadata": {"window": "and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "904f6680-ef74-4dfb-a157-e44d4820fc47", "node_type": "1", "metadata": {"window": "The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32cb20d65ca909c02b245d448840bf7d6c394b0124dd360a46868571fdd472e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f00ac51-a67a-411f-b0c3-af46156d560d", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S. ", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. "}, "hash": "8e2a310b62b0b9d3554233088ed387529e787d3ecd35533795c9177f5ef77e8f", "class_name": "RelatedNodeInfo"}}, "text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "start_char_idx": 1383, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f00ac51-a67a-411f-b0c3-af46156d560d": {"__data__": {"id_": "9f00ac51-a67a-411f-b0c3-af46156d560d", "embedding": null, "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S. ", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86c1be64-bc3d-4ca1-becc-afd5d160910e", "node_type": "1", "metadata": {"window": "and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b09cb946eb45891efae5355ee385f26a135c2029e1212a635d82d0e8bc259296", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fce86bc9-a518-403f-8fdc-c9ebd2e63ed0", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. ", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. "}, "hash": "457cc8f3d379a067e49a8c756706aeb10a5ebc3e395d69aaf62fc0741fcfc306", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "start_char_idx": 1733, "end_char_idx": 1895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fce86bc9-a518-403f-8fdc-c9ebd2e63ed0": {"__data__": {"id_": "fce86bc9-a518-403f-8fdc-c9ebd2e63ed0", "embedding": null, "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. ", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f00ac51-a67a-411f-b0c3-af46156d560d", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S. ", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71a4f265c22dc7fadcead8533b208b57090ee43ba343935e989bcbf8dd907f72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8c5bc2b-179e-4f52-8a69-86c5e3e98f71", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. ", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. "}, "hash": "a8c83447e386adddb4c5520e7350179e89fbda972270e7ddb2ea489c2d2b839c", "class_name": "RelatedNodeInfo"}}, "text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "start_char_idx": 1895, "end_char_idx": 2094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8c5bc2b-179e-4f52-8a69-86c5e3e98f71": {"__data__": {"id_": "a8c5bc2b-179e-4f52-8a69-86c5e3e98f71", "embedding": null, "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. ", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fce86bc9-a518-403f-8fdc-c9ebd2e63ed0", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. ", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07b53ce7f28da6843f0b9490abc03fe3ed4d64ad6358a6392cc6b8d14c4ec623", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5bde54b-78d8-4177-9fe2-8465feee7796", "node_type": "1", "metadata": {"window": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n", "original_text": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S. "}, "hash": "e193479383021b0ae4d9218687c4ec25fe5e68b8b48c401cb71ee086d56e423d", "class_name": "RelatedNodeInfo"}}, "text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "start_char_idx": 2094, "end_char_idx": 4134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5bde54b-78d8-4177-9fe2-8465feee7796": {"__data__": {"id_": "a5bde54b-78d8-4177-9fe2-8465feee7796", "embedding": null, "metadata": {"window": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n", "original_text": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8c5bc2b-179e-4f52-8a69-86c5e3e98f71", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. ", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab021f34d2f1985d6e6cc352d076b2a395e585a5ddbfbf91a002a549e1993d4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0458e319-7c6f-45eb-84d7-465e675d34cd", "node_type": "1", "metadata": {"window": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. "}, "hash": "3b4d79cf1b0a48da4f5186bef1046c214655d9cfa7c181d10c9001ad049e37b0", "class_name": "RelatedNodeInfo"}}, "text": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S. ", "start_char_idx": 4134, "end_char_idx": 4706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0458e319-7c6f-45eb-84d7-465e675d34cd": {"__data__": {"id_": "0458e319-7c6f-45eb-84d7-465e675d34cd", "embedding": null, "metadata": {"window": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5bde54b-78d8-4177-9fe2-8465feee7796", "node_type": "1", "metadata": {"window": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n", "original_text": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc65ec0751771012425795fe9510c779cdadbef2fb632162363992bd8ba5fcbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6cbe76a-0dbc-4e04-b00d-0adcb8152852", "node_type": "1", "metadata": {"window": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "original_text": "Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. "}, "hash": "24479f56de5239baffb7ba117061652ae62d58f71fbc4e4d833b94043764609a", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. ", "start_char_idx": 4706, "end_char_idx": 6383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6cbe76a-0dbc-4e04-b00d-0adcb8152852": {"__data__": {"id_": "d6cbe76a-0dbc-4e04-b00d-0adcb8152852", "embedding": null, "metadata": {"window": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "original_text": "Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0458e319-7c6f-45eb-84d7-465e675d34cd", "node_type": "1", "metadata": {"window": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ded00261240dab15d3ff203b6f85903ae167b7460d716eb9b2a1eccd83a35273", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24fe7ce4-9536-4955-b92f-cce780c96465", "node_type": "1", "metadata": {"window": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n"}, "hash": "37a69f42495f320975c0bfea7b1df2a7a6b26f7f28cc3fdc3ab56aaba07dda5c", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. ", "start_char_idx": 6383, "end_char_idx": 6798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24fe7ce4-9536-4955-b92f-cce780c96465": {"__data__": {"id_": "24fe7ce4-9536-4955-b92f-cce780c96465", "embedding": null, "metadata": {"window": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6cbe76a-0dbc-4e04-b00d-0adcb8152852", "node_type": "1", "metadata": {"window": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "original_text": "Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. ", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26264bdb38d73bb895b6077ae8a823bfd4cbb78d160b0529923fd5158be5f9a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d54feedd-f3ee-4815-b821-80370e5aa5bd", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4"}, "hash": "fcafdc6d0276c3c4c42e10f05ade97fcf8e66d10e1cc1808e565b97b629c5cf9", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n", "start_char_idx": 6798, "end_char_idx": 6949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d54feedd-f3ee-4815-b821-80370e5aa5bd": {"__data__": {"id_": "d54feedd-f3ee-4815-b821-80370e5aa5bd", "embedding": null, "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c992a98489f6e52a97d9bf68c22fdfa618df3a31c43b3bbd03c48e48f56d83ae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24fe7ce4-9536-4955-b92f-cce780c96465", "node_type": "1", "metadata": {"window": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60b74cfe3cd1e25a45c881d8f9f81bb6d1fa2d6dfb4ee73dc7db502f1b9e81f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f50c2e9-d43b-4999-a3c9-7709abd91489", "node_type": "1", "metadata": {"window": "\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a0$45,239,265 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a044,008,026 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,225,716 \u00a0\u00a02.70% \u00a01,231,239 \u00a0\u00a02.72% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0666,885 \u00a0\u00a01.47% \u00a0656,943 \u00a0\u00a01.45% \u00a01.5%\nDepreciation and amortization \u00a095,415 \u00a0\u00a00.21% \u00a0107,596 \u00a0\u00a00.24% \u00a0(11.3)%\nEmployee severance, litigation, and other 3 \u00a058,585 \u00a0\u00a0\u00a0 \u00a060,006 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0820,885 \u00a0\u00a01.81% \u00a0824,545 \u00a0\u00a01.82% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0404,831 \u00a0\u00a00.89% \u00a0406,694 \u00a0\u00a00.90% \u00a0(0.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a01,073 \u00a0\u00a0\u00a0 \u00a0(342) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a037,748 \u00a0\u00a0\u00a0 \u00a035,921 \u00a0\u00a0\u00a0 \u00a05.1%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0343,835 \u00a0\u00a00.76% \u00a0371,115 \u00a0\u00a00.82% \u00a0(7.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a056,567 \u00a0\u00a0\u00a0 \u00a069,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0287,268 \u00a0\u00a00.63% \u00a0302,002 \u00a0\u00a00.67% \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interest \u00a02,171 \u00a0\u00a0\u00a0 \u00a0(43) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$289,439 \u00a0\u00a00.64% \u00a0$301,959 \u00a0\u00a00.67% \u00a0(4.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$1.44 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0$1.43 \u00a0\u00a0\u00a0 \u00a0(1.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0203,654 \u00a0\u00a0\u00a0 \u00a0209,705 \u00a0\u00a0\u00a0 \u00a0(2.9)%\n5", "original_text": "\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a0$45,239,265 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a044,008,026 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,225,716 \u00a0\u00a02.70% \u00a01,231,239 \u00a0\u00a02.72% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0666,885 \u00a0\u00a01.47% \u00a0656,943 \u00a0\u00a01.45% \u00a01.5%\nDepreciation and amortization \u00a095,415 \u00a0\u00a00.21% \u00a0107,596 \u00a0\u00a00.24% \u00a0(11.3)%\nEmployee severance, litigation, and other 3 \u00a058,585 \u00a0\u00a0\u00a0 \u00a060,006 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0820,885 \u00a0\u00a01.81% \u00a0824,545 \u00a0\u00a01.82% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0404,831 \u00a0\u00a00.89% \u00a0406,694 \u00a0\u00a00.90% \u00a0(0.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a01,073 \u00a0\u00a0\u00a0 \u00a0(342) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a037,748 \u00a0\u00a0\u00a0 \u00a035,921 \u00a0\u00a0\u00a0 \u00a05.1%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0343,835 \u00a0\u00a00.76% \u00a0371,115 \u00a0\u00a00.82% \u00a0(7.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a056,567 \u00a0\u00a0\u00a0 \u00a069,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0287,268 \u00a0\u00a00.63% \u00a0302,002 \u00a0\u00a00.67% \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interest \u00a02,171 \u00a0\u00a0\u00a0 \u00a0(43) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$289,439 \u00a0\u00a00.64% \u00a0$301,959 \u00a0\u00a00.67% \u00a0(4.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$1.44 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0$1.43 \u00a0\u00a0\u00a0 \u00a0(1.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0203,654 \u00a0\u00a0\u00a0 \u00a0209,705 \u00a0\u00a0\u00a0 \u00a0(2.9)%\n5"}, "hash": "7b93730f6f566abf24468a8cd0f9d6662922851feb715cdfc7802eaf372d4556", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "start_char_idx": 6949, "end_char_idx": 7054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f50c2e9-d43b-4999-a3c9-7709abd91489": {"__data__": {"id_": "0f50c2e9-d43b-4999-a3c9-7709abd91489", "embedding": null, "metadata": {"window": "\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a0$45,239,265 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a044,008,026 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,225,716 \u00a0\u00a02.70% \u00a01,231,239 \u00a0\u00a02.72% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0666,885 \u00a0\u00a01.47% \u00a0656,943 \u00a0\u00a01.45% \u00a01.5%\nDepreciation and amortization \u00a095,415 \u00a0\u00a00.21% \u00a0107,596 \u00a0\u00a00.24% \u00a0(11.3)%\nEmployee severance, litigation, and other 3 \u00a058,585 \u00a0\u00a0\u00a0 \u00a060,006 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0820,885 \u00a0\u00a01.81% \u00a0824,545 \u00a0\u00a01.82% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0404,831 \u00a0\u00a00.89% \u00a0406,694 \u00a0\u00a00.90% \u00a0(0.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a01,073 \u00a0\u00a0\u00a0 \u00a0(342) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a037,748 \u00a0\u00a0\u00a0 \u00a035,921 \u00a0\u00a0\u00a0 \u00a05.1%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0343,835 \u00a0\u00a00.76% \u00a0371,115 \u00a0\u00a00.82% \u00a0(7.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a056,567 \u00a0\u00a0\u00a0 \u00a069,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0287,268 \u00a0\u00a00.63% \u00a0302,002 \u00a0\u00a00.67% \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interest \u00a02,171 \u00a0\u00a0\u00a0 \u00a0(43) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$289,439 \u00a0\u00a00.64% \u00a0$301,959 \u00a0\u00a00.67% \u00a0(4.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$1.44 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0$1.43 \u00a0\u00a0\u00a0 \u00a0(1.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0203,654 \u00a0\u00a0\u00a0 \u00a0209,705 \u00a0\u00a0\u00a0 \u00a0(2.9)%\n5", "original_text": "\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a0$45,239,265 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a044,008,026 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,225,716 \u00a0\u00a02.70% \u00a01,231,239 \u00a0\u00a02.72% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0666,885 \u00a0\u00a01.47% \u00a0656,943 \u00a0\u00a01.45% \u00a01.5%\nDepreciation and amortization \u00a095,415 \u00a0\u00a00.21% \u00a0107,596 \u00a0\u00a00.24% \u00a0(11.3)%\nEmployee severance, litigation, and other 3 \u00a058,585 \u00a0\u00a0\u00a0 \u00a060,006 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0820,885 \u00a0\u00a01.81% \u00a0824,545 \u00a0\u00a01.82% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0404,831 \u00a0\u00a00.89% \u00a0406,694 \u00a0\u00a00.90% \u00a0(0.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a01,073 \u00a0\u00a0\u00a0 \u00a0(342) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a037,748 \u00a0\u00a0\u00a0 \u00a035,921 \u00a0\u00a0\u00a0 \u00a05.1%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0343,835 \u00a0\u00a00.76% \u00a0371,115 \u00a0\u00a00.82% \u00a0(7.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a056,567 \u00a0\u00a0\u00a0 \u00a069,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0287,268 \u00a0\u00a00.63% \u00a0302,002 \u00a0\u00a00.67% \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interest \u00a02,171 \u00a0\u00a0\u00a0 \u00a0(43) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$289,439 \u00a0\u00a00.64% \u00a0$301,959 \u00a0\u00a00.67% \u00a0(4.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$1.44 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0$1.43 \u00a0\u00a0\u00a0 \u00a0(1.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0203,654 \u00a0\u00a0\u00a0 \u00a0209,705 \u00a0\u00a0\u00a0 \u00a0(2.9)%\n5", "page_label": "5", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "59500035-e69c-4271-84ef-bd94e205147b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c33328036d12d0856367f9d4e8d6c571565ef3b515a7aded4bdd573c1d48b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d54feedd-f3ee-4815-b821-80370e5aa5bd", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n4", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "891a471da2674796333387691aee1ae161c8afc88a73d68be800600f9165fbe7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c427d0e-d902-4857-a5a5-e589ec524299", "node_type": "1", "metadata": {"window": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n"}, "hash": "a855a59b98cda3f51a06937874e071ea343458d2bcc1466dc72646ee61dc61d6", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a0$45,239,265 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a044,008,026 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,225,716 \u00a0\u00a02.70% \u00a01,231,239 \u00a0\u00a02.72% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0666,885 \u00a0\u00a01.47% \u00a0656,943 \u00a0\u00a01.45% \u00a01.5%\nDepreciation and amortization \u00a095,415 \u00a0\u00a00.21% \u00a0107,596 \u00a0\u00a00.24% \u00a0(11.3)%\nEmployee severance, litigation, and other 3 \u00a058,585 \u00a0\u00a0\u00a0 \u00a060,006 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0820,885 \u00a0\u00a01.81% \u00a0824,545 \u00a0\u00a01.82% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0404,831 \u00a0\u00a00.89% \u00a0406,694 \u00a0\u00a00.90% \u00a0(0.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a01,073 \u00a0\u00a0\u00a0 \u00a0(342) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a037,748 \u00a0\u00a0\u00a0 \u00a035,921 \u00a0\u00a0\u00a0 \u00a05.1%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0343,835 \u00a0\u00a00.76% \u00a0371,115 \u00a0\u00a00.82% \u00a0(7.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a056,567 \u00a0\u00a0\u00a0 \u00a069,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0287,268 \u00a0\u00a00.63% \u00a0302,002 \u00a0\u00a00.67% \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interest \u00a02,171 \u00a0\u00a0\u00a0 \u00a0(43) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$289,439 \u00a0\u00a00.64% \u00a0$301,959 \u00a0\u00a00.67% \u00a0(4.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$1.44 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0$1.43 \u00a0\u00a0\u00a0 \u00a0(1.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0203,654 \u00a0\u00a0\u00a0 \u00a0209,705 \u00a0\u00a0\u00a0 \u00a0(2.9)%\n5", "start_char_idx": 0, "end_char_idx": 1592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c427d0e-d902-4857-a5a5-e589ec524299": {"__data__": {"id_": "5c427d0e-d902-4857-a5a5-e589ec524299", "embedding": null, "metadata": {"window": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "180116b2-3c32-45cb-bd95-292191d67a86", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53df6d3c752f42eef000ea448cb440991b5d6c5c50ea6bf5ef80261badc998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f50c2e9-d43b-4999-a3c9-7709abd91489", "node_type": "1", "metadata": {"window": "\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a0$45,239,265 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a044,008,026 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,225,716 \u00a0\u00a02.70% \u00a01,231,239 \u00a0\u00a02.72% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0666,885 \u00a0\u00a01.47% \u00a0656,943 \u00a0\u00a01.45% \u00a01.5%\nDepreciation and amortization \u00a095,415 \u00a0\u00a00.21% \u00a0107,596 \u00a0\u00a00.24% \u00a0(11.3)%\nEmployee severance, litigation, and other 3 \u00a058,585 \u00a0\u00a0\u00a0 \u00a060,006 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0820,885 \u00a0\u00a01.81% \u00a0824,545 \u00a0\u00a01.82% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0404,831 \u00a0\u00a00.89% \u00a0406,694 \u00a0\u00a00.90% \u00a0(0.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a01,073 \u00a0\u00a0\u00a0 \u00a0(342) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a037,748 \u00a0\u00a0\u00a0 \u00a035,921 \u00a0\u00a0\u00a0 \u00a05.1%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0343,835 \u00a0\u00a00.76% \u00a0371,115 \u00a0\u00a00.82% \u00a0(7.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a056,567 \u00a0\u00a0\u00a0 \u00a069,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0287,268 \u00a0\u00a00.63% \u00a0302,002 \u00a0\u00a00.67% \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interest \u00a02,171 \u00a0\u00a0\u00a0 \u00a0(43) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$289,439 \u00a0\u00a00.64% \u00a0$301,959 \u00a0\u00a00.67% \u00a0(4.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$1.44 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0$1.43 \u00a0\u00a0\u00a0 \u00a0(1.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0203,654 \u00a0\u00a0\u00a0 \u00a0209,705 \u00a0\u00a0\u00a0 \u00a0(2.9)%\n5", "original_text": "\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a0$45,239,265 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a044,008,026 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,225,716 \u00a0\u00a02.70% \u00a01,231,239 \u00a0\u00a02.72% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0666,885 \u00a0\u00a01.47% \u00a0656,943 \u00a0\u00a01.45% \u00a01.5%\nDepreciation and amortization \u00a095,415 \u00a0\u00a00.21% \u00a0107,596 \u00a0\u00a00.24% \u00a0(11.3)%\nEmployee severance, litigation, and other 3 \u00a058,585 \u00a0\u00a0\u00a0 \u00a060,006 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0820,885 \u00a0\u00a01.81% \u00a0824,545 \u00a0\u00a01.82% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0404,831 \u00a0\u00a00.89% \u00a0406,694 \u00a0\u00a00.90% \u00a0(0.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a01,073 \u00a0\u00a0\u00a0 \u00a0(342) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a037,748 \u00a0\u00a0\u00a0 \u00a035,921 \u00a0\u00a0\u00a0 \u00a05.1%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0343,835 \u00a0\u00a00.76% \u00a0371,115 \u00a0\u00a00.82% \u00a0(7.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a056,567 \u00a0\u00a0\u00a0 \u00a069,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0287,268 \u00a0\u00a00.63% \u00a0302,002 \u00a0\u00a00.67% \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interest \u00a02,171 \u00a0\u00a0\u00a0 \u00a0(43) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$289,439 \u00a0\u00a00.64% \u00a0$301,959 \u00a0\u00a00.67% \u00a0(4.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$1.44 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0$1.43 \u00a0\u00a0\u00a0 \u00a0(1.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0203,654 \u00a0\u00a0\u00a0 \u00a0209,705 \u00a0\u00a0\u00a0 \u00a0(2.9)%\n5", "page_label": "5", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83482ef63f7432809aa51f4b913d5faf100f0e3f367ee180de61c0c29a34ad2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e3fb727-d560-41f2-a117-8ed1383d584c", "node_type": "1", "metadata": {"window": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020. ", "original_text": "Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n"}, "hash": "7abe8963e0d664c248b804493024eb34ef7e8363e95f723ac39f80b793bac91c", "class_name": "RelatedNodeInfo"}}, "text": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n", "start_char_idx": 0, "end_char_idx": 208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e3fb727-d560-41f2-a117-8ed1383d584c": {"__data__": {"id_": "7e3fb727-d560-41f2-a117-8ed1383d584c", "embedding": null, "metadata": {"window": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020. ", "original_text": "Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "180116b2-3c32-45cb-bd95-292191d67a86", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53df6d3c752f42eef000ea448cb440991b5d6c5c50ea6bf5ef80261badc998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c427d0e-d902-4857-a5a5-e589ec524299", "node_type": "1", "metadata": {"window": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3316b85679f3d92a0b684cbdff1464bd16180aaa53f8ce25e75802b5b80a4995", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fbb6439-e309-4c88-975b-24a53dac8fbc", "node_type": "1", "metadata": {"window": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n", "original_text": "2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020. "}, "hash": "460bed8dd861ab04215987ba257fc53d5051bb957b79c3ada5a5dd2b8fa95f26", "class_name": "RelatedNodeInfo"}}, "text": "Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n", "start_char_idx": 208, "end_char_idx": 398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fbb6439-e309-4c88-975b-24a53dac8fbc": {"__data__": {"id_": "4fbb6439-e309-4c88-975b-24a53dac8fbc", "embedding": null, "metadata": {"window": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n", "original_text": "2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020. ", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "180116b2-3c32-45cb-bd95-292191d67a86", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53df6d3c752f42eef000ea448cb440991b5d6c5c50ea6bf5ef80261badc998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e3fb727-d560-41f2-a117-8ed1383d584c", "node_type": "1", "metadata": {"window": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020. ", "original_text": "Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab034cb75db4dc7a5257316fd8275938b0897789d25aed65ccd2cac090507f7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20058860-9d0e-44e2-b215-546887dfbebf", "node_type": "1", "metadata": {"window": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n"}, "hash": "b22ff8f5b7dccdc096b5cd31498a4d112a7d25d55851bdb2554b3ff6112ec666", "class_name": "RelatedNodeInfo"}}, "text": "2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020. ", "start_char_idx": 398, "end_char_idx": 492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20058860-9d0e-44e2-b215-546887dfbebf": {"__data__": {"id_": "20058860-9d0e-44e2-b215-546887dfbebf", "embedding": null, "metadata": {"window": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "180116b2-3c32-45cb-bd95-292191d67a86", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53df6d3c752f42eef000ea448cb440991b5d6c5c50ea6bf5ef80261badc998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fbb6439-e309-4c88-975b-24a53dac8fbc", "node_type": "1", "metadata": {"window": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n", "original_text": "2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020. ", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "811a9fa0f3681428b0541759ba6b0dc09ba90a4ac7d6bcdc437d79bb67f75ed6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c159df7-d277-4e0a-9012-706265c28ed5", "node_type": "1", "metadata": {"window": "Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020. "}, "hash": "d8b453f1bc53b64e9307c0e579eaa81711c6a3fb6a3dae388f1e3bf517291164", "class_name": "RelatedNodeInfo"}}, "text": "Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n", "start_char_idx": 492, "end_char_idx": 590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c159df7-d277-4e0a-9012-706265c28ed5": {"__data__": {"id_": "8c159df7-d277-4e0a-9012-706265c28ed5", "embedding": null, "metadata": {"window": "Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020. ", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "180116b2-3c32-45cb-bd95-292191d67a86", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53df6d3c752f42eef000ea448cb440991b5d6c5c50ea6bf5ef80261badc998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20058860-9d0e-44e2-b215-546887dfbebf", "node_type": "1", "metadata": {"window": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e542baf4af994121b1d8eda8b1d637e31bb7c1238954723e575a9ee0f3e66ac3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07b694fd-876b-46e1-a35a-20bdb2b0660f", "node_type": "1", "metadata": {"window": "2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n"}, "hash": "c0503a746c241c9749becbc2834b740c0baa33ee03f18717f1bcc1513264d9c0", "class_name": "RelatedNodeInfo"}}, "text": "3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020. ", "start_char_idx": 590, "end_char_idx": 958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07b694fd-876b-46e1-a35a-20bdb2b0660f": {"__data__": {"id_": "07b694fd-876b-46e1-a35a-20bdb2b0660f", "embedding": null, "metadata": {"window": "2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "180116b2-3c32-45cb-bd95-292191d67a86", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53df6d3c752f42eef000ea448cb440991b5d6c5c50ea6bf5ef80261badc998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c159df7-d277-4e0a-9012-706265c28ed5", "node_type": "1", "metadata": {"window": "Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020. ", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "960c7d30c2d05177b88c155f9ace7409866aec4c7801a97300b5ec610b2f365e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b27a0407-8a21-495a-8653-1f33ce712187", "node_type": "1", "metadata": {"window": "Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6"}, "hash": "2774beb94c66552c5dadc6a99bf11a523eb68c958ebec6d0ade79779a0172719", "class_name": "RelatedNodeInfo"}}, "text": "Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n", "start_char_idx": 958, "end_char_idx": 1327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b27a0407-8a21-495a-8653-1f33ce712187": {"__data__": {"id_": "b27a0407-8a21-495a-8653-1f33ce712187", "embedding": null, "metadata": {"window": "Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "180116b2-3c32-45cb-bd95-292191d67a86", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53df6d3c752f42eef000ea448cb440991b5d6c5c50ea6bf5ef80261badc998ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07b694fd-876b-46e1-a35a-20bdb2b0660f", "node_type": "1", "metadata": {"window": "2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34fd19eeefbbcbef44a0fd66ca4c4a6d94d86c389060733965535f5a09ce100c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6aad0138-9cc3-4219-a7c4-90cbdd806c4f", "node_type": "1", "metadata": {"window": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020.  Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020. "}, "hash": "ec67ee6349a13c444b036f08c42e7b37cecac9d9d03377924248a4ad15b35514", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "start_char_idx": 1327, "end_char_idx": 2315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6aad0138-9cc3-4219-a7c4-90cbdd806c4f": {"__data__": {"id_": "6aad0138-9cc3-4219-a7c4-90cbdd806c4f", "embedding": null, "metadata": {"window": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020.  Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020. ", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a22921e2-8a35-41db-a332-2986693373ce", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57e4bfd4f76113747a32acfa150f83bff739d8183a7bbe79eb9fc473e6ecf5bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b27a0407-8a21-495a-8653-1f33ce712187", "node_type": "1", "metadata": {"window": "Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $6.5 million of employee severance, $31.4 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $20.7 million of other costs in connection with business transformation efforts, acquisition-\nrelated deal and integration costs, and other restructuring initiatives in the three months ended June 30, 2020.  Includes $10.8\nmillion of employee severance, $18.8 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $30.4 million of other costs in connection with business transformation efforts, acquisition-related deal and\nintegration costs, and other restructuring initiatives in the three months ended June 30, 2019.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$140,649,158 \u00a0\u00a0\u00a0 \u00a0$133,951,319 \u00a0\u00a0\u00a0 \u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0136,804,121 \u00a0\u00a0\u00a0 \u00a0129,997,744 \u00a0\u00a0\u00a0 \u00a05.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a03,845,037 \u00a0\u00a02.73% \u00a03,953,575 \u00a0\u00a02.95% \u00a0(2.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,046,251 \u00a0\u00a01.45% \u00a01,941,564 \u00a0\u00a01.45% \u00a05.4%\nDepreciation and amortization \u00a0293,725 \u00a0\u00a00.21% \u00a0353,862 \u00a0\u00a00.26% \u00a0(17.0)%\nEmployee severance, litigation, and other 3 \u00a0165,626 \u00a0\u00a0\u00a0 \u00a0156,067 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,867,254 \u00a0\u00a02.04% \u00a03,021,493 \u00a0\u00a02.26% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0977,783 \u00a0\u00a00.70% \u00a0932,082 \u00a0\u00a00.70% \u00a04.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a02,806 \u00a0\u00a0\u00a0 \u00a0(11,739) \u00a0\u00a0\u00a0 \u00a0\u00a0\n6", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96e07018a5c0f99f50195347cbe9dd5e437e39f9bf9949755a1d7e24144a196a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "666b43ce-d4cc-4e1d-ba9d-65baa758748e", "node_type": "1", "metadata": {"window": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020.  Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020. ", "original_text": "Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n"}, "hash": "bdc6e56a1eeca4fd47608ccfb4ddd8f60f6fa02fcae086bbc7d40eaf0e5f204c", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020. ", "start_char_idx": 0, "end_char_idx": 1096, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "666b43ce-d4cc-4e1d-ba9d-65baa758748e": {"__data__": {"id_": "666b43ce-d4cc-4e1d-ba9d-65baa758748e", "embedding": null, "metadata": {"window": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020.  Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020. ", "original_text": "Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a22921e2-8a35-41db-a332-2986693373ce", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57e4bfd4f76113747a32acfa150f83bff739d8183a7bbe79eb9fc473e6ecf5bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6aad0138-9cc3-4219-a7c4-90cbdd806c4f", "node_type": "1", "metadata": {"window": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020.  Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020. ", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92774a198879f9665258354ba3b45eb2276bdcb0884418933162ab298337d068", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d1c29d1-c8d7-4d6a-87e2-b56bce5733c8", "node_type": "1", "metadata": {"window": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020.  Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020. "}, "hash": "29efb28dee5c0f6198f6e78f1e51536b500467dc2b6ddd5564c25d86d1caf6f3", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "start_char_idx": 1096, "end_char_idx": 1397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d1c29d1-c8d7-4d6a-87e2-b56bce5733c8": {"__data__": {"id_": "8d1c29d1-c8d7-4d6a-87e2-b56bce5733c8", "embedding": null, "metadata": {"window": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020.  Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020. ", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a22921e2-8a35-41db-a332-2986693373ce", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57e4bfd4f76113747a32acfa150f83bff739d8183a7bbe79eb9fc473e6ecf5bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "666b43ce-d4cc-4e1d-ba9d-65baa758748e", "node_type": "1", "metadata": {"window": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020.  Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020. ", "original_text": "Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f183036ce8dfa9d8a3c67a95f862dccb36a21843e273c5ab7b64cc0b03fe5ff2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "707d2033-8985-4813-9649-91984dbd61d9", "node_type": "1", "metadata": {"window": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020.  Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n"}, "hash": "dcf73156844d5cd245c6f811e05c913df5dee4678446b91ada079755bf81845d", "class_name": "RelatedNodeInfo"}}, "text": "2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020. ", "start_char_idx": 1397, "end_char_idx": 1660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "707d2033-8985-4813-9649-91984dbd61d9": {"__data__": {"id_": "707d2033-8985-4813-9649-91984dbd61d9", "embedding": null, "metadata": {"window": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020.  Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a22921e2-8a35-41db-a332-2986693373ce", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57e4bfd4f76113747a32acfa150f83bff739d8183a7bbe79eb9fc473e6ecf5bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d1c29d1-c8d7-4d6a-87e2-b56bce5733c8", "node_type": "1", "metadata": {"window": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020.  Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020. ", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f667ee2069c2472f7241782cdf34eac37d24bcdbba5546a8506f4ab7a5ee30c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd7118f8-550d-4cb2-9d0a-21567dc8a579", "node_type": "1", "metadata": {"window": "Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020. ", "original_text": "3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020. "}, "hash": "be595e4e4018518704ec0534b4b4b6ea0fe2814b32d4d7da7e3d7c883d4ee671", "class_name": "RelatedNodeInfo"}}, "text": "Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "start_char_idx": 1660, "end_char_idx": 1758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd7118f8-550d-4cb2-9d0a-21567dc8a579": {"__data__": {"id_": "bd7118f8-550d-4cb2-9d0a-21567dc8a579", "embedding": null, "metadata": {"window": "Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020. ", "original_text": "3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020. ", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a22921e2-8a35-41db-a332-2986693373ce", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57e4bfd4f76113747a32acfa150f83bff739d8183a7bbe79eb9fc473e6ecf5bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "707d2033-8985-4813-9649-91984dbd61d9", "node_type": "1", "metadata": {"window": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020.  Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb8bd3c6496f55ae0f0cd2bd1e2da0aef866acafbf0190d5b22a64ac14342a61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2896a06c-05e2-434f-a673-ab88603153f6", "node_type": "1", "metadata": {"window": "2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020.  Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "original_text": "Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n"}, "hash": "0e37c2a8e460857cb348170d807d66031e484d9b05ca670ab8f45dd55790bdba", "class_name": "RelatedNodeInfo"}}, "text": "3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020. ", "start_char_idx": 1758, "end_char_idx": 2125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2896a06c-05e2-434f-a673-ab88603153f6": {"__data__": {"id_": "2896a06c-05e2-434f-a673-ab88603153f6", "embedding": null, "metadata": {"window": "2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020.  Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "original_text": "Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a22921e2-8a35-41db-a332-2986693373ce", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57e4bfd4f76113747a32acfa150f83bff739d8183a7bbe79eb9fc473e6ecf5bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd7118f8-550d-4cb2-9d0a-21567dc8a579", "node_type": "1", "metadata": {"window": "Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020. ", "original_text": "3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020. ", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6adfdc01256e2ae4aebcb916568f57080f780e2d9562ab29d806dae33dc8e86c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "214fd6b2-a69c-4515-93ee-6bf1cd59b4b3", "node_type": "1", "metadata": {"window": "Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020.  Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "original_text": "4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n"}, "hash": "1981db27be36b2f93008fba3b90b5c3eeecb44115ffe79f255c317f55590ce1f", "class_name": "RelatedNodeInfo"}}, "text": "Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "start_char_idx": 2125, "end_char_idx": 2494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "214fd6b2-a69c-4515-93ee-6bf1cd59b4b3": {"__data__": {"id_": "214fd6b2-a69c-4515-93ee-6bf1cd59b4b3", "embedding": null, "metadata": {"window": "Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020.  Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "original_text": "4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a22921e2-8a35-41db-a332-2986693373ce", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57e4bfd4f76113747a32acfa150f83bff739d8183a7bbe79eb9fc473e6ecf5bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2896a06c-05e2-434f-a673-ab88603153f6", "node_type": "1", "metadata": {"window": "2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020.  Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "original_text": "Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d010202987ae48d3297de09805e5f769c6ab656e9067c284ddb8b8db20d0ea68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b953c94-71f9-4a1d-afbd-6335d167b8d9", "node_type": "1", "metadata": {"window": "3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020.  Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "original_text": "5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020. "}, "hash": "04382811c062154a2f9d714a1f2736bb4b141be08be492f8307f343577e8b1ea", "class_name": "RelatedNodeInfo"}}, "text": "4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "start_char_idx": 2494, "end_char_idx": 2604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b953c94-71f9-4a1d-afbd-6335d167b8d9": {"__data__": {"id_": "4b953c94-71f9-4a1d-afbd-6335d167b8d9", "embedding": null, "metadata": {"window": "3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020.  Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "original_text": "5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020. ", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a22921e2-8a35-41db-a332-2986693373ce", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57e4bfd4f76113747a32acfa150f83bff739d8183a7bbe79eb9fc473e6ecf5bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "214fd6b2-a69c-4515-93ee-6bf1cd59b4b3", "node_type": "1", "metadata": {"window": "Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020.  Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "original_text": "4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53b66d9c44121f0864c577f32536668f1a76e2ae94985a09bf930f09f788fc85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31b803d2-4afe-4123-9a38-6230d9730ac4", "node_type": "1", "metadata": {"window": "Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020.  Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "original_text": "Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7"}, "hash": "0d5ef5d5da5f11aafade446e53fdfe2fdfef75d828df6bc0c6eadf83d2566cd4", "class_name": "RelatedNodeInfo"}}, "text": "5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020. ", "start_char_idx": 2604, "end_char_idx": 2801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31b803d2-4afe-4123-9a38-6230d9730ac4": {"__data__": {"id_": "31b803d2-4afe-4123-9a38-6230d9730ac4", "embedding": null, "metadata": {"window": "Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020.  Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "original_text": "Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a22921e2-8a35-41db-a332-2986693373ce", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57e4bfd4f76113747a32acfa150f83bff739d8183a7bbe79eb9fc473e6ecf5bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b953c94-71f9-4a1d-afbd-6335d167b8d9", "node_type": "1", "metadata": {"window": "3Includes $32.4 million of employee severance, $86.9 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $46.4 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the nine months ended June 30, 2020.  Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020.  Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "original_text": "5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020. ", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1621580e061d4371da195a6bd4a176892d3847289aca06295ab41f82fbaa412a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44939be8-2b11-4e52-b9ba-8dd61a73038c", "node_type": "1", "metadata": {"window": "2019.\n\u00a0\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income \n Tax Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er Shar e\u00a0\nGAAP \u00a0$1,225,716 \u00a0\u00a0$820,885 \u00a0\u00a0$404,831 \u00a0 \u00a0$ 343,835 \u00a0 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$ 1.41 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(15) \u00a0\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u00a0\u2014 \u00a0\u00a06,061 \u00a0 \u00a06,061 \u00a0 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0432 \u00a0\u00a0(12,504) \u00a0\u00a012,936 \u00a0 \u00a012,936 \u00a0 \u00a03,264 \u00a0\u00a0\u2014 \u00a0\u00a09,672 \u00a0\u00a00.05 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,109) \u00a0\u00a025,109 \u00a0 \u00a025,109 \u00a0 \u00a06,276 \u00a0\u00a0(437) \u00a0\u00a018,396 \u00a0\u00a00.09 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(58,585) \u00a0\u00a058,585 \u00a0 \u00a058,585 \u00a0 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638) \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(22) \u00a0\u00a0(1,833) \u00a0\u00a0(1,811) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n$1232209 $724687 $507522 $ 468701 $88295 $ (99) $380307 $ 185\n8", "original_text": "2019.\n\u00a0\n\u00a0\n"}, "hash": "415f7391bad7559df70123b44d1d011253ad1599fb500e564217a482ba071a42", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "start_char_idx": 2801, "end_char_idx": 2983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44939be8-2b11-4e52-b9ba-8dd61a73038c": {"__data__": {"id_": "44939be8-2b11-4e52-b9ba-8dd61a73038c", "embedding": null, "metadata": {"window": "2019.\n\u00a0\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income \n Tax Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er Shar e\u00a0\nGAAP \u00a0$1,225,716 \u00a0\u00a0$820,885 \u00a0\u00a0$404,831 \u00a0 \u00a0$ 343,835 \u00a0 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$ 1.41 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(15) \u00a0\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u00a0\u2014 \u00a0\u00a06,061 \u00a0 \u00a06,061 \u00a0 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0432 \u00a0\u00a0(12,504) \u00a0\u00a012,936 \u00a0 \u00a012,936 \u00a0 \u00a03,264 \u00a0\u00a0\u2014 \u00a0\u00a09,672 \u00a0\u00a00.05 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,109) \u00a0\u00a025,109 \u00a0 \u00a025,109 \u00a0 \u00a06,276 \u00a0\u00a0(437) \u00a0\u00a018,396 \u00a0\u00a00.09 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(58,585) \u00a0\u00a058,585 \u00a0 \u00a058,585 \u00a0 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638) \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(22) \u00a0\u00a0(1,833) \u00a0\u00a0(1,811) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n$1232209 $724687 $507522 $ 468701 $88295 $ (99) $380307 $ 185\n8", "original_text": "2019.\n\u00a0\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b848607e-c6c6-4df1-9963-86d9f547f5a3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f81ce044715b46a6850e571d423feecf88edab17c590eba7d6f7c1ec9e4c5c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31b803d2-4afe-4123-9a38-6230d9730ac4", "node_type": "1", "metadata": {"window": "Includes\n$29.6 million of employee severance, $47.2 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $79.3 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 4Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 5Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the nine months ended June 30, 2020.  Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "original_text": "Includes a $37.0 million measurement period adjustment\nof the one-time transition tax on historical earnings and profits through December 31, 2017 in the nine months ended June 30,\n7", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "129478bdd26c03443e94231df9d780646851683d969c164a6b3be00f616035ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd1ab706-3e10-4013-b5e1-89c1d113c7f9", "node_type": "1", "metadata": {"window": "2019.\n\u00a0\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income \n Tax Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er Shar e\u00a0\nGAAP \u00a0$1,225,716 \u00a0\u00a0$820,885 \u00a0\u00a0$404,831 \u00a0 \u00a0$ 343,835 \u00a0 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$ 1.41 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(15) \u00a0\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u00a0\u2014 \u00a0\u00a06,061 \u00a0 \u00a06,061 \u00a0 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0432 \u00a0\u00a0(12,504) \u00a0\u00a012,936 \u00a0 \u00a012,936 \u00a0 \u00a03,264 \u00a0\u00a0\u2014 \u00a0\u00a09,672 \u00a0\u00a00.05 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,109) \u00a0\u00a025,109 \u00a0 \u00a025,109 \u00a0 \u00a06,276 \u00a0\u00a0(437) \u00a0\u00a018,396 \u00a0\u00a00.09 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(58,585) \u00a0\u00a058,585 \u00a0 \u00a058,585 \u00a0 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638) \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(22) \u00a0\u00a0(1,833) \u00a0\u00a0(1,811) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n$1232209 $724687 $507522 $ 468701 $88295 $ (99) $380307 $ 185\n8", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income \n Tax Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er Shar e\u00a0\nGAAP \u00a0$1,225,716 \u00a0\u00a0$820,885 \u00a0\u00a0$404,831 \u00a0 \u00a0$ 343,835 \u00a0 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$ 1.41 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(15) \u00a0\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u00a0\u2014 \u00a0\u00a06,061 \u00a0 \u00a06,061 \u00a0 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0432 \u00a0\u00a0(12,504) \u00a0\u00a012,936 \u00a0 \u00a012,936 \u00a0 \u00a03,264 \u00a0\u00a0\u2014 \u00a0\u00a09,672 \u00a0\u00a00.05 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,109) \u00a0\u00a025,109 \u00a0 \u00a025,109 \u00a0 \u00a06,276 \u00a0\u00a0(437) \u00a0\u00a018,396 \u00a0\u00a00.09 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(58,585) \u00a0\u00a058,585 \u00a0 \u00a058,585 \u00a0 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638) \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(22) \u00a0\u00a0(1,833) \u00a0\u00a0(1,811) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n$1232209 $724687 $507522 $ 468701 $88295 $ (99) $380307 $ 185\n8"}, "hash": "30d0cdcb44ed7bbb7411da4bc274dae0bbfc0e80440d9fd311f4cf8c409266cd", "class_name": "RelatedNodeInfo"}}, "text": "2019.\n\u00a0\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 10, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd1ab706-3e10-4013-b5e1-89c1d113c7f9": {"__data__": {"id_": "dd1ab706-3e10-4013-b5e1-89c1d113c7f9", "embedding": null, "metadata": {"window": "2019.\n\u00a0\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income \n Tax Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er Shar e\u00a0\nGAAP \u00a0$1,225,716 \u00a0\u00a0$820,885 \u00a0\u00a0$404,831 \u00a0 \u00a0$ 343,835 \u00a0 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$ 1.41 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(15) \u00a0\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u00a0\u2014 \u00a0\u00a06,061 \u00a0 \u00a06,061 \u00a0 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0432 \u00a0\u00a0(12,504) \u00a0\u00a012,936 \u00a0 \u00a012,936 \u00a0 \u00a03,264 \u00a0\u00a0\u2014 \u00a0\u00a09,672 \u00a0\u00a00.05 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,109) \u00a0\u00a025,109 \u00a0 \u00a025,109 \u00a0 \u00a06,276 \u00a0\u00a0(437) \u00a0\u00a018,396 \u00a0\u00a00.09 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(58,585) \u00a0\u00a058,585 \u00a0 \u00a058,585 \u00a0 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638) \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(22) \u00a0\u00a0(1,833) \u00a0\u00a0(1,811) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n$1232209 $724687 $507522 $ 468701 $88295 $ (99) $380307 $ 185\n8", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income \n Tax Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er Shar e\u00a0\nGAAP \u00a0$1,225,716 \u00a0\u00a0$820,885 \u00a0\u00a0$404,831 \u00a0 \u00a0$ 343,835 \u00a0 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$ 1.41 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(15) \u00a0\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u00a0\u2014 \u00a0\u00a06,061 \u00a0 \u00a06,061 \u00a0 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0432 \u00a0\u00a0(12,504) \u00a0\u00a012,936 \u00a0 \u00a012,936 \u00a0 \u00a03,264 \u00a0\u00a0\u2014 \u00a0\u00a09,672 \u00a0\u00a00.05 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,109) \u00a0\u00a025,109 \u00a0 \u00a025,109 \u00a0 \u00a06,276 \u00a0\u00a0(437) \u00a0\u00a018,396 \u00a0\u00a00.09 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(58,585) \u00a0\u00a058,585 \u00a0 \u00a058,585 \u00a0 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638) \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(22) \u00a0\u00a0(1,833) \u00a0\u00a0(1,811) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n$1232209 $724687 $507522 $ 468701 $88295 $ (99) $380307 $ 185\n8", "page_label": "8", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b848607e-c6c6-4df1-9963-86d9f547f5a3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f81ce044715b46a6850e571d423feecf88edab17c590eba7d6f7c1ec9e4c5c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44939be8-2b11-4e52-b9ba-8dd61a73038c", "node_type": "1", "metadata": {"window": "2019.\n\u00a0\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income \n Tax Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er Shar e\u00a0\nGAAP \u00a0$1,225,716 \u00a0\u00a0$820,885 \u00a0\u00a0$404,831 \u00a0 \u00a0$ 343,835 \u00a0 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$ 1.41 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(15) \u00a0\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u00a0\u2014 \u00a0\u00a06,061 \u00a0 \u00a06,061 \u00a0 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0432 \u00a0\u00a0(12,504) \u00a0\u00a012,936 \u00a0 \u00a012,936 \u00a0 \u00a03,264 \u00a0\u00a0\u2014 \u00a0\u00a09,672 \u00a0\u00a00.05 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,109) \u00a0\u00a025,109 \u00a0 \u00a025,109 \u00a0 \u00a06,276 \u00a0\u00a0(437) \u00a0\u00a018,396 \u00a0\u00a00.09 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(58,585) \u00a0\u00a058,585 \u00a0 \u00a058,585 \u00a0 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638) \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(22) \u00a0\u00a0(1,833) \u00a0\u00a0(1,811) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n$1232209 $724687 $507522 $ 468701 $88295 $ (99) $380307 $ 185\n8", "original_text": "2019.\n\u00a0\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca191f8dfb7d58ed1a83146a73af6e720f68cebad5b7780684388f75501624e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ad84de5-a231-4002-8d42-63ffea721df8", "node_type": "1", "metadata": {"window": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n"}, "hash": "1f9d8aedd39760457eeb8feeba1d78f72dc73b0f19c6947e4e12e3a814dabd6c", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income \n Tax Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er Shar e\u00a0\nGAAP \u00a0$1,225,716 \u00a0\u00a0$820,885 \u00a0\u00a0$404,831 \u00a0 \u00a0$ 343,835 \u00a0 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$ 1.41 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(15) \u00a0\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u00a0\u2014 \u00a0\u00a06,061 \u00a0 \u00a06,061 \u00a0 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0432 \u00a0\u00a0(12,504) \u00a0\u00a012,936 \u00a0 \u00a012,936 \u00a0 \u00a03,264 \u00a0\u00a0\u2014 \u00a0\u00a09,672 \u00a0\u00a00.05 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,109) \u00a0\u00a025,109 \u00a0 \u00a025,109 \u00a0 \u00a06,276 \u00a0\u00a0(437) \u00a0\u00a018,396 \u00a0\u00a00.09 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(58,585) \u00a0\u00a058,585 \u00a0 \u00a058,585 \u00a0 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638) \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(22) \u00a0\u00a0(1,833) \u00a0\u00a0(1,811) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n$1232209 $724687 $507522 $ 468701 $88295 $ (99) $380307 $ 185\n8", "start_char_idx": 10, "end_char_idx": 1565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ad84de5-a231-4002-8d42-63ffea721df8": {"__data__": {"id_": "3ad84de5-a231-4002-8d42-63ffea721df8", "embedding": null, "metadata": {"window": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "9", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82064b6d-623d-4086-abd7-c97481b0d37a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6813debf5103a0636fd192cda12d0ffbfd97586a8d3b82084252064c0b088aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd1ab706-3e10-4013-b5e1-89c1d113c7f9", "node_type": "1", "metadata": {"window": "2019.\n\u00a0\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income \n Tax Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er Shar e\u00a0\nGAAP \u00a0$1,225,716 \u00a0\u00a0$820,885 \u00a0\u00a0$404,831 \u00a0 \u00a0$ 343,835 \u00a0 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$ 1.41 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(15) \u00a0\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u00a0\u2014 \u00a0\u00a06,061 \u00a0 \u00a06,061 \u00a0 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0432 \u00a0\u00a0(12,504) \u00a0\u00a012,936 \u00a0 \u00a012,936 \u00a0 \u00a03,264 \u00a0\u00a0\u2014 \u00a0\u00a09,672 \u00a0\u00a00.05 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,109) \u00a0\u00a025,109 \u00a0 \u00a025,109 \u00a0 \u00a06,276 \u00a0\u00a0(437) \u00a0\u00a018,396 \u00a0\u00a00.09 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(58,585) \u00a0\u00a058,585 \u00a0 \u00a058,585 \u00a0 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638) \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(22) \u00a0\u00a0(1,833) \u00a0\u00a0(1,811) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n$1232209 $724687 $507522 $ 468701 $88295 $ (99) $380307 $ 185\n8", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income \n Tax Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er Shar e\u00a0\nGAAP \u00a0$1,225,716 \u00a0\u00a0$820,885 \u00a0\u00a0$404,831 \u00a0 \u00a0$ 343,835 \u00a0 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$ 1.41 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(15) \u00a0\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u00a0\u2014 \u00a0\u00a06,061 \u00a0 \u00a06,061 \u00a0 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0432 \u00a0\u00a0(12,504) \u00a0\u00a012,936 \u00a0 \u00a012,936 \u00a0 \u00a03,264 \u00a0\u00a0\u2014 \u00a0\u00a09,672 \u00a0\u00a00.05 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,109) \u00a0\u00a025,109 \u00a0 \u00a025,109 \u00a0 \u00a06,276 \u00a0\u00a0(437) \u00a0\u00a018,396 \u00a0\u00a00.09 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(58,585) \u00a0\u00a058,585 \u00a0 \u00a058,585 \u00a0 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638) \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(22) \u00a0\u00a0(1,833) \u00a0\u00a0(1,811) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n$1232209 $724687 $507522 $ 468701 $88295 $ (99) $380307 $ 185\n8", "page_label": "8", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5a12914d6906a54fd30380c596d4e943b12e62f80a1e7aa51654752a2e358ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e43c5b66-0996-447f-a490-387ccf77d556", "node_type": "1", "metadata": {"window": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n"}, "hash": "33d96726e6ddf99f83bfe87b14743312e6a565f5569dd881c3f5bfc1fa6a3301", "class_name": "RelatedNodeInfo"}}, "text": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e43c5b66-0996-447f-a490-387ccf77d556": {"__data__": {"id_": "e43c5b66-0996-447f-a490-387ccf77d556", "embedding": null, "metadata": {"window": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "9", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82064b6d-623d-4086-abd7-c97481b0d37a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6813debf5103a0636fd192cda12d0ffbfd97586a8d3b82084252064c0b088aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ad84de5-a231-4002-8d42-63ffea721df8", "node_type": "1", "metadata": {"window": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "9", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "000bfbac7d8a9000271272342427e6470991b34c7d152a4375a41ab2d4846ced", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77dfded4-6891-4eee-a114-d7b016812b81", "node_type": "1", "metadata": {"window": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9"}, "hash": "9a1db84431d94488bf9581afe4c64f8e0fb0f4c5ded0cdf9f30a011eabb7cb98", "class_name": "RelatedNodeInfo"}}, "text": "prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "start_char_idx": 159, "end_char_idx": 603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77dfded4-6891-4eee-a114-d7b016812b81": {"__data__": {"id_": "77dfded4-6891-4eee-a114-d7b016812b81", "embedding": null, "metadata": {"window": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "page_label": "9", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82064b6d-623d-4086-abd7-c97481b0d37a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6813debf5103a0636fd192cda12d0ffbfd97586a8d3b82084252064c0b088aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e43c5b66-0996-447f-a490-387ccf77d556", "node_type": "1", "metadata": {"window": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "9", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02f914519c346d3844145c25bd62fdcd494dc06e155bd231ceaad4769581c3de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed8d293a-1959-49cb-8388-aa5c5ea59cc0", "node_type": "1", "metadata": {"window": "New York\nState Opioid\nStewardship\nAct \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(149) \u00a0\u00a0\u2014 \u00a0\u00a0149 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,024) \u00a0 \u00a034,024 \u00a0\u00a034,024 \u00a0\u00a09,511 \u00a0\u00a0(440) \u00a0\u00a024,073 \u00a0\u00a00.11 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(60,006) \u00a0 \u00a060,006 \u00a0\u00a060,006 \u00a0\u00a016,329 \u00a0\u00a0\u2014 \u00a0\u00a043,677 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,848 \u00a0\u00a0\u2014 \u00a0\u00a0(3,848) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(93) \u00a0\u00a0\u2014 \u00a0\u00a093 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,229,544 \u00a0\u00a0$ 722,869 \u00a0 \u00a0$ 506,675 \u00a0\u00a0$471,096 \u00a0\u00a0$98,950 \u00a0\u00a0$ (483) \u00a0\u00a0$371,663 \u00a0\u00a0$ 1.76 \u00a0 \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.72% \u00a02.72%\nOperating expenses \u00a01.82% \u00a01.60%\nOperating income \u00a00.90% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n10", "original_text": "New York\nState Opioid\nStewardship\nAct \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(149) \u00a0\u00a0\u2014 \u00a0\u00a0149 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,024) \u00a0 \u00a034,024 \u00a0\u00a034,024 \u00a0\u00a09,511 \u00a0\u00a0(440) \u00a0\u00a024,073 \u00a0\u00a00.11 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(60,006) \u00a0 \u00a060,006 \u00a0\u00a060,006 \u00a0\u00a016,329 \u00a0\u00a0\u2014 \u00a0\u00a043,677 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,848 \u00a0\u00a0\u2014 \u00a0\u00a0(3,848) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(93) \u00a0\u00a0\u2014 \u00a0\u00a093 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,229,544 \u00a0\u00a0$ 722,869 \u00a0 \u00a0$ 506,675 \u00a0\u00a0$471,096 \u00a0\u00a0$98,950 \u00a0\u00a0$ (483) \u00a0\u00a0$371,663 \u00a0\u00a0$ 1.76 \u00a0 \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.72% \u00a02.72%\nOperating expenses \u00a01.82% \u00a01.60%\nOperating income \u00a00.90% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n"}, "hash": "1118f166f01ad40e23fe4e23066cfeefd944d6c4719d4f59c6c9637e2b561a80", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "start_char_idx": 603, "end_char_idx": 1501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed8d293a-1959-49cb-8388-aa5c5ea59cc0": {"__data__": {"id_": "ed8d293a-1959-49cb-8388-aa5c5ea59cc0", "embedding": null, "metadata": {"window": "New York\nState Opioid\nStewardship\nAct \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(149) \u00a0\u00a0\u2014 \u00a0\u00a0149 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,024) \u00a0 \u00a034,024 \u00a0\u00a034,024 \u00a0\u00a09,511 \u00a0\u00a0(440) \u00a0\u00a024,073 \u00a0\u00a00.11 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(60,006) \u00a0 \u00a060,006 \u00a0\u00a060,006 \u00a0\u00a016,329 \u00a0\u00a0\u2014 \u00a0\u00a043,677 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,848 \u00a0\u00a0\u2014 \u00a0\u00a0(3,848) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(93) \u00a0\u00a0\u2014 \u00a0\u00a093 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,229,544 \u00a0\u00a0$ 722,869 \u00a0 \u00a0$ 506,675 \u00a0\u00a0$471,096 \u00a0\u00a0$98,950 \u00a0\u00a0$ (483) \u00a0\u00a0$371,663 \u00a0\u00a0$ 1.76 \u00a0 \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.72% \u00a02.72%\nOperating expenses \u00a01.82% \u00a01.60%\nOperating income \u00a00.90% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n10", "original_text": "New York\nState Opioid\nStewardship\nAct \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(149) \u00a0\u00a0\u2014 \u00a0\u00a0149 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,024) \u00a0 \u00a034,024 \u00a0\u00a034,024 \u00a0\u00a09,511 \u00a0\u00a0(440) \u00a0\u00a024,073 \u00a0\u00a00.11 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(60,006) \u00a0 \u00a060,006 \u00a0\u00a060,006 \u00a0\u00a016,329 \u00a0\u00a0\u2014 \u00a0\u00a043,677 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,848 \u00a0\u00a0\u2014 \u00a0\u00a0(3,848) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(93) \u00a0\u00a0\u2014 \u00a0\u00a093 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,229,544 \u00a0\u00a0$ 722,869 \u00a0 \u00a0$ 506,675 \u00a0\u00a0$471,096 \u00a0\u00a0$98,950 \u00a0\u00a0$ (483) \u00a0\u00a0$371,663 \u00a0\u00a0$ 1.76 \u00a0 \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.72% \u00a02.72%\nOperating expenses \u00a01.82% \u00a01.60%\nOperating income \u00a00.90% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd42e72d-411a-4d6f-acf2-179de2e96ba0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04656d1ce318cc0e87c48ba3c750cd3593d681ca92e35dcb9c0ebf09f216dfce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77dfded4-6891-4eee-a114-d7b016812b81", "node_type": "1", "metadata": {"window": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "page_label": "9", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff9875807471123ff9b8fb84a4e30351fde2faec1594f892e93d286057ce5b8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e0d6826-5cbf-4432-a0bc-1bfc58cac9ec", "node_type": "1", "metadata": {"window": "New York\nState Opioid\nStewardship\nAct \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(149) \u00a0\u00a0\u2014 \u00a0\u00a0149 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,024) \u00a0 \u00a034,024 \u00a0\u00a034,024 \u00a0\u00a09,511 \u00a0\u00a0(440) \u00a0\u00a024,073 \u00a0\u00a00.11 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(60,006) \u00a0 \u00a060,006 \u00a0\u00a060,006 \u00a0\u00a016,329 \u00a0\u00a0\u2014 \u00a0\u00a043,677 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,848 \u00a0\u00a0\u2014 \u00a0\u00a0(3,848) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(93) \u00a0\u00a0\u2014 \u00a0\u00a093 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,229,544 \u00a0\u00a0$ 722,869 \u00a0 \u00a0$ 506,675 \u00a0\u00a0$471,096 \u00a0\u00a0$98,950 \u00a0\u00a0$ (483) \u00a0\u00a0$371,663 \u00a0\u00a0$ 1.76 \u00a0 \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.72% \u00a02.72%\nOperating expenses \u00a01.82% \u00a01.60%\nOperating income \u00a00.90% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n10"}, "hash": "78c9c60b0042f34ec28bc19e03433b9b2bcc96119abed1cda17859cb7fe5106a", "class_name": "RelatedNodeInfo"}}, "text": "New York\nState Opioid\nStewardship\nAct \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(149) \u00a0\u00a0\u2014 \u00a0\u00a0149 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,024) \u00a0 \u00a034,024 \u00a0\u00a034,024 \u00a0\u00a09,511 \u00a0\u00a0(440) \u00a0\u00a024,073 \u00a0\u00a00.11 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(60,006) \u00a0 \u00a060,006 \u00a0\u00a060,006 \u00a0\u00a016,329 \u00a0\u00a0\u2014 \u00a0\u00a043,677 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,848 \u00a0\u00a0\u2014 \u00a0\u00a0(3,848) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(93) \u00a0\u00a0\u2014 \u00a0\u00a093 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,229,544 \u00a0\u00a0$ 722,869 \u00a0 \u00a0$ 506,675 \u00a0\u00a0$471,096 \u00a0\u00a0$98,950 \u00a0\u00a0$ (483) \u00a0\u00a0$371,663 \u00a0\u00a0$ 1.76 \u00a0 \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.72% \u00a02.72%\nOperating expenses \u00a01.82% \u00a01.60%\nOperating income \u00a00.90% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 1083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e0d6826-5cbf-4432-a0bc-1bfc58cac9ec": {"__data__": {"id_": "2e0d6826-5cbf-4432-a0bc-1bfc58cac9ec", "embedding": null, "metadata": {"window": "New York\nState Opioid\nStewardship\nAct \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(149) \u00a0\u00a0\u2014 \u00a0\u00a0149 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,024) \u00a0 \u00a034,024 \u00a0\u00a034,024 \u00a0\u00a09,511 \u00a0\u00a0(440) \u00a0\u00a024,073 \u00a0\u00a00.11 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(60,006) \u00a0 \u00a060,006 \u00a0\u00a060,006 \u00a0\u00a016,329 \u00a0\u00a0\u2014 \u00a0\u00a043,677 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,848 \u00a0\u00a0\u2014 \u00a0\u00a0(3,848) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(93) \u00a0\u00a0\u2014 \u00a0\u00a093 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,229,544 \u00a0\u00a0$ 722,869 \u00a0 \u00a0$ 506,675 \u00a0\u00a0$471,096 \u00a0\u00a0$98,950 \u00a0\u00a0$ (483) \u00a0\u00a0$371,663 \u00a0\u00a0$ 1.76 \u00a0 \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.72% \u00a02.72%\nOperating expenses \u00a01.82% \u00a01.60%\nOperating income \u00a00.90% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n10", "page_label": "10", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd42e72d-411a-4d6f-acf2-179de2e96ba0", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04656d1ce318cc0e87c48ba3c750cd3593d681ca92e35dcb9c0ebf09f216dfce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed8d293a-1959-49cb-8388-aa5c5ea59cc0", "node_type": "1", "metadata": {"window": "New York\nState Opioid\nStewardship\nAct \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(149) \u00a0\u00a0\u2014 \u00a0\u00a0149 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,024) \u00a0 \u00a034,024 \u00a0\u00a034,024 \u00a0\u00a09,511 \u00a0\u00a0(440) \u00a0\u00a024,073 \u00a0\u00a00.11 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(60,006) \u00a0 \u00a060,006 \u00a0\u00a060,006 \u00a0\u00a016,329 \u00a0\u00a0\u2014 \u00a0\u00a043,677 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,848 \u00a0\u00a0\u2014 \u00a0\u00a0(3,848) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(93) \u00a0\u00a0\u2014 \u00a0\u00a093 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,229,544 \u00a0\u00a0$ 722,869 \u00a0 \u00a0$ 506,675 \u00a0\u00a0$471,096 \u00a0\u00a0$98,950 \u00a0\u00a0$ (483) \u00a0\u00a0$371,663 \u00a0\u00a0$ 1.76 \u00a0 \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.72% \u00a02.72%\nOperating expenses \u00a01.82% \u00a01.60%\nOperating income \u00a00.90% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n10", "original_text": "New York\nState Opioid\nStewardship\nAct \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(149) \u00a0\u00a0\u2014 \u00a0\u00a0149 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,024) \u00a0 \u00a034,024 \u00a0\u00a034,024 \u00a0\u00a09,511 \u00a0\u00a0(440) \u00a0\u00a024,073 \u00a0\u00a00.11 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(60,006) \u00a0 \u00a060,006 \u00a0\u00a060,006 \u00a0\u00a016,329 \u00a0\u00a0\u2014 \u00a0\u00a043,677 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,848 \u00a0\u00a0\u2014 \u00a0\u00a0(3,848) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(93) \u00a0\u00a0\u2014 \u00a0\u00a093 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,229,544 \u00a0\u00a0$ 722,869 \u00a0 \u00a0$ 506,675 \u00a0\u00a0$471,096 \u00a0\u00a0$98,950 \u00a0\u00a0$ (483) \u00a0\u00a0$371,663 \u00a0\u00a0$ 1.76 \u00a0 \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.72% \u00a02.72%\nOperating expenses \u00a01.82% \u00a01.60%\nOperating income \u00a00.90% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d322427bb01181081343f3b10bf58914c18db9eabaa99101e5f70a0d046a3e5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d14e0cb7-2acf-400e-912b-73bc6c49b1fc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \nInterest \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0$2,867,254 \u00a0\u00a0$977,783 \u00a0\u00a0$ 849,626 \u00a0 \u00a0$(595,321) \u00a0\u00a0$(7,591) \u00a0\u00a0$1,437,356 \u00a0\u00a0$ 6.95 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546) \u00a0\u00a0\u2014 \u00a0\u00a0(8,546) \u00a0\u00a0(8,546) \u00a0 \u00a0(2,100) \u00a0\u00a0\u2014 \u00a0\u00a0(6,446) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u2014 \u00a0\u00a043,195 \u00a0\u00a043,195 \u00a0 \u00a010,614 \u00a0\u00a0\u2014 \u00a0\u00a032,581 \u00a0\u00a00.16 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(49,015) \u00a0\u00a061,571 \u00a0\u00a061,571 \u00a0 \u00a015,128 \u00a0\u00a0\u2014 \u00a0\u00a046,443 \u00a0\u00a00.22 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(85,345) \u00a0\u00a085,345 \u00a0\u00a085,345 \u00a0 \u00a020,971 \u00a0\u00a0(1,308) \u00a0\u00a063,066 \u00a0\u00a00.31 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(165,626) \u00a0\u00a0165,626 \u00a0\u00a0165,626 \u00a0 \u00a040,697 \u00a0\u00a0\u2014 \u00a0\u00a0124,929 \u00a0\u00a00.60 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0 \u00a088,865 \u00a0\u00a0\u2014 \u00a0\u00a0272,787 \u00a0\u00a01.32 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0 \u00a0(2,987) \u00a0\u00a05,678 \u00a0\u00a0(3,488) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015) \u00a0\u00a0(3.58) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0$2,217,769 \u00a0\u00a0$1,674,473 \u00a0\u00a0$ 1,568,491 \u00a0 \u00a0$322,331 \u00a0\u00a0$(3,221) \u00a0\u00a0$1,242,939 \u00a0\u00a0$ 6.01 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a03.8 %\u00a02.9 %\u00a05.0 %\u00a06.6 % \u00a04.9 %\u00a0\u00a0 \u00a06.8 %\u00a09.1 % \u00a0\n\u00a0\n11", "original_text": "\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \nInterest \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0$2,867,254 \u00a0\u00a0$977,783 \u00a0\u00a0$ 849,626 \u00a0 \u00a0$(595,321) \u00a0\u00a0$(7,591) \u00a0\u00a0$1,437,356 \u00a0\u00a0$ 6.95 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546) \u00a0\u00a0\u2014 \u00a0\u00a0(8,546) \u00a0\u00a0(8,546) \u00a0 \u00a0(2,100) \u00a0\u00a0\u2014 \u00a0\u00a0(6,446) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u2014 \u00a0\u00a043,195 \u00a0\u00a043,195 \u00a0 \u00a010,614 \u00a0\u00a0\u2014 \u00a0\u00a032,581 \u00a0\u00a00.16 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(49,015) \u00a0\u00a061,571 \u00a0\u00a061,571 \u00a0 \u00a015,128 \u00a0\u00a0\u2014 \u00a0\u00a046,443 \u00a0\u00a00.22 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(85,345) \u00a0\u00a085,345 \u00a0\u00a085,345 \u00a0 \u00a020,971 \u00a0\u00a0(1,308) \u00a0\u00a063,066 \u00a0\u00a00.31 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(165,626) \u00a0\u00a0165,626 \u00a0\u00a0165,626 \u00a0 \u00a040,697 \u00a0\u00a0\u2014 \u00a0\u00a0124,929 \u00a0\u00a00.60 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0 \u00a088,865 \u00a0\u00a0\u2014 \u00a0\u00a0272,787 \u00a0\u00a01.32 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0 \u00a0(2,987) \u00a0\u00a05,678 \u00a0\u00a0(3,488) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015) \u00a0\u00a0(3.58) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0$2,217,769 \u00a0\u00a0$1,674,473 \u00a0\u00a0$ 1,568,491 \u00a0 \u00a0$322,331 \u00a0\u00a0$(3,221) \u00a0\u00a0$1,242,939 \u00a0\u00a0$ 6.01 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n"}, "hash": "01cb78cf1b4acd382632d324feff86b8902643361b4421baadc3a79f6d767ca6", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n10", "start_char_idx": 1083, "end_char_idx": 1206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d14e0cb7-2acf-400e-912b-73bc6c49b1fc": {"__data__": {"id_": "d14e0cb7-2acf-400e-912b-73bc6c49b1fc", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \nInterest \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0$2,867,254 \u00a0\u00a0$977,783 \u00a0\u00a0$ 849,626 \u00a0 \u00a0$(595,321) \u00a0\u00a0$(7,591) \u00a0\u00a0$1,437,356 \u00a0\u00a0$ 6.95 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546) \u00a0\u00a0\u2014 \u00a0\u00a0(8,546) \u00a0\u00a0(8,546) \u00a0 \u00a0(2,100) \u00a0\u00a0\u2014 \u00a0\u00a0(6,446) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u2014 \u00a0\u00a043,195 \u00a0\u00a043,195 \u00a0 \u00a010,614 \u00a0\u00a0\u2014 \u00a0\u00a032,581 \u00a0\u00a00.16 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(49,015) \u00a0\u00a061,571 \u00a0\u00a061,571 \u00a0 \u00a015,128 \u00a0\u00a0\u2014 \u00a0\u00a046,443 \u00a0\u00a00.22 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(85,345) \u00a0\u00a085,345 \u00a0\u00a085,345 \u00a0 \u00a020,971 \u00a0\u00a0(1,308) \u00a0\u00a063,066 \u00a0\u00a00.31 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(165,626) \u00a0\u00a0165,626 \u00a0\u00a0165,626 \u00a0 \u00a040,697 \u00a0\u00a0\u2014 \u00a0\u00a0124,929 \u00a0\u00a00.60 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0 \u00a088,865 \u00a0\u00a0\u2014 \u00a0\u00a0272,787 \u00a0\u00a01.32 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0 \u00a0(2,987) \u00a0\u00a05,678 \u00a0\u00a0(3,488) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015) \u00a0\u00a0(3.58) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0$2,217,769 \u00a0\u00a0$1,674,473 \u00a0\u00a0$ 1,568,491 \u00a0 \u00a0$322,331 \u00a0\u00a0$(3,221) \u00a0\u00a0$1,242,939 \u00a0\u00a0$ 6.01 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a03.8 %\u00a02.9 %\u00a05.0 %\u00a06.6 % \u00a04.9 %\u00a0\u00a0 \u00a06.8 %\u00a09.1 % \u00a0\n\u00a0\n11", "original_text": "\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \nInterest \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0$2,867,254 \u00a0\u00a0$977,783 \u00a0\u00a0$ 849,626 \u00a0 \u00a0$(595,321) \u00a0\u00a0$(7,591) \u00a0\u00a0$1,437,356 \u00a0\u00a0$ 6.95 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546) \u00a0\u00a0\u2014 \u00a0\u00a0(8,546) \u00a0\u00a0(8,546) \u00a0 \u00a0(2,100) \u00a0\u00a0\u2014 \u00a0\u00a0(6,446) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u2014 \u00a0\u00a043,195 \u00a0\u00a043,195 \u00a0 \u00a010,614 \u00a0\u00a0\u2014 \u00a0\u00a032,581 \u00a0\u00a00.16 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(49,015) \u00a0\u00a061,571 \u00a0\u00a061,571 \u00a0 \u00a015,128 \u00a0\u00a0\u2014 \u00a0\u00a046,443 \u00a0\u00a00.22 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(85,345) \u00a0\u00a085,345 \u00a0\u00a085,345 \u00a0 \u00a020,971 \u00a0\u00a0(1,308) \u00a0\u00a063,066 \u00a0\u00a00.31 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(165,626) \u00a0\u00a0165,626 \u00a0\u00a0165,626 \u00a0 \u00a040,697 \u00a0\u00a0\u2014 \u00a0\u00a0124,929 \u00a0\u00a00.60 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0 \u00a088,865 \u00a0\u00a0\u2014 \u00a0\u00a0272,787 \u00a0\u00a01.32 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0 \u00a0(2,987) \u00a0\u00a05,678 \u00a0\u00a0(3,488) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015) \u00a0\u00a0(3.58) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0$2,217,769 \u00a0\u00a0$1,674,473 \u00a0\u00a0$ 1,568,491 \u00a0 \u00a0$322,331 \u00a0\u00a0$(3,221) \u00a0\u00a0$1,242,939 \u00a0\u00a0$ 6.01 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "11", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fac4174-b67d-4b9e-8bf6-ba77db9fddc8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0000a6e0b8d82b17bab90acf94557a8cf9b04b03c71f3747ebea3b7a7f5c5c6a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e0d6826-5cbf-4432-a0bc-1bfc58cac9ec", "node_type": "1", "metadata": {"window": "New York\nState Opioid\nStewardship\nAct \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(149) \u00a0\u00a0\u2014 \u00a0\u00a0149 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,024) \u00a0 \u00a034,024 \u00a0\u00a034,024 \u00a0\u00a09,511 \u00a0\u00a0(440) \u00a0\u00a024,073 \u00a0\u00a00.11 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(60,006) \u00a0 \u00a060,006 \u00a0\u00a060,006 \u00a0\u00a016,329 \u00a0\u00a0\u2014 \u00a0\u00a043,677 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,848 \u00a0\u00a0\u2014 \u00a0\u00a0(3,848) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(93) \u00a0\u00a0\u2014 \u00a0\u00a093 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,229,544 \u00a0\u00a0$ 722,869 \u00a0 \u00a0$ 506,675 \u00a0\u00a0$471,096 \u00a0\u00a0$98,950 \u00a0\u00a0$ (483) \u00a0\u00a0$371,663 \u00a0\u00a0$ 1.76 \u00a0 \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.72% \u00a02.72%\nOperating expenses \u00a01.82% \u00a01.60%\nOperating income \u00a00.90% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n10", "page_label": "10", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "954ae588168746ac342009e13cc196147b1b34d314fddcee598d702e7f59fa09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f66226d-e101-4790-b0fb-72ca7cf48a35", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \nInterest \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0$2,867,254 \u00a0\u00a0$977,783 \u00a0\u00a0$ 849,626 \u00a0 \u00a0$(595,321) \u00a0\u00a0$(7,591) \u00a0\u00a0$1,437,356 \u00a0\u00a0$ 6.95 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546) \u00a0\u00a0\u2014 \u00a0\u00a0(8,546) \u00a0\u00a0(8,546) \u00a0 \u00a0(2,100) \u00a0\u00a0\u2014 \u00a0\u00a0(6,446) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u2014 \u00a0\u00a043,195 \u00a0\u00a043,195 \u00a0 \u00a010,614 \u00a0\u00a0\u2014 \u00a0\u00a032,581 \u00a0\u00a00.16 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(49,015) \u00a0\u00a061,571 \u00a0\u00a061,571 \u00a0 \u00a015,128 \u00a0\u00a0\u2014 \u00a0\u00a046,443 \u00a0\u00a00.22 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(85,345) \u00a0\u00a085,345 \u00a0\u00a085,345 \u00a0 \u00a020,971 \u00a0\u00a0(1,308) \u00a0\u00a063,066 \u00a0\u00a00.31 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(165,626) \u00a0\u00a0165,626 \u00a0\u00a0165,626 \u00a0 \u00a040,697 \u00a0\u00a0\u2014 \u00a0\u00a0124,929 \u00a0\u00a00.60 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0 \u00a088,865 \u00a0\u00a0\u2014 \u00a0\u00a0272,787 \u00a0\u00a01.32 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0 \u00a0(2,987) \u00a0\u00a05,678 \u00a0\u00a0(3,488) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015) \u00a0\u00a0(3.58) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0$2,217,769 \u00a0\u00a0$1,674,473 \u00a0\u00a0$ 1,568,491 \u00a0 \u00a0$322,331 \u00a0\u00a0$(3,221) \u00a0\u00a0$1,242,939 \u00a0\u00a0$ 6.01 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a03.8 %\u00a02.9 %\u00a05.0 %\u00a06.6 % \u00a04.9 %\u00a0\u00a0 \u00a06.8 %\u00a09.1 % \u00a0\n\u00a0\n11", "original_text": "prior year\nperiod \u00a03.8 %\u00a02.9 %\u00a05.0 %\u00a06.6 % \u00a04.9 %\u00a0\u00a0 \u00a06.8 %\u00a09.1 % \u00a0\n\u00a0\n11"}, "hash": "0adbf3f9e8630d1c5d25dfd123574fe4a3f0e3f8ff0c98323b9a462c36dd6696", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \nInterest \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0$2,867,254 \u00a0\u00a0$977,783 \u00a0\u00a0$ 849,626 \u00a0 \u00a0$(595,321) \u00a0\u00a0$(7,591) \u00a0\u00a0$1,437,356 \u00a0\u00a0$ 6.95 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546) \u00a0\u00a0\u2014 \u00a0\u00a0(8,546) \u00a0\u00a0(8,546) \u00a0 \u00a0(2,100) \u00a0\u00a0\u2014 \u00a0\u00a0(6,446) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u2014 \u00a0\u00a043,195 \u00a0\u00a043,195 \u00a0 \u00a010,614 \u00a0\u00a0\u2014 \u00a0\u00a032,581 \u00a0\u00a00.16 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(49,015) \u00a0\u00a061,571 \u00a0\u00a061,571 \u00a0 \u00a015,128 \u00a0\u00a0\u2014 \u00a0\u00a046,443 \u00a0\u00a00.22 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(85,345) \u00a0\u00a085,345 \u00a0\u00a085,345 \u00a0 \u00a020,971 \u00a0\u00a0(1,308) \u00a0\u00a063,066 \u00a0\u00a00.31 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(165,626) \u00a0\u00a0165,626 \u00a0\u00a0165,626 \u00a0 \u00a040,697 \u00a0\u00a0\u2014 \u00a0\u00a0124,929 \u00a0\u00a00.60 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0 \u00a088,865 \u00a0\u00a0\u2014 \u00a0\u00a0272,787 \u00a0\u00a01.32 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0 \u00a0(2,987) \u00a0\u00a05,678 \u00a0\u00a0(3,488) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015) \u00a0\u00a0(3.58) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0$2,217,769 \u00a0\u00a0$1,674,473 \u00a0\u00a0$ 1,568,491 \u00a0 \u00a0$322,331 \u00a0\u00a0$(3,221) \u00a0\u00a0$1,242,939 \u00a0\u00a0$ 6.01 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 1767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f66226d-e101-4790-b0fb-72ca7cf48a35": {"__data__": {"id_": "6f66226d-e101-4790-b0fb-72ca7cf48a35", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \nInterest \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0$2,867,254 \u00a0\u00a0$977,783 \u00a0\u00a0$ 849,626 \u00a0 \u00a0$(595,321) \u00a0\u00a0$(7,591) \u00a0\u00a0$1,437,356 \u00a0\u00a0$ 6.95 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546) \u00a0\u00a0\u2014 \u00a0\u00a0(8,546) \u00a0\u00a0(8,546) \u00a0 \u00a0(2,100) \u00a0\u00a0\u2014 \u00a0\u00a0(6,446) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u2014 \u00a0\u00a043,195 \u00a0\u00a043,195 \u00a0 \u00a010,614 \u00a0\u00a0\u2014 \u00a0\u00a032,581 \u00a0\u00a00.16 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(49,015) \u00a0\u00a061,571 \u00a0\u00a061,571 \u00a0 \u00a015,128 \u00a0\u00a0\u2014 \u00a0\u00a046,443 \u00a0\u00a00.22 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(85,345) \u00a0\u00a085,345 \u00a0\u00a085,345 \u00a0 \u00a020,971 \u00a0\u00a0(1,308) \u00a0\u00a063,066 \u00a0\u00a00.31 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(165,626) \u00a0\u00a0165,626 \u00a0\u00a0165,626 \u00a0 \u00a040,697 \u00a0\u00a0\u2014 \u00a0\u00a0124,929 \u00a0\u00a00.60 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0 \u00a088,865 \u00a0\u00a0\u2014 \u00a0\u00a0272,787 \u00a0\u00a01.32 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0 \u00a0(2,987) \u00a0\u00a05,678 \u00a0\u00a0(3,488) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015) \u00a0\u00a0(3.58) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0$2,217,769 \u00a0\u00a0$1,674,473 \u00a0\u00a0$ 1,568,491 \u00a0 \u00a0$322,331 \u00a0\u00a0$(3,221) \u00a0\u00a0$1,242,939 \u00a0\u00a0$ 6.01 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a03.8 %\u00a02.9 %\u00a05.0 %\u00a06.6 % \u00a04.9 %\u00a0\u00a0 \u00a06.8 %\u00a09.1 % \u00a0\n\u00a0\n11", "original_text": "prior year\nperiod \u00a03.8 %\u00a02.9 %\u00a05.0 %\u00a06.6 % \u00a04.9 %\u00a0\u00a0 \u00a06.8 %\u00a09.1 % \u00a0\n\u00a0\n11", "page_label": "11", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2fac4174-b67d-4b9e-8bf6-ba77db9fddc8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0000a6e0b8d82b17bab90acf94557a8cf9b04b03c71f3747ebea3b7a7f5c5c6a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d14e0cb7-2acf-400e-912b-73bc6c49b1fc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \nInterest \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0$2,867,254 \u00a0\u00a0$977,783 \u00a0\u00a0$ 849,626 \u00a0 \u00a0$(595,321) \u00a0\u00a0$(7,591) \u00a0\u00a0$1,437,356 \u00a0\u00a0$ 6.95 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546) \u00a0\u00a0\u2014 \u00a0\u00a0(8,546) \u00a0\u00a0(8,546) \u00a0 \u00a0(2,100) \u00a0\u00a0\u2014 \u00a0\u00a0(6,446) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u2014 \u00a0\u00a043,195 \u00a0\u00a043,195 \u00a0 \u00a010,614 \u00a0\u00a0\u2014 \u00a0\u00a032,581 \u00a0\u00a00.16 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(49,015) \u00a0\u00a061,571 \u00a0\u00a061,571 \u00a0 \u00a015,128 \u00a0\u00a0\u2014 \u00a0\u00a046,443 \u00a0\u00a00.22 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(85,345) \u00a0\u00a085,345 \u00a0\u00a085,345 \u00a0 \u00a020,971 \u00a0\u00a0(1,308) \u00a0\u00a063,066 \u00a0\u00a00.31 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(165,626) \u00a0\u00a0165,626 \u00a0\u00a0165,626 \u00a0 \u00a040,697 \u00a0\u00a0\u2014 \u00a0\u00a0124,929 \u00a0\u00a00.60 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0 \u00a088,865 \u00a0\u00a0\u2014 \u00a0\u00a0272,787 \u00a0\u00a01.32 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0 \u00a0(2,987) \u00a0\u00a05,678 \u00a0\u00a0(3,488) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015) \u00a0\u00a0(3.58) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0$2,217,769 \u00a0\u00a0$1,674,473 \u00a0\u00a0$ 1,568,491 \u00a0 \u00a0$322,331 \u00a0\u00a0$(3,221) \u00a0\u00a0$1,242,939 \u00a0\u00a0$ 6.01 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a03.8 %\u00a02.9 %\u00a05.0 %\u00a06.6 % \u00a04.9 %\u00a0\u00a0 \u00a06.8 %\u00a09.1 % \u00a0\n\u00a0\n11", "original_text": "\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \nInterest \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0$2,867,254 \u00a0\u00a0$977,783 \u00a0\u00a0$ 849,626 \u00a0 \u00a0$(595,321) \u00a0\u00a0$(7,591) \u00a0\u00a0$1,437,356 \u00a0\u00a0$ 6.95 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546) \u00a0\u00a0\u2014 \u00a0\u00a0(8,546) \u00a0\u00a0(8,546) \u00a0 \u00a0(2,100) \u00a0\u00a0\u2014 \u00a0\u00a0(6,446) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u2014 \u00a0\u00a043,195 \u00a0\u00a043,195 \u00a0 \u00a010,614 \u00a0\u00a0\u2014 \u00a0\u00a032,581 \u00a0\u00a00.16 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(49,015) \u00a0\u00a061,571 \u00a0\u00a061,571 \u00a0 \u00a015,128 \u00a0\u00a0\u2014 \u00a0\u00a046,443 \u00a0\u00a00.22 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(85,345) \u00a0\u00a085,345 \u00a0\u00a085,345 \u00a0 \u00a020,971 \u00a0\u00a0(1,308) \u00a0\u00a063,066 \u00a0\u00a00.31 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(165,626) \u00a0\u00a0165,626 \u00a0\u00a0165,626 \u00a0 \u00a040,697 \u00a0\u00a0\u2014 \u00a0\u00a0124,929 \u00a0\u00a00.60 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0 \u00a088,865 \u00a0\u00a0\u2014 \u00a0\u00a0272,787 \u00a0\u00a01.32 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0 \u00a0(2,987) \u00a0\u00a05,678 \u00a0\u00a0(3,488) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015) \u00a0\u00a0(3.58) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0$2,217,769 \u00a0\u00a0$1,674,473 \u00a0\u00a0$ 1,568,491 \u00a0 \u00a0$322,331 \u00a0\u00a0$(3,221) \u00a0\u00a0$1,242,939 \u00a0\u00a0$ 6.01 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "11", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "338c0d904b2c94c5b592f3d65495615e7d7c11d4433a9daa4723b15e18f678ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f7edfa1-69f3-4eff-8ac8-8ee5720cd073", "node_type": "1", "metadata": {"window": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n"}, "hash": "f07876a23138507fcc53e91c32e0e910f98f586f92efa8fc6b45a72e071477e6", "class_name": "RelatedNodeInfo"}}, "text": "prior year\nperiod \u00a03.8 %\u00a02.9 %\u00a05.0 %\u00a06.6 % \u00a04.9 %\u00a0\u00a0 \u00a06.8 %\u00a09.1 % \u00a0\n\u00a0\n11", "start_char_idx": 1767, "end_char_idx": 1838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f7edfa1-69f3-4eff-8ac8-8ee5720cd073": {"__data__": {"id_": "5f7edfa1-69f3-4eff-8ac8-8ee5720cd073", "embedding": null, "metadata": {"window": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78dafa05-72a0-4f55-9ecf-9c84d83ac748", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81e6193c4318ffa4cecd890226217c28aa3bd172f58092d373b2c519c4981818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f66226d-e101-4790-b0fb-72ca7cf48a35", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \nInterest \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0$2,867,254 \u00a0\u00a0$977,783 \u00a0\u00a0$ 849,626 \u00a0 \u00a0$(595,321) \u00a0\u00a0$(7,591) \u00a0\u00a0$1,437,356 \u00a0\u00a0$ 6.95 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546) \u00a0\u00a0\u2014 \u00a0\u00a0(8,546) \u00a0\u00a0(8,546) \u00a0 \u00a0(2,100) \u00a0\u00a0\u2014 \u00a0\u00a0(6,446) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u2014 \u00a0\u00a043,195 \u00a0\u00a043,195 \u00a0 \u00a010,614 \u00a0\u00a0\u2014 \u00a0\u00a032,581 \u00a0\u00a00.16 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(49,015) \u00a0\u00a061,571 \u00a0\u00a061,571 \u00a0 \u00a015,128 \u00a0\u00a0\u2014 \u00a0\u00a046,443 \u00a0\u00a00.22 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(85,345) \u00a0\u00a085,345 \u00a0\u00a085,345 \u00a0 \u00a020,971 \u00a0\u00a0(1,308) \u00a0\u00a063,066 \u00a0\u00a00.31 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(165,626) \u00a0\u00a0165,626 \u00a0\u00a0165,626 \u00a0 \u00a040,697 \u00a0\u00a0\u2014 \u00a0\u00a0124,929 \u00a0\u00a00.60 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0 \u00a088,865 \u00a0\u00a0\u2014 \u00a0\u00a0272,787 \u00a0\u00a01.32 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0 \u00a0(2,987) \u00a0\u00a05,678 \u00a0\u00a0(3,488) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015) \u00a0\u00a0(3.58) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0$2,217,769 \u00a0\u00a0$1,674,473 \u00a0\u00a0$ 1,568,491 \u00a0 \u00a0$322,331 \u00a0\u00a0$(3,221) \u00a0\u00a0$1,242,939 \u00a0\u00a0$ 6.01 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a03.8 %\u00a02.9 %\u00a05.0 %\u00a06.6 % \u00a04.9 %\u00a0\u00a0 \u00a06.8 %\u00a09.1 % \u00a0\n\u00a0\n11", "original_text": "prior year\nperiod \u00a03.8 %\u00a02.9 %\u00a05.0 %\u00a06.6 % \u00a04.9 %\u00a0\u00a0 \u00a06.8 %\u00a09.1 % \u00a0\n\u00a0\n11", "page_label": "11", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22c7f1a93c887cf43ee9d04f0db14c1f59d52aae298cb96b47a5d248a78f0c14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04552432-55c9-4a63-9ed1-58a06dbf980a", "node_type": "1", "metadata": {"window": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n"}, "hash": "9ac3615397d624eff7522782d4048aa4c0aeb83ef6173a00b9c16aa99f47b688", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04552432-55c9-4a63-9ed1-58a06dbf980a": {"__data__": {"id_": "04552432-55c9-4a63-9ed1-58a06dbf980a", "embedding": null, "metadata": {"window": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78dafa05-72a0-4f55-9ecf-9c84d83ac748", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81e6193c4318ffa4cecd890226217c28aa3bd172f58092d373b2c519c4981818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f7edfa1-69f3-4eff-8ac8-8ee5720cd073", "node_type": "1", "metadata": {"window": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd2742a9b52588f3939e8e8a04b259d8b113181a2a9898310f8283cd3d29f45d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d79906c0-ed53-425c-84d6-b0e95ce9541f", "node_type": "1", "metadata": {"window": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12"}, "hash": "e23b13e4c2138d1d62a3b356031ffd64938a0944f077e35282ca97a38dafae80", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "start_char_idx": 349, "end_char_idx": 528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d79906c0-ed53-425c-84d6-b0e95ce9541f": {"__data__": {"id_": "d79906c0-ed53-425c-84d6-b0e95ce9541f", "embedding": null, "metadata": {"window": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "page_label": "12", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "78dafa05-72a0-4f55-9ecf-9c84d83ac748", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81e6193c4318ffa4cecd890226217c28aa3bd172f58092d373b2c519c4981818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04552432-55c9-4a63-9ed1-58a06dbf980a", "node_type": "1", "metadata": {"window": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca2990cabc698f17067f6a94380a133f1cdb18d88ddb9334bd21cb702a11fa00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c48b0260-3bb8-410a-a4ed-b642b9ef947d", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n13", "original_text": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n"}, "hash": "950a9f38dac25149391cc02cda3d2d9d7c4882cf925d333d9d76c9b973629819", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "start_char_idx": 528, "end_char_idx": 1587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c48b0260-3bb8-410a-a4ed-b642b9ef947d": {"__data__": {"id_": "c48b0260-3bb8-410a-a4ed-b642b9ef947d", "embedding": null, "metadata": {"window": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n13", "original_text": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n", "page_label": "13", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f13d13a-c232-4e6e-b135-f644cdeadb64", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "011c64198336034ef01a9779bcd936bcef6d2eb1f9407dc9e3efc7ef73fb1ad1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d79906c0-ed53-425c-84d6-b0e95ce9541f", "node_type": "1", "metadata": {"window": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "page_label": "12", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba67d4f785c7f6bd23a8ff1b526c3b77eb60f26dcbac2dcddb75bd7068d15259", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89c240da-2e50-4874-95ef-6c7165cb4ac8", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n13", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n"}, "hash": "bfab31339cbc43c5505ad459ad8700a48997121d7f3112180169a509d6ef9d54", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n", "start_char_idx": 0, "end_char_idx": 1081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89c240da-2e50-4874-95ef-6c7165cb4ac8": {"__data__": {"id_": "89c240da-2e50-4874-95ef-6c7165cb4ac8", "embedding": null, "metadata": {"window": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n13", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n", "page_label": "13", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f13d13a-c232-4e6e-b135-f644cdeadb64", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "011c64198336034ef01a9779bcd936bcef6d2eb1f9407dc9e3efc7ef73fb1ad1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c48b0260-3bb8-410a-a4ed-b642b9ef947d", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n13", "original_text": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n", "page_label": "13", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "340f6c148a7741bfb6901e70ff1e5e5d63234064c2b36b521bcb8d950f34a5dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a85c0113-388b-403c-b583-6289dad83352", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n"}, "hash": "256a6b60585c17f6417a7325d2c8468de88c7e8cda49b77762994310917a9933", "class_name": "RelatedNodeInfo"}}, "text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n", "start_char_idx": 1081, "end_char_idx": 1153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a85c0113-388b-403c-b583-6289dad83352": {"__data__": {"id_": "a85c0113-388b-403c-b583-6289dad83352", "embedding": null, "metadata": {"window": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f13d13a-c232-4e6e-b135-f644cdeadb64", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "011c64198336034ef01a9779bcd936bcef6d2eb1f9407dc9e3efc7ef73fb1ad1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89c240da-2e50-4874-95ef-6c7165cb4ac8", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n13", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n", "page_label": "13", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e82f4affaadf10a0004c4a87e245cb327335775dbd035ecbc84921cc737adca1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b66ac0aa-3216-4501-9cbe-7bdce0c280b4", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n13", "original_text": "AMERISOURCEBERGEN CORPORATION \n13"}, "hash": "0d46a025baa8d5884c11503c530215e4e2e24b2068dd6624b1ebd16953e23612", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "start_char_idx": 1153, "end_char_idx": 1332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b66ac0aa-3216-4501-9cbe-7bdce0c280b4": {"__data__": {"id_": "b66ac0aa-3216-4501-9cbe-7bdce0c280b4", "embedding": null, "metadata": {"window": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n13", "original_text": "AMERISOURCEBERGEN CORPORATION \n13", "page_label": "13", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f13d13a-c232-4e6e-b135-f644cdeadb64", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "011c64198336034ef01a9779bcd936bcef6d2eb1f9407dc9e3efc7ef73fb1ad1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a85c0113-388b-403c-b583-6289dad83352", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8375f885d0ce3692b7858e5fd00350004e19e5e096241e4809504e07e0435e52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8dd1933-92b1-41d9-bf6f-6b1c7e7927a2", "node_type": "1", "metadata": {"window": "SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$43,579,119 \u00a0\u00a0$43,527,552 \u00a0\u00a00.1%\nOther \u00a01,810,533 \u00a0\u00a01,734,538 \u00a0\u00a04.4%\nIntersegment eliminations \u00a0(22,875) \u00a0\u00a0(22,825) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$45,366,777 \u00a0\u00a0$45,239,265 \u00a0\u00a00.3%\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$426,643 \u00a0\u00a0$411,707 \u00a0\u00a03.6%\nOther \u00a082,875 \u00a0\u00a095,110 \u00a0\u00a0(12.9)%\nIntersegment eliminations \u00a0(1,996) \u00a0\u00a0(142) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0507,522 \u00a0\u00a0506,675 \u00a0\u00a00.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a03,480 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(6,061) \u00a0\u00a09,913 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(12,936) \u00a0\u00a0(19,344) \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,109) \u00a0\u00a0(34,024) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(58,585) \u00a0\u00a0(60,006) \u00a0\u00a0\u00a0\nOperating income \u00a0$404,831 \u00a0\u00a0$406,694 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.08% \u00a02.08% \u00a0\u00a0\nOperating expenses \u00a01.10% \u00a01.13% \u00a0\u00a0\nOperating income \u00a00.98% \u00a00.95% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.17% \u00a018.77% \u00a0\u00a0\nOperating expenses \u00a013.59% \u00a013.29% \u00a0\u00a0\nOperating income \u00a04.58% \u00a05.48% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n14", "original_text": "SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$43,579,119 \u00a0\u00a0$43,527,552 \u00a0\u00a00.1%\nOther \u00a01,810,533 \u00a0\u00a01,734,538 \u00a0\u00a04.4%\nIntersegment eliminations \u00a0(22,875) \u00a0\u00a0(22,825) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$45,366,777 \u00a0\u00a0$45,239,265 \u00a0\u00a00.3%\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$426,643 \u00a0\u00a0$411,707 \u00a0\u00a03.6%\nOther \u00a082,875 \u00a0\u00a095,110 \u00a0\u00a0(12.9)%\nIntersegment eliminations \u00a0(1,996) \u00a0\u00a0(142) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0507,522 \u00a0\u00a0506,675 \u00a0\u00a00.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a03,480 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(6,061) \u00a0\u00a09,913 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(12,936) \u00a0\u00a0(19,344) \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,109) \u00a0\u00a0(34,024) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(58,585) \u00a0\u00a0(60,006) \u00a0\u00a0\u00a0\nOperating income \u00a0$404,831 \u00a0\u00a0$406,694 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.08% \u00a02.08% \u00a0\u00a0\nOperating expenses \u00a01.10% \u00a01.13% \u00a0\u00a0\nOperating income \u00a00.98% \u00a00.95% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.17% \u00a018.77% \u00a0\u00a0\nOperating expenses \u00a013.59% \u00a013.29% \u00a0\u00a0\nOperating income \u00a04.58% \u00a05.48% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n14"}, "hash": "10dddc387360d6422adc84dddc3996f4f219b5354f73019f00cf6bbdf4bb8e98", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n13", "start_char_idx": 1332, "end_char_idx": 1365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8dd1933-92b1-41d9-bf6f-6b1c7e7927a2": {"__data__": {"id_": "f8dd1933-92b1-41d9-bf6f-6b1c7e7927a2", "embedding": null, "metadata": {"window": "SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$43,579,119 \u00a0\u00a0$43,527,552 \u00a0\u00a00.1%\nOther \u00a01,810,533 \u00a0\u00a01,734,538 \u00a0\u00a04.4%\nIntersegment eliminations \u00a0(22,875) \u00a0\u00a0(22,825) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$45,366,777 \u00a0\u00a0$45,239,265 \u00a0\u00a00.3%\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$426,643 \u00a0\u00a0$411,707 \u00a0\u00a03.6%\nOther \u00a082,875 \u00a0\u00a095,110 \u00a0\u00a0(12.9)%\nIntersegment eliminations \u00a0(1,996) \u00a0\u00a0(142) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0507,522 \u00a0\u00a0506,675 \u00a0\u00a00.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a03,480 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(6,061) \u00a0\u00a09,913 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(12,936) \u00a0\u00a0(19,344) \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,109) \u00a0\u00a0(34,024) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(58,585) \u00a0\u00a0(60,006) \u00a0\u00a0\u00a0\nOperating income \u00a0$404,831 \u00a0\u00a0$406,694 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.08% \u00a02.08% \u00a0\u00a0\nOperating expenses \u00a01.10% \u00a01.13% \u00a0\u00a0\nOperating income \u00a00.98% \u00a00.95% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.17% \u00a018.77% \u00a0\u00a0\nOperating expenses \u00a013.59% \u00a013.29% \u00a0\u00a0\nOperating income \u00a04.58% \u00a05.48% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n14", "original_text": "SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$43,579,119 \u00a0\u00a0$43,527,552 \u00a0\u00a00.1%\nOther \u00a01,810,533 \u00a0\u00a01,734,538 \u00a0\u00a04.4%\nIntersegment eliminations \u00a0(22,875) \u00a0\u00a0(22,825) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$45,366,777 \u00a0\u00a0$45,239,265 \u00a0\u00a00.3%\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$426,643 \u00a0\u00a0$411,707 \u00a0\u00a03.6%\nOther \u00a082,875 \u00a0\u00a095,110 \u00a0\u00a0(12.9)%\nIntersegment eliminations \u00a0(1,996) \u00a0\u00a0(142) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0507,522 \u00a0\u00a0506,675 \u00a0\u00a00.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a03,480 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(6,061) \u00a0\u00a09,913 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(12,936) \u00a0\u00a0(19,344) \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,109) \u00a0\u00a0(34,024) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(58,585) \u00a0\u00a0(60,006) \u00a0\u00a0\u00a0\nOperating income \u00a0$404,831 \u00a0\u00a0$406,694 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.08% \u00a02.08% \u00a0\u00a0\nOperating expenses \u00a01.10% \u00a01.13% \u00a0\u00a0\nOperating income \u00a00.98% \u00a00.95% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.17% \u00a018.77% \u00a0\u00a0\nOperating expenses \u00a013.59% \u00a013.29% \u00a0\u00a0\nOperating income \u00a04.58% \u00a05.48% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n14", "page_label": "14", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3b9e143-b08e-4d68-aadd-e7de5f60634b", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "826f2848d0b3af19f2533e6d60eb21e2e4c419692845d35f2d3a6d0654559259", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b66ac0aa-3216-4501-9cbe-7bdce0c280b4", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n13", "original_text": "AMERISOURCEBERGEN CORPORATION \n13", "page_label": "13", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d83ec7e5ac345c42cb361f728634c22997bfce7546513bba91e5aaeb0ebbde21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8bf31c0-8b0d-44f3-aae0-0079d5eb66be", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.70% \u00a02.72% \u00a0\u00a0\nOperating expenses \u00a01.81% \u00a01.82% \u00a0\u00a0\nOperating income \u00a00.89% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72% \u00a02.72% \u00a0\u00a0\nAdjusted operating expenses \u00a01.60% \u00a01.60% \u00a0\u00a0\nAdjusted operating income \u00a01.12% \u00a01.12% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$135,178,617 \u00a0\u00a0$128,948,097 \u00a0\u00a04.8%\nOther \u00a05,534,110 \u00a0\u00a05,070,905 \u00a0\u00a09.1%\nIntersegment eliminations \u00a0(63,569) \u00a0\u00a0(67,683) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,649,158 \u00a0\u00a0$133,951,319 \u00a0\u00a05.0%\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,381,434 \u00a0\u00a0$1,301,948 \u00a0\u00a06.1%\nOther \u00a0295,614 \u00a0\u00a0293,923 \u00a0\u00a00.6%\nIntersegment eliminations \u00a0(2,575) \u00a0\u00a0(698) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,674,473 \u00a0\u00a01,595,173 \u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0142,735 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(43,195) \u00a0\u00a079,747 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(61,571) \u00a0\u00a0(55,736) \u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\n15", "original_text": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.70% \u00a02.72% \u00a0\u00a0\nOperating expenses \u00a01.81% \u00a01.82% \u00a0\u00a0\nOperating income \u00a00.89% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72% \u00a02.72% \u00a0\u00a0\nAdjusted operating expenses \u00a01.60% \u00a01.60% \u00a0\u00a0\nAdjusted operating income \u00a01.12% \u00a01.12% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "e455ccfce93716abb07ee4347b6a9e4f8c30548387ed9c3f62b2138ddc9ed1d3", "class_name": "RelatedNodeInfo"}}, "text": "SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$43,579,119 \u00a0\u00a0$43,527,552 \u00a0\u00a00.1%\nOther \u00a01,810,533 \u00a0\u00a01,734,538 \u00a0\u00a04.4%\nIntersegment eliminations \u00a0(22,875) \u00a0\u00a0(22,825) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$45,366,777 \u00a0\u00a0$45,239,265 \u00a0\u00a00.3%\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$426,643 \u00a0\u00a0$411,707 \u00a0\u00a03.6%\nOther \u00a082,875 \u00a0\u00a095,110 \u00a0\u00a0(12.9)%\nIntersegment eliminations \u00a0(1,996) \u00a0\u00a0(142) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0507,522 \u00a0\u00a0506,675 \u00a0\u00a00.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a03,480 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(6,061) \u00a0\u00a09,913 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(12,936) \u00a0\u00a0(19,344) \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,109) \u00a0\u00a0(34,024) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(58,585) \u00a0\u00a0(60,006) \u00a0\u00a0\u00a0\nOperating income \u00a0$404,831 \u00a0\u00a0$406,694 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.08% \u00a02.08% \u00a0\u00a0\nOperating expenses \u00a01.10% \u00a01.13% \u00a0\u00a0\nOperating income \u00a00.98% \u00a00.95% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.17% \u00a018.77% \u00a0\u00a0\nOperating expenses \u00a013.59% \u00a013.29% \u00a0\u00a0\nOperating income \u00a04.58% \u00a05.48% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n14", "start_char_idx": 0, "end_char_idx": 1319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8bf31c0-8b0d-44f3-aae0-0079d5eb66be": {"__data__": {"id_": "a8bf31c0-8b0d-44f3-aae0-0079d5eb66be", "embedding": null, "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.70% \u00a02.72% \u00a0\u00a0\nOperating expenses \u00a01.81% \u00a01.82% \u00a0\u00a0\nOperating income \u00a00.89% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72% \u00a02.72% \u00a0\u00a0\nAdjusted operating expenses \u00a01.60% \u00a01.60% \u00a0\u00a0\nAdjusted operating income \u00a01.12% \u00a01.12% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$135,178,617 \u00a0\u00a0$128,948,097 \u00a0\u00a04.8%\nOther \u00a05,534,110 \u00a0\u00a05,070,905 \u00a0\u00a09.1%\nIntersegment eliminations \u00a0(63,569) \u00a0\u00a0(67,683) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,649,158 \u00a0\u00a0$133,951,319 \u00a0\u00a05.0%\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,381,434 \u00a0\u00a0$1,301,948 \u00a0\u00a06.1%\nOther \u00a0295,614 \u00a0\u00a0293,923 \u00a0\u00a00.6%\nIntersegment eliminations \u00a0(2,575) \u00a0\u00a0(698) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,674,473 \u00a0\u00a01,595,173 \u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0142,735 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(43,195) \u00a0\u00a079,747 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(61,571) \u00a0\u00a0(55,736) \u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\n15", "original_text": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.70% \u00a02.72% \u00a0\u00a0\nOperating expenses \u00a01.81% \u00a01.82% \u00a0\u00a0\nOperating income \u00a00.89% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72% \u00a02.72% \u00a0\u00a0\nAdjusted operating expenses \u00a01.60% \u00a01.60% \u00a0\u00a0\nAdjusted operating income \u00a01.12% \u00a01.12% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65bd7d66-d65b-4437-b407-bb11349b5661", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0862d2cf14410bf4da1181139a5d3e36f322767466601c01a5728f62793ba2b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8dd1933-92b1-41d9-bf6f-6b1c7e7927a2", "node_type": "1", "metadata": {"window": "SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$43,579,119 \u00a0\u00a0$43,527,552 \u00a0\u00a00.1%\nOther \u00a01,810,533 \u00a0\u00a01,734,538 \u00a0\u00a04.4%\nIntersegment eliminations \u00a0(22,875) \u00a0\u00a0(22,825) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$45,366,777 \u00a0\u00a0$45,239,265 \u00a0\u00a00.3%\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$426,643 \u00a0\u00a0$411,707 \u00a0\u00a03.6%\nOther \u00a082,875 \u00a0\u00a095,110 \u00a0\u00a0(12.9)%\nIntersegment eliminations \u00a0(1,996) \u00a0\u00a0(142) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0507,522 \u00a0\u00a0506,675 \u00a0\u00a00.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a03,480 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(6,061) \u00a0\u00a09,913 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(12,936) \u00a0\u00a0(19,344) \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,109) \u00a0\u00a0(34,024) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(58,585) \u00a0\u00a0(60,006) \u00a0\u00a0\u00a0\nOperating income \u00a0$404,831 \u00a0\u00a0$406,694 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.08% \u00a02.08% \u00a0\u00a0\nOperating expenses \u00a01.10% \u00a01.13% \u00a0\u00a0\nOperating income \u00a00.98% \u00a00.95% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.17% \u00a018.77% \u00a0\u00a0\nOperating expenses \u00a013.59% \u00a013.29% \u00a0\u00a0\nOperating income \u00a04.58% \u00a05.48% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n14", "original_text": "SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$43,579,119 \u00a0\u00a0$43,527,552 \u00a0\u00a00.1%\nOther \u00a01,810,533 \u00a0\u00a01,734,538 \u00a0\u00a04.4%\nIntersegment eliminations \u00a0(22,875) \u00a0\u00a0(22,825) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$45,366,777 \u00a0\u00a0$45,239,265 \u00a0\u00a00.3%\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$426,643 \u00a0\u00a0$411,707 \u00a0\u00a03.6%\nOther \u00a082,875 \u00a0\u00a095,110 \u00a0\u00a0(12.9)%\nIntersegment eliminations \u00a0(1,996) \u00a0\u00a0(142) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0507,522 \u00a0\u00a0506,675 \u00a0\u00a00.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a03,480 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(6,061) \u00a0\u00a09,913 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(12,936) \u00a0\u00a0(19,344) \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,109) \u00a0\u00a0(34,024) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(58,585) \u00a0\u00a0(60,006) \u00a0\u00a0\u00a0\nOperating income \u00a0$404,831 \u00a0\u00a0$406,694 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.08% \u00a02.08% \u00a0\u00a0\nOperating expenses \u00a01.10% \u00a01.13% \u00a0\u00a0\nOperating income \u00a00.98% \u00a00.95% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.17% \u00a018.77% \u00a0\u00a0\nOperating expenses \u00a013.59% \u00a013.29% \u00a0\u00a0\nOperating income \u00a04.58% \u00a05.48% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n14", "page_label": "14", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8d26f16459b1651aa4bc9f14f92966b9345f57d84e1a579599709a1fb2dfb74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e22ef0b-1020-4bc1-abb8-2ac626ed3fc2", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.70% \u00a02.72% \u00a0\u00a0\nOperating expenses \u00a01.81% \u00a01.82% \u00a0\u00a0\nOperating income \u00a00.89% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72% \u00a02.72% \u00a0\u00a0\nAdjusted operating expenses \u00a01.60% \u00a01.60% \u00a0\u00a0\nAdjusted operating income \u00a01.12% \u00a01.12% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$135,178,617 \u00a0\u00a0$128,948,097 \u00a0\u00a04.8%\nOther \u00a05,534,110 \u00a0\u00a05,070,905 \u00a0\u00a09.1%\nIntersegment eliminations \u00a0(63,569) \u00a0\u00a0(67,683) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,649,158 \u00a0\u00a0$133,951,319 \u00a0\u00a05.0%\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,381,434 \u00a0\u00a0$1,301,948 \u00a0\u00a06.1%\nOther \u00a0295,614 \u00a0\u00a0293,923 \u00a0\u00a00.6%\nIntersegment eliminations \u00a0(2,575) \u00a0\u00a0(698) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,674,473 \u00a0\u00a01,595,173 \u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0142,735 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(43,195) \u00a0\u00a079,747 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(61,571) \u00a0\u00a0(55,736) \u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\n15", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$135,178,617 \u00a0\u00a0$128,948,097 \u00a0\u00a04.8%\nOther \u00a05,534,110 \u00a0\u00a05,070,905 \u00a0\u00a09.1%\nIntersegment eliminations \u00a0(63,569) \u00a0\u00a0(67,683) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,649,158 \u00a0\u00a0$133,951,319 \u00a0\u00a05.0%\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,381,434 \u00a0\u00a0$1,301,948 \u00a0\u00a06.1%\nOther \u00a0295,614 \u00a0\u00a0293,923 \u00a0\u00a00.6%\nIntersegment eliminations \u00a0(2,575) \u00a0\u00a0(698) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,674,473 \u00a0\u00a01,595,173 \u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0142,735 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(43,195) \u00a0\u00a079,747 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(61,571) \u00a0\u00a0(55,736) \u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\n15"}, "hash": "0c0ebe16266de5532826877bbbb0fae8b62958755cc13d8f80d5b4fa8d69ce48", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.70% \u00a02.72% \u00a0\u00a0\nOperating expenses \u00a01.81% \u00a01.82% \u00a0\u00a0\nOperating income \u00a00.89% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72% \u00a02.72% \u00a0\u00a0\nAdjusted operating expenses \u00a01.60% \u00a01.60% \u00a0\u00a0\nAdjusted operating income \u00a01.12% \u00a01.12% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e22ef0b-1020-4bc1-abb8-2ac626ed3fc2": {"__data__": {"id_": "2e22ef0b-1020-4bc1-abb8-2ac626ed3fc2", "embedding": null, "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.70% \u00a02.72% \u00a0\u00a0\nOperating expenses \u00a01.81% \u00a01.82% \u00a0\u00a0\nOperating income \u00a00.89% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72% \u00a02.72% \u00a0\u00a0\nAdjusted operating expenses \u00a01.60% \u00a01.60% \u00a0\u00a0\nAdjusted operating income \u00a01.12% \u00a01.12% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$135,178,617 \u00a0\u00a0$128,948,097 \u00a0\u00a04.8%\nOther \u00a05,534,110 \u00a0\u00a05,070,905 \u00a0\u00a09.1%\nIntersegment eliminations \u00a0(63,569) \u00a0\u00a0(67,683) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,649,158 \u00a0\u00a0$133,951,319 \u00a0\u00a05.0%\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,381,434 \u00a0\u00a0$1,301,948 \u00a0\u00a06.1%\nOther \u00a0295,614 \u00a0\u00a0293,923 \u00a0\u00a00.6%\nIntersegment eliminations \u00a0(2,575) \u00a0\u00a0(698) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,674,473 \u00a0\u00a01,595,173 \u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0142,735 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(43,195) \u00a0\u00a079,747 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(61,571) \u00a0\u00a0(55,736) \u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\n15", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$135,178,617 \u00a0\u00a0$128,948,097 \u00a0\u00a04.8%\nOther \u00a05,534,110 \u00a0\u00a05,070,905 \u00a0\u00a09.1%\nIntersegment eliminations \u00a0(63,569) \u00a0\u00a0(67,683) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,649,158 \u00a0\u00a0$133,951,319 \u00a0\u00a05.0%\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,381,434 \u00a0\u00a0$1,301,948 \u00a0\u00a06.1%\nOther \u00a0295,614 \u00a0\u00a0293,923 \u00a0\u00a00.6%\nIntersegment eliminations \u00a0(2,575) \u00a0\u00a0(698) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,674,473 \u00a0\u00a01,595,173 \u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0142,735 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(43,195) \u00a0\u00a079,747 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(61,571) \u00a0\u00a0(55,736) \u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\n15", "page_label": "15", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65bd7d66-d65b-4437-b407-bb11349b5661", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0862d2cf14410bf4da1181139a5d3e36f322767466601c01a5728f62793ba2b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8bf31c0-8b0d-44f3-aae0-0079d5eb66be", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.70% \u00a02.72% \u00a0\u00a0\nOperating expenses \u00a01.81% \u00a01.82% \u00a0\u00a0\nOperating income \u00a00.89% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72% \u00a02.72% \u00a0\u00a0\nAdjusted operating expenses \u00a01.60% \u00a01.60% \u00a0\u00a0\nAdjusted operating income \u00a01.12% \u00a01.12% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$135,178,617 \u00a0\u00a0$128,948,097 \u00a0\u00a04.8%\nOther \u00a05,534,110 \u00a0\u00a05,070,905 \u00a0\u00a09.1%\nIntersegment eliminations \u00a0(63,569) \u00a0\u00a0(67,683) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,649,158 \u00a0\u00a0$133,951,319 \u00a0\u00a05.0%\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,381,434 \u00a0\u00a0$1,301,948 \u00a0\u00a06.1%\nOther \u00a0295,614 \u00a0\u00a0293,923 \u00a0\u00a00.6%\nIntersegment eliminations \u00a0(2,575) \u00a0\u00a0(698) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,674,473 \u00a0\u00a01,595,173 \u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0142,735 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(43,195) \u00a0\u00a079,747 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(61,571) \u00a0\u00a0(55,736) \u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\n15", "original_text": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.70% \u00a02.72% \u00a0\u00a0\nOperating expenses \u00a01.81% \u00a01.82% \u00a0\u00a0\nOperating income \u00a00.89% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72% \u00a02.72% \u00a0\u00a0\nAdjusted operating expenses \u00a01.60% \u00a01.60% \u00a0\u00a0\nAdjusted operating income \u00a01.12% \u00a01.12% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ba9c0f3232a3d9c9e57ba717a7f0f5392442b0d3b7b1103f41c4a013c1c0b59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28e31d3b-d6e2-43d9-9570-4827f6d81c62", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(85,345) \u00a0\u00a0(125,770) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(165,626) \u00a0\u00a0(156,067) \u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652) \u00a0\u00a0(570,000) \u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$977,783 \u00a0\u00a0$932,082 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.11% \u00a02.15% \u00a0\u00a0\nOperating expenses \u00a01.09% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.02% \u00a01.01% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.78% \u00a019.27% \u00a0\u00a0\nOperating expenses \u00a013.44% \u00a013.47% \u00a0\u00a0\nOperating income \u00a05.34% \u00a05.80% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73% \u00a02.95% \u00a0\u00a0\nOperating expenses \u00a02.04% \u00a02.26% \u00a0\u00a0\nOperating income \u00a00.70% \u00a00.70% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.77% \u00a02.80% \u00a0\u00a0\nAdjusted operating expenses \u00a01.58% \u00a01.61% \u00a0\u00a0\nAdjusted operating income \u00a01.19% \u00a01.19% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n16", "original_text": "Acquisition-related intangibles amortization \u00a0(85,345) \u00a0\u00a0(125,770) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(165,626) \u00a0\u00a0(156,067) \u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652) \u00a0\u00a0(570,000) \u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$977,783 \u00a0\u00a0$932,082 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.11% \u00a02.15% \u00a0\u00a0\nOperating expenses \u00a01.09% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.02% \u00a01.01% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.78% \u00a019.27% \u00a0\u00a0\nOperating expenses \u00a013.44% \u00a013.47% \u00a0\u00a0\nOperating income \u00a05.34% \u00a05.80% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73% \u00a02.95% \u00a0\u00a0\nOperating expenses \u00a02.04% \u00a02.26% \u00a0\u00a0\nOperating income \u00a00.70% \u00a00.70% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.77% \u00a02.80% \u00a0\u00a0\nAdjusted operating expenses \u00a01.58% \u00a01.61% \u00a0\u00a0\nAdjusted operating income \u00a01.19% \u00a01.19% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "f721942f902fb0495b3a2623b16f36a6b13b638285b6eb5f6ccc5a987511e2d4", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$135,178,617 \u00a0\u00a0$128,948,097 \u00a0\u00a04.8%\nOther \u00a05,534,110 \u00a0\u00a05,070,905 \u00a0\u00a09.1%\nIntersegment eliminations \u00a0(63,569) \u00a0\u00a0(67,683) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,649,158 \u00a0\u00a0$133,951,319 \u00a0\u00a05.0%\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,381,434 \u00a0\u00a0$1,301,948 \u00a0\u00a06.1%\nOther \u00a0295,614 \u00a0\u00a0293,923 \u00a0\u00a00.6%\nIntersegment eliminations \u00a0(2,575) \u00a0\u00a0(698) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,674,473 \u00a0\u00a01,595,173 \u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0142,735 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(43,195) \u00a0\u00a079,747 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(61,571) \u00a0\u00a0(55,736) \u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\n15", "start_char_idx": 511, "end_char_idx": 1412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28e31d3b-d6e2-43d9-9570-4827f6d81c62": {"__data__": {"id_": "28e31d3b-d6e2-43d9-9570-4827f6d81c62", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(85,345) \u00a0\u00a0(125,770) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(165,626) \u00a0\u00a0(156,067) \u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652) \u00a0\u00a0(570,000) \u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$977,783 \u00a0\u00a0$932,082 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.11% \u00a02.15% \u00a0\u00a0\nOperating expenses \u00a01.09% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.02% \u00a01.01% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.78% \u00a019.27% \u00a0\u00a0\nOperating expenses \u00a013.44% \u00a013.47% \u00a0\u00a0\nOperating income \u00a05.34% \u00a05.80% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73% \u00a02.95% \u00a0\u00a0\nOperating expenses \u00a02.04% \u00a02.26% \u00a0\u00a0\nOperating income \u00a00.70% \u00a00.70% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.77% \u00a02.80% \u00a0\u00a0\nAdjusted operating expenses \u00a01.58% \u00a01.61% \u00a0\u00a0\nAdjusted operating income \u00a01.19% \u00a01.19% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n16", "original_text": "Acquisition-related intangibles amortization \u00a0(85,345) \u00a0\u00a0(125,770) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(165,626) \u00a0\u00a0(156,067) \u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652) \u00a0\u00a0(570,000) \u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$977,783 \u00a0\u00a0$932,082 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.11% \u00a02.15% \u00a0\u00a0\nOperating expenses \u00a01.09% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.02% \u00a01.01% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.78% \u00a019.27% \u00a0\u00a0\nOperating expenses \u00a013.44% \u00a013.47% \u00a0\u00a0\nOperating income \u00a05.34% \u00a05.80% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73% \u00a02.95% \u00a0\u00a0\nOperating expenses \u00a02.04% \u00a02.26% \u00a0\u00a0\nOperating income \u00a00.70% \u00a00.70% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.77% \u00a02.80% \u00a0\u00a0\nAdjusted operating expenses \u00a01.58% \u00a01.61% \u00a0\u00a0\nAdjusted operating income \u00a01.19% \u00a01.19% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "16", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6544b14f-783d-42de-ac54-af861b6c02ef", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9434fe0fb87894a51ab6aef22d21cdb17cf54aaaa712bfe6d403eb125939a089", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e22ef0b-1020-4bc1-abb8-2ac626ed3fc2", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.70% \u00a02.72% \u00a0\u00a0\nOperating expenses \u00a01.81% \u00a01.82% \u00a0\u00a0\nOperating income \u00a00.89% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72% \u00a02.72% \u00a0\u00a0\nAdjusted operating expenses \u00a01.60% \u00a01.60% \u00a0\u00a0\nAdjusted operating income \u00a01.12% \u00a01.12% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$135,178,617 \u00a0\u00a0$128,948,097 \u00a0\u00a04.8%\nOther \u00a05,534,110 \u00a0\u00a05,070,905 \u00a0\u00a09.1%\nIntersegment eliminations \u00a0(63,569) \u00a0\u00a0(67,683) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,649,158 \u00a0\u00a0$133,951,319 \u00a0\u00a05.0%\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,381,434 \u00a0\u00a0$1,301,948 \u00a0\u00a06.1%\nOther \u00a0295,614 \u00a0\u00a0293,923 \u00a0\u00a00.6%\nIntersegment eliminations \u00a0(2,575) \u00a0\u00a0(698) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,674,473 \u00a0\u00a01,595,173 \u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0142,735 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(43,195) \u00a0\u00a079,747 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(61,571) \u00a0\u00a0(55,736) \u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\n15", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$135,178,617 \u00a0\u00a0$128,948,097 \u00a0\u00a04.8%\nOther \u00a05,534,110 \u00a0\u00a05,070,905 \u00a0\u00a09.1%\nIntersegment eliminations \u00a0(63,569) \u00a0\u00a0(67,683) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,649,158 \u00a0\u00a0$133,951,319 \u00a0\u00a05.0%\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,381,434 \u00a0\u00a0$1,301,948 \u00a0\u00a06.1%\nOther \u00a0295,614 \u00a0\u00a0293,923 \u00a0\u00a00.6%\nIntersegment eliminations \u00a0(2,575) \u00a0\u00a0(698) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,674,473 \u00a0\u00a01,595,173 \u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0142,735 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(43,195) \u00a0\u00a079,747 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(61,571) \u00a0\u00a0(55,736) \u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\n15", "page_label": "15", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2344f3bee0d3a9d20a76f00b042c35218f73490b16ffe9c8b06ffa1cc6cc9699", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6850ae5f-ae50-42b1-8330-41be1b18f522", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(85,345) \u00a0\u00a0(125,770) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(165,626) \u00a0\u00a0(156,067) \u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652) \u00a0\u00a0(570,000) \u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$977,783 \u00a0\u00a0$932,082 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.11% \u00a02.15% \u00a0\u00a0\nOperating expenses \u00a01.09% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.02% \u00a01.01% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.78% \u00a019.27% \u00a0\u00a0\nOperating expenses \u00a013.44% \u00a013.47% \u00a0\u00a0\nOperating income \u00a05.34% \u00a05.80% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73% \u00a02.95% \u00a0\u00a0\nOperating expenses \u00a02.04% \u00a02.26% \u00a0\u00a0\nOperating income \u00a00.70% \u00a00.70% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.77% \u00a02.80% \u00a0\u00a0\nAdjusted operating expenses \u00a01.58% \u00a01.61% \u00a0\u00a0\nAdjusted operating income \u00a01.19% \u00a01.19% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n16", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n16"}, "hash": "f1fd5052b56692a3291195722b7248622a0993b88b265b62a5c091c7ce8c97be", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization \u00a0(85,345) \u00a0\u00a0(125,770) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(165,626) \u00a0\u00a0(156,067) \u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652) \u00a0\u00a0(570,000) \u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$977,783 \u00a0\u00a0$932,082 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.11% \u00a02.15% \u00a0\u00a0\nOperating expenses \u00a01.09% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.02% \u00a01.01% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.78% \u00a019.27% \u00a0\u00a0\nOperating expenses \u00a013.44% \u00a013.47% \u00a0\u00a0\nOperating income \u00a05.34% \u00a05.80% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73% \u00a02.95% \u00a0\u00a0\nOperating expenses \u00a02.04% \u00a02.26% \u00a0\u00a0\nOperating income \u00a00.70% \u00a00.70% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.77% \u00a02.80% \u00a0\u00a0\nAdjusted operating expenses \u00a01.58% \u00a01.61% \u00a0\u00a0\nAdjusted operating income \u00a01.19% \u00a01.19% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 1146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6850ae5f-ae50-42b1-8330-41be1b18f522": {"__data__": {"id_": "6850ae5f-ae50-42b1-8330-41be1b18f522", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(85,345) \u00a0\u00a0(125,770) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(165,626) \u00a0\u00a0(156,067) \u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652) \u00a0\u00a0(570,000) \u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$977,783 \u00a0\u00a0$932,082 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.11% \u00a02.15% \u00a0\u00a0\nOperating expenses \u00a01.09% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.02% \u00a01.01% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.78% \u00a019.27% \u00a0\u00a0\nOperating expenses \u00a013.44% \u00a013.47% \u00a0\u00a0\nOperating income \u00a05.34% \u00a05.80% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73% \u00a02.95% \u00a0\u00a0\nOperating expenses \u00a02.04% \u00a02.26% \u00a0\u00a0\nOperating income \u00a00.70% \u00a00.70% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.77% \u00a02.80% \u00a0\u00a0\nAdjusted operating expenses \u00a01.58% \u00a01.61% \u00a0\u00a0\nAdjusted operating income \u00a01.19% \u00a01.19% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n16", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n16", "page_label": "16", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6544b14f-783d-42de-ac54-af861b6c02ef", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9434fe0fb87894a51ab6aef22d21cdb17cf54aaaa712bfe6d403eb125939a089", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28e31d3b-d6e2-43d9-9570-4827f6d81c62", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(85,345) \u00a0\u00a0(125,770) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(165,626) \u00a0\u00a0(156,067) \u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652) \u00a0\u00a0(570,000) \u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$977,783 \u00a0\u00a0$932,082 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.11% \u00a02.15% \u00a0\u00a0\nOperating expenses \u00a01.09% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.02% \u00a01.01% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.78% \u00a019.27% \u00a0\u00a0\nOperating expenses \u00a013.44% \u00a013.47% \u00a0\u00a0\nOperating income \u00a05.34% \u00a05.80% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73% \u00a02.95% \u00a0\u00a0\nOperating expenses \u00a02.04% \u00a02.26% \u00a0\u00a0\nOperating income \u00a00.70% \u00a00.70% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.77% \u00a02.80% \u00a0\u00a0\nAdjusted operating expenses \u00a01.58% \u00a01.61% \u00a0\u00a0\nAdjusted operating income \u00a01.19% \u00a01.19% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n16", "original_text": "Acquisition-related intangibles amortization \u00a0(85,345) \u00a0\u00a0(125,770) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(165,626) \u00a0\u00a0(156,067) \u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652) \u00a0\u00a0(570,000) \u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$977,783 \u00a0\u00a0$932,082 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.11% \u00a02.15% \u00a0\u00a0\nOperating expenses \u00a01.09% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.02% \u00a01.01% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.78% \u00a019.27% \u00a0\u00a0\nOperating expenses \u00a013.44% \u00a013.47% \u00a0\u00a0\nOperating income \u00a05.34% \u00a05.80% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73% \u00a02.95% \u00a0\u00a0\nOperating expenses \u00a02.04% \u00a02.26% \u00a0\u00a0\nOperating income \u00a00.70% \u00a00.70% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.77% \u00a02.80% \u00a0\u00a0\nAdjusted operating expenses \u00a01.58% \u00a01.61% \u00a0\u00a0\nAdjusted operating income \u00a01.19% \u00a01.19% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "16", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8258159b286f4407ce60d77ee8611db83a1819f880dbe7003fc6af7b4f822970", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ec50963-8393-410d-87f0-c07c6dc534a3", "node_type": "1", "metadata": {"window": "\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,420,272 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,548,399 \u00a0\u00a012,386,879 \u00a0\nInventories 11,849,201 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,340,935 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 596,024 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 163,741 \u00a0\u00a0157,385 \u00a0\nTotal current assets 29,918,572 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,455,008 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,615,677 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,446 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,145,149 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 966,712 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 519,710 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,631,571 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,620,641 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 268,519 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,806,260 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 494,761 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,967,951 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n17", "original_text": "\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,420,272 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,548,399 \u00a0\u00a012,386,879 \u00a0\nInventories 11,849,201 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,340,935 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 596,024 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 163,741 \u00a0\u00a0157,385 \u00a0\nTotal current assets 29,918,572 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,455,008 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,615,677 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,446 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,145,149 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 966,712 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 519,710 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,631,571 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,620,641 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 268,519 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,806,260 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 494,761 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,967,951 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n17"}, "hash": "e758bc0bb8bad6b8c6fef6d8c50c2240a9e91736d1aeea2def140c889dd3f829", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n16", "start_char_idx": 1146, "end_char_idx": 1279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ec50963-8393-410d-87f0-c07c6dc534a3": {"__data__": {"id_": "2ec50963-8393-410d-87f0-c07c6dc534a3", "embedding": null, "metadata": {"window": "\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,420,272 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,548,399 \u00a0\u00a012,386,879 \u00a0\nInventories 11,849,201 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,340,935 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 596,024 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 163,741 \u00a0\u00a0157,385 \u00a0\nTotal current assets 29,918,572 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,455,008 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,615,677 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,446 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,145,149 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 966,712 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 519,710 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,631,571 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,620,641 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 268,519 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,806,260 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 494,761 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,967,951 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n17", "original_text": "\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,420,272 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,548,399 \u00a0\u00a012,386,879 \u00a0\nInventories 11,849,201 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,340,935 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 596,024 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 163,741 \u00a0\u00a0157,385 \u00a0\nTotal current assets 29,918,572 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,455,008 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,615,677 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,446 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,145,149 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 966,712 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 519,710 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,631,571 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,620,641 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 268,519 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,806,260 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 494,761 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,967,951 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n17", "page_label": "17", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2b115b8-ed93-4cda-b2c7-89b8e9882f6f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8af6c9ef691861633585b416b3cd85646b71d45ad92a7d8955db1af70509d2f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6850ae5f-ae50-42b1-8330-41be1b18f522", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(85,345) \u00a0\u00a0(125,770) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(165,626) \u00a0\u00a0(156,067) \u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652) \u00a0\u00a0(570,000) \u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$977,783 \u00a0\u00a0$932,082 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.11% \u00a02.15% \u00a0\u00a0\nOperating expenses \u00a01.09% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.02% \u00a01.01% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.78% \u00a019.27% \u00a0\u00a0\nOperating expenses \u00a013.44% \u00a013.47% \u00a0\u00a0\nOperating income \u00a05.34% \u00a05.80% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73% \u00a02.95% \u00a0\u00a0\nOperating expenses \u00a02.04% \u00a02.26% \u00a0\u00a0\nOperating income \u00a00.70% \u00a00.70% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.77% \u00a02.80% \u00a0\u00a0\nAdjusted operating expenses \u00a01.58% \u00a01.61% \u00a0\u00a0\nAdjusted operating income \u00a01.19% \u00a01.19% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n16", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n16", "page_label": "16", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "594f6aa324f6a03192c78b80cee05cf8e03fe77908b6b0284402c8576d1e0c84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "178fe94d-8412-4a4c-8f6d-7683665c0205", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,444,947 \u00a0\u00a0$721,828 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1822,005 \u00a0\u00a0957,240 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (436,237) \u00a0\u00a0(672,742) \u00a0\nInventories (910,828) \u00a0\u00a0(280,148) \u00a0\nAccounts payable 824,105 \u00a0\u00a0964,667 \u00a0\nOther, net 2 (836,184) \u00a0\u00a0(19,644) \u00a0\nNet cash provided by operating activities 907,808 \u00a0\u00a01,671,201 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (251,101) \u00a0\u00a0(230,767) \u00a0\nCost of equity investments and acquired companies, net of cash acquired (34,830) \u00a0\u00a0(64,044) \u00a0\nOther, net 7,824 \u00a0\u00a0(2,222) \u00a0\nNet cash used in investing activities (278,107) \u00a0\u00a0(297,033) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (10,960) \u00a0\u00a0(130,493) \u00a0\nPayment of premium on early retirement of debt (21,448) \u00a0\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449) \u00a0\u00a0(522,778) \u00a0\nExercises of stock options 137,748 \u00a0\u00a054,860 \u00a0\nCash dividends on common stock (256,764) \u00a0\u00a0(255,064) \u00a0\nOther (11,750) \u00a0\u00a0(13,650) \u00a0\nNet cash used in financing activities (583,623) \u00a0\u00a0(867,125) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 46,078 \u00a0\u00a0507,043 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,420,272 \u00a0\u00a0$2,999,559 \u00a0\n18", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,444,947 \u00a0\u00a0$721,828 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1822,005 \u00a0\u00a0957,240 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (436,237) \u00a0\u00a0(672,742) \u00a0\nInventories (910,828) \u00a0\u00a0(280,148) \u00a0\nAccounts payable 824,105 \u00a0\u00a0964,667 \u00a0\nOther, net 2 (836,184) \u00a0\u00a0(19,644) \u00a0\nNet cash provided by operating activities 907,808 \u00a0\u00a01,671,201 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (251,101) \u00a0\u00a0(230,767) \u00a0\nCost of equity investments and acquired companies, net of cash acquired (34,830) \u00a0\u00a0(64,044) \u00a0\nOther, net 7,824 \u00a0\u00a0(2,222) \u00a0\nNet cash used in investing activities (278,107) \u00a0\u00a0(297,033) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (10,960) \u00a0\u00a0(130,493) \u00a0\nPayment of premium on early retirement of debt (21,448) \u00a0\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449) \u00a0\u00a0(522,778) \u00a0\nExercises of stock options 137,748 \u00a0\u00a054,860 \u00a0\nCash dividends on common stock (256,764) \u00a0\u00a0(255,064) \u00a0\nOther (11,750) \u00a0\u00a0(13,650) \u00a0\nNet cash used in financing activities (583,623) \u00a0\u00a0(867,125) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 46,078 \u00a0\u00a0507,043 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,420,272 \u00a0\u00a0$2,999,559 \u00a0\n18"}, "hash": "22ddf43f070ec7ef5dc9b786ab1b367de00f067b25d688c1fa9adfcade295701", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,420,272 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,548,399 \u00a0\u00a012,386,879 \u00a0\nInventories 11,849,201 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,340,935 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 596,024 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 163,741 \u00a0\u00a0157,385 \u00a0\nTotal current assets 29,918,572 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,455,008 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,615,677 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,446 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,145,149 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 966,712 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 519,710 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,631,571 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,620,641 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 268,519 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,806,260 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 494,761 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,967,951 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n17", "start_char_idx": 0, "end_char_idx": 1147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "178fe94d-8412-4a4c-8f6d-7683665c0205": {"__data__": {"id_": "178fe94d-8412-4a4c-8f6d-7683665c0205", "embedding": null, "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,444,947 \u00a0\u00a0$721,828 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1822,005 \u00a0\u00a0957,240 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (436,237) \u00a0\u00a0(672,742) \u00a0\nInventories (910,828) \u00a0\u00a0(280,148) \u00a0\nAccounts payable 824,105 \u00a0\u00a0964,667 \u00a0\nOther, net 2 (836,184) \u00a0\u00a0(19,644) \u00a0\nNet cash provided by operating activities 907,808 \u00a0\u00a01,671,201 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (251,101) \u00a0\u00a0(230,767) \u00a0\nCost of equity investments and acquired companies, net of cash acquired (34,830) \u00a0\u00a0(64,044) \u00a0\nOther, net 7,824 \u00a0\u00a0(2,222) \u00a0\nNet cash used in investing activities (278,107) \u00a0\u00a0(297,033) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (10,960) \u00a0\u00a0(130,493) \u00a0\nPayment of premium on early retirement of debt (21,448) \u00a0\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449) \u00a0\u00a0(522,778) \u00a0\nExercises of stock options 137,748 \u00a0\u00a054,860 \u00a0\nCash dividends on common stock (256,764) \u00a0\u00a0(255,064) \u00a0\nOther (11,750) \u00a0\u00a0(13,650) \u00a0\nNet cash used in financing activities (583,623) \u00a0\u00a0(867,125) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 46,078 \u00a0\u00a0507,043 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,420,272 \u00a0\u00a0$2,999,559 \u00a0\n18", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,444,947 \u00a0\u00a0$721,828 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1822,005 \u00a0\u00a0957,240 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (436,237) \u00a0\u00a0(672,742) \u00a0\nInventories (910,828) \u00a0\u00a0(280,148) \u00a0\nAccounts payable 824,105 \u00a0\u00a0964,667 \u00a0\nOther, net 2 (836,184) \u00a0\u00a0(19,644) \u00a0\nNet cash provided by operating activities 907,808 \u00a0\u00a01,671,201 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (251,101) \u00a0\u00a0(230,767) \u00a0\nCost of equity investments and acquired companies, net of cash acquired (34,830) \u00a0\u00a0(64,044) \u00a0\nOther, net 7,824 \u00a0\u00a0(2,222) \u00a0\nNet cash used in investing activities (278,107) \u00a0\u00a0(297,033) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (10,960) \u00a0\u00a0(130,493) \u00a0\nPayment of premium on early retirement of debt (21,448) \u00a0\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449) \u00a0\u00a0(522,778) \u00a0\nExercises of stock options 137,748 \u00a0\u00a054,860 \u00a0\nCash dividends on common stock (256,764) \u00a0\u00a0(255,064) \u00a0\nOther (11,750) \u00a0\u00a0(13,650) \u00a0\nNet cash used in financing activities (583,623) \u00a0\u00a0(867,125) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 46,078 \u00a0\u00a0507,043 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,420,272 \u00a0\u00a0$2,999,559 \u00a0\n18", "page_label": "18", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "060b78bd-9e1d-4ea8-a1ad-b3aff4f72097", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f33c5a272bb0aff538b0e365896232e58855dcc6e57663926f6a4a5cc11e23ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ec50963-8393-410d-87f0-c07c6dc534a3", "node_type": "1", "metadata": {"window": "\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,420,272 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,548,399 \u00a0\u00a012,386,879 \u00a0\nInventories 11,849,201 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,340,935 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 596,024 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 163,741 \u00a0\u00a0157,385 \u00a0\nTotal current assets 29,918,572 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,455,008 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,615,677 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,446 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,145,149 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 966,712 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 519,710 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,631,571 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,620,641 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 268,519 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,806,260 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 494,761 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,967,951 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n17", "original_text": "\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,420,272 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,548,399 \u00a0\u00a012,386,879 \u00a0\nInventories 11,849,201 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,340,935 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 596,024 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 163,741 \u00a0\u00a0157,385 \u00a0\nTotal current assets 29,918,572 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,455,008 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,615,677 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,446 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,145,149 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 966,712 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 519,710 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,631,571 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,620,641 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 268,519 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,806,260 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 494,761 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,967,951 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n17", "page_label": "17", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6881c11cae757f22723c060a88c380694faa82001eec8fb797824553ce8c7ed3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26a4f67b-5c17-4762-af4f-9c0c30eecc7e", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020.  Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019. ", "original_text": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020. "}, "hash": "6d1553bcd5c1da34029056b9c96860b15dfb7fa1082efb2bbe09b3dd594bce54", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,444,947 \u00a0\u00a0$721,828 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1822,005 \u00a0\u00a0957,240 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (436,237) \u00a0\u00a0(672,742) \u00a0\nInventories (910,828) \u00a0\u00a0(280,148) \u00a0\nAccounts payable 824,105 \u00a0\u00a0964,667 \u00a0\nOther, net 2 (836,184) \u00a0\u00a0(19,644) \u00a0\nNet cash provided by operating activities 907,808 \u00a0\u00a01,671,201 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (251,101) \u00a0\u00a0(230,767) \u00a0\nCost of equity investments and acquired companies, net of cash acquired (34,830) \u00a0\u00a0(64,044) \u00a0\nOther, net 7,824 \u00a0\u00a0(2,222) \u00a0\nNet cash used in investing activities (278,107) \u00a0\u00a0(297,033) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (10,960) \u00a0\u00a0(130,493) \u00a0\nPayment of premium on early retirement of debt (21,448) \u00a0\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449) \u00a0\u00a0(522,778) \u00a0\nExercises of stock options 137,748 \u00a0\u00a054,860 \u00a0\nCash dividends on common stock (256,764) \u00a0\u00a0(255,064) \u00a0\nOther (11,750) \u00a0\u00a0(13,650) \u00a0\nNet cash used in financing activities (583,623) \u00a0\u00a0(867,125) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 46,078 \u00a0\u00a0507,043 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,420,272 \u00a0\u00a0$2,999,559 \u00a0\n18", "start_char_idx": 0, "end_char_idx": 1490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26a4f67b-5c17-4762-af4f-9c0c30eecc7e": {"__data__": {"id_": "26a4f67b-5c17-4762-af4f-9c0c30eecc7e", "embedding": null, "metadata": {"window": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020.  Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019. ", "original_text": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "178fe94d-8412-4a4c-8f6d-7683665c0205", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,444,947 \u00a0\u00a0$721,828 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1822,005 \u00a0\u00a0957,240 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (436,237) \u00a0\u00a0(672,742) \u00a0\nInventories (910,828) \u00a0\u00a0(280,148) \u00a0\nAccounts payable 824,105 \u00a0\u00a0964,667 \u00a0\nOther, net 2 (836,184) \u00a0\u00a0(19,644) \u00a0\nNet cash provided by operating activities 907,808 \u00a0\u00a01,671,201 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (251,101) \u00a0\u00a0(230,767) \u00a0\nCost of equity investments and acquired companies, net of cash acquired (34,830) \u00a0\u00a0(64,044) \u00a0\nOther, net 7,824 \u00a0\u00a0(2,222) \u00a0\nNet cash used in investing activities (278,107) \u00a0\u00a0(297,033) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (10,960) \u00a0\u00a0(130,493) \u00a0\nPayment of premium on early retirement of debt (21,448) \u00a0\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449) \u00a0\u00a0(522,778) \u00a0\nExercises of stock options 137,748 \u00a0\u00a054,860 \u00a0\nCash dividends on common stock (256,764) \u00a0\u00a0(255,064) \u00a0\nOther (11,750) \u00a0\u00a0(13,650) \u00a0\nNet cash used in financing activities (583,623) \u00a0\u00a0(867,125) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 46,078 \u00a0\u00a0507,043 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,420,272 \u00a0\u00a0$2,999,559 \u00a0\n18", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,444,947 \u00a0\u00a0$721,828 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1822,005 \u00a0\u00a0957,240 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (436,237) \u00a0\u00a0(672,742) \u00a0\nInventories (910,828) \u00a0\u00a0(280,148) \u00a0\nAccounts payable 824,105 \u00a0\u00a0964,667 \u00a0\nOther, net 2 (836,184) \u00a0\u00a0(19,644) \u00a0\nNet cash provided by operating activities 907,808 \u00a0\u00a01,671,201 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (251,101) \u00a0\u00a0(230,767) \u00a0\nCost of equity investments and acquired companies, net of cash acquired (34,830) \u00a0\u00a0(64,044) \u00a0\nOther, net 7,824 \u00a0\u00a0(2,222) \u00a0\nNet cash used in investing activities (278,107) \u00a0\u00a0(297,033) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (10,960) \u00a0\u00a0(130,493) \u00a0\nPayment of premium on early retirement of debt (21,448) \u00a0\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449) \u00a0\u00a0(522,778) \u00a0\nExercises of stock options 137,748 \u00a0\u00a054,860 \u00a0\nCash dividends on common stock (256,764) \u00a0\u00a0(255,064) \u00a0\nOther (11,750) \u00a0\u00a0(13,650) \u00a0\nNet cash used in financing activities (583,623) \u00a0\u00a0(867,125) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 46,078 \u00a0\u00a0507,043 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,420,272 \u00a0\u00a0$2,999,559 \u00a0\n18", "page_label": "18", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91ff1a97f7b0545abdd4a9be4817e1d77027f4af564e10122f49b8f944b8c5ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc51873d-b3a8-4e26-bc8e-4777492320df", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020.  Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n", "original_text": "Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n"}, "hash": "08e4666d19f416eee871f5f7a6364ab65bc38c8f35dc8655ba9abcadf4bc3a3a", "class_name": "RelatedNodeInfo"}}, "text": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020. ", "start_char_idx": 0, "end_char_idx": 180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc51873d-b3a8-4e26-bc8e-4777492320df": {"__data__": {"id_": "fc51873d-b3a8-4e26-bc8e-4777492320df", "embedding": null, "metadata": {"window": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020.  Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n", "original_text": "Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26a4f67b-5c17-4762-af4f-9c0c30eecc7e", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020.  Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019. ", "original_text": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3f0fe8fa47a6f25513ec9a28358610481325dd27b47562a4652a143683376c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92c34571-edff-48bb-a596-98840875de43", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020.  Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n"}, "hash": "dcc6a6a215682406975704b989aeec1df8b99b83c39d2f232c4ee8e95864a0f6", "class_name": "RelatedNodeInfo"}}, "text": "Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n", "start_char_idx": 180, "end_char_idx": 317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92c34571-edff-48bb-a596-98840875de43": {"__data__": {"id_": "92c34571-edff-48bb-a596-98840875de43", "embedding": null, "metadata": {"window": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020.  Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc51873d-b3a8-4e26-bc8e-4777492320df", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020.  Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n", "original_text": "Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a05d4135185b365cae577f591e392d1a8d24c34d8f0a6477a4c9549121af387", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf32f49b-72d3-4557-9df8-291da68812b7", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020.  Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019. "}, "hash": "d3907a2a106925aa80427cc624d59008744b4e208b8d8feadbde20734d8e565f", "class_name": "RelatedNodeInfo"}}, "text": "2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n", "start_char_idx": 317, "end_char_idx": 486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf32f49b-72d3-4557-9df8-291da68812b7": {"__data__": {"id_": "bf32f49b-72d3-4557-9df8-291da68812b7", "embedding": null, "metadata": {"window": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020.  Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92c34571-edff-48bb-a596-98840875de43", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020.  Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65b217f70d8dd644cc4c25352a99c34d28eed61371096aee0160e63e3fe9a867", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1df983a-99ee-404a-a040-8f3d3107f03a", "node_type": "1", "metadata": {"window": "Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n"}, "hash": "d4320866595bb8bb2be89738c0cc5cf1dfe09dbeccbddfb05549127609439c09", "class_name": "RelatedNodeInfo"}}, "text": "3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019. ", "start_char_idx": 486, "end_char_idx": 638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1df983a-99ee-404a-a040-8f3d3107f03a": {"__data__": {"id_": "f1df983a-99ee-404a-a040-8f3d3107f03a", "embedding": null, "metadata": {"window": "Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf32f49b-72d3-4557-9df8-291da68812b7", "node_type": "1", "metadata": {"window": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020.  Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "362df9bea0cc1319eb85b4fd291e5479fac4ac230fdb5d950c685e4add4e4dbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04331851-9731-49fb-a667-ec5a7226375e", "node_type": "1", "metadata": {"window": "2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "08b03b4c662183ad40b5404f8b5c89e08ee5c1e24f33204391f09ac73c45e2f4", "class_name": "RelatedNodeInfo"}}, "text": "Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n", "start_char_idx": 638, "end_char_idx": 869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04331851-9731-49fb-a667-ec5a7226375e": {"__data__": {"id_": "04331851-9731-49fb-a667-ec5a7226375e", "embedding": null, "metadata": {"window": "2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1df983a-99ee-404a-a040-8f3d3107f03a", "node_type": "1", "metadata": {"window": "Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f51e4f574dcad19bc19922a1c157e4c325d10fa83a216e62d032e9197d55a146", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70af933b-b328-40b4-90b4-68026826b6c4", "node_type": "1", "metadata": {"window": "3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "aca5c5f0d4b19b23476b131ea85ffd9d8d4ec3b6ea732e9f1531f093ab275d61", "class_name": "RelatedNodeInfo"}}, "text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 869, "end_char_idx": 1007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70af933b-b328-40b4-90b4-68026826b6c4": {"__data__": {"id_": "70af933b-b328-40b4-90b4-68026826b6c4", "embedding": null, "metadata": {"window": "3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04331851-9731-49fb-a667-ec5a7226375e", "node_type": "1", "metadata": {"window": "2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37292e6ff2b084260fc6fe0920c154fab6a42cfa569951c2ac957a8417f11653", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4e53a5f-9177-4317-9928-1b2854361d02", "node_type": "1", "metadata": {"window": "Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "98a803a98ec4e8b3c7a1db6e48e74d24fa1ef8e8048277d21f7a09b5af39ffa7", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 1007, "end_char_idx": 1122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4e53a5f-9177-4317-9928-1b2854361d02": {"__data__": {"id_": "a4e53a5f-9177-4317-9928-1b2854361d02", "embedding": null, "metadata": {"window": "Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70af933b-b328-40b4-90b4-68026826b6c4", "node_type": "1", "metadata": {"window": "3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd9d63832a393fc05ea241f74857b2272b01b7f2786b028008f5e403338424a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4046d57-5ebf-4a13-849d-c423261c6463", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "d7f41ea6e423d600cac2fbc4858ef319d95447153d4c26be00f5ad76552c02d8", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 1122, "end_char_idx": 1262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4046d57-5ebf-4a13-849d-c423261c6463": {"__data__": {"id_": "c4046d57-5ebf-4a13-849d-c423261c6463", "embedding": null, "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4e53a5f-9177-4317-9928-1b2854361d02", "node_type": "1", "metadata": {"window": "Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled\nin July 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b080dfea2f8ddfe10a21bd7c63e6df8de35c27b33c31732160a0ea08be580ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b10e31d-47e7-40b1-b5c9-29d3b4703628", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "5fbd7a9bc52b9ebcdbb866683a179146ede8607428bf2ec9ce7c15d54e19b2df", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 1262, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b10e31d-47e7-40b1-b5c9-29d3b4703628": {"__data__": {"id_": "9b10e31d-47e7-40b1-b5c9-29d3b4703628", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4046d57-5ebf-4a13-849d-c423261c6463", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b4ba9e90372057ccdc8629c6c59b06451867dc7047299aae031190de5547d68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1eee06ca-34b2-4dc7-9b3a-b38541848ec5", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "966e68cb33ff5a7e802919072ba2d9bd3610a4db87f80c6ac53a21a9bb57831b", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 1381, "end_char_idx": 1600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1eee06ca-34b2-4dc7-9b3a-b38541848ec5": {"__data__": {"id_": "1eee06ca-34b2-4dc7-9b3a-b38541848ec5", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b10e31d-47e7-40b1-b5c9-29d3b4703628", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11fd60a951fc85f95f42eed4afb78a77081ee57261ef285acdcb940e147fa7b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7f6a791-e045-42f8-a28a-56bb9c351603", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "10b8cb83a9ea4093f80d960fc2230de203d330cbb023d3bc8c17a901168687ec", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 1600, "end_char_idx": 1782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7f6a791-e045-42f8-a28a-56bb9c351603": {"__data__": {"id_": "e7f6a791-e045-42f8-a28a-56bb9c351603", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1eee06ca-34b2-4dc7-9b3a-b38541848ec5", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9be2d3c6c45f07cc50ffc06e8e408b335cc07eb7d069f3f6f3e31a630ff9d183", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ffc71c6-3022-4a8c-bb7c-3d7316fa2a30", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). "}, "hash": "d48206520e13d6caf9cb6321e2b934378735bf2e209ac0f603a8a99dfd259395", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 1782, "end_char_idx": 2063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ffc71c6-3022-4a8c-bb7c-3d7316fa2a30": {"__data__": {"id_": "4ffc71c6-3022-4a8c-bb7c-3d7316fa2a30", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7f6a791-e045-42f8-a28a-56bb9c351603", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb8c641b6eca4ebaf296958774b18833fd272f69e0a8971f1734f444334e63aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ba64d31-f0ed-4cad-bdde-a81c5e10bc68", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "original_text": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. "}, "hash": "620afde49e54ce483dc587a51c6b123f4daeb71797562b559365ae3080c87bf5", "class_name": "RelatedNodeInfo"}}, "text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "start_char_idx": 2063, "end_char_idx": 2519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ba64d31-f0ed-4cad-bdde-a81c5e10bc68": {"__data__": {"id_": "3ba64d31-f0ed-4cad-bdde-a81c5e10bc68", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "original_text": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ffc71c6-3022-4a8c-bb7c-3d7316fa2a30", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b592a4a96a677c0cd855ca476eadcf0d40e57cb702df204b092979600fe798e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b03e8a4c-909a-454e-a293-f42cbfcc5f88", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n"}, "hash": "1c795e3ecbf8d988525f9c864c1c00487f7263a63ca60cfd7fd2a93915881e7d", "class_name": "RelatedNodeInfo"}}, "text": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "start_char_idx": 2519, "end_char_idx": 2685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b03e8a4c-909a-454e-a293-f42cbfcc5f88": {"__data__": {"id_": "b03e8a4c-909a-454e-a293-f42cbfcc5f88", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ba64d31-f0ed-4cad-bdde-a81c5e10bc68", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "original_text": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7bddb57503217b069e8c67564b90d903fc1eb31f6426cac6da3b5986ca21177", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "719faa34-917b-46d6-9fea-d3d7ca94e5c2", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "original_text": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. "}, "hash": "bedfa803b8076e924a7a2e779cd616edd27779107e09f82108d52bae57e0c074", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "start_char_idx": 2685, "end_char_idx": 2768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "719faa34-917b-46d6-9fea-d3d7ca94e5c2": {"__data__": {"id_": "719faa34-917b-46d6-9fea-d3d7ca94e5c2", "embedding": null, "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "original_text": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b03e8a4c-909a-454e-a293-f42cbfcc5f88", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "285e998bb8bc07ed882ce635b109fd6773916f133de23d0202afcf36569e8463", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "383af777-f0cf-4fcf-a4d3-007c36ad3544", "node_type": "1", "metadata": {"window": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. "}, "hash": "0dc4695f9d267e063df8b3363881d1caa11c63be1eb4b11e35745e0b81d76637", "class_name": "RelatedNodeInfo"}}, "text": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. ", "start_char_idx": 2768, "end_char_idx": 2953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "383af777-f0cf-4fcf-a4d3-007c36ad3544": {"__data__": {"id_": "383af777-f0cf-4fcf-a4d3-007c36ad3544", "embedding": null, "metadata": {"window": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "719faa34-917b-46d6-9fea-d3d7ca94e5c2", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "original_text": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faea6463f7801bb759aee1a360d18c68b1795acf237ccd1bc9aea16556edf40e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0c4d8c9-ada3-4b08-87c9-a5a07fa18905", "node_type": "1", "metadata": {"window": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "3ed25a7c41624faab46770ce27ce38b6997812a242b4704a240aa333d84caa3e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "start_char_idx": 2953, "end_char_idx": 3038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0c4d8c9-ada3-4b08-87c9-a5a07fa18905": {"__data__": {"id_": "c0c4d8c9-ada3-4b08-87c9-a5a07fa18905", "embedding": null, "metadata": {"window": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "383af777-f0cf-4fcf-a4d3-007c36ad3544", "node_type": "1", "metadata": {"window": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e4d507700b1aae7c34a4a894528986f827db8749f441959943e15a30ec83c07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2e2c247-07f3-4721-893e-f7b9c14b950a", "node_type": "1", "metadata": {"window": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. ", "original_text": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. "}, "hash": "2dae74fc8a36fac852162d17c6b733309958ffa1df5b27a049cea6e5c9974825", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 3038, "end_char_idx": 3195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2e2c247-07f3-4721-893e-f7b9c14b950a": {"__data__": {"id_": "e2e2c247-07f3-4721-893e-f7b9c14b950a", "embedding": null, "metadata": {"window": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. ", "original_text": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0c4d8c9-ada3-4b08-87c9-a5a07fa18905", "node_type": "1", "metadata": {"window": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef424d1ecff54061af5009773d832edcb20e76bd4793eb6821f3fbe4bb889446", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e832e67e-0ae5-4388-b03e-4783aab99162", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. "}, "hash": "e21f93b9f4535f2b18220e6a0a7d12f36ac137e6e44c165abb6569fdb8d5e14a", "class_name": "RelatedNodeInfo"}}, "text": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "start_char_idx": 3195, "end_char_idx": 3495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e832e67e-0ae5-4388-b03e-4783aab99162": {"__data__": {"id_": "e832e67e-0ae5-4388-b03e-4783aab99162", "embedding": null, "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2e2c247-07f3-4721-893e-f7b9c14b950a", "node_type": "1", "metadata": {"window": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. ", "original_text": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fd39d7073d4a1797277fc897531540461e87a57640315ecb478e3ab045945fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "790dc9e7-a22b-4d23-b3c6-a54cbfb9e8a8", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. ", "original_text": "Food and Drug Administration inspections. "}, "hash": "84a173650f93cc66efb7463ced2cd2f72ceebc02bfda6682e3685874e77b1071", "class_name": "RelatedNodeInfo"}}, "text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "start_char_idx": 3495, "end_char_idx": 3619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "790dc9e7-a22b-4d23-b3c6-a54cbfb9e8a8": {"__data__": {"id_": "790dc9e7-a22b-4d23-b3c6-a54cbfb9e8a8", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e832e67e-0ae5-4388-b03e-4783aab99162", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbc9e883549db1ff2a78c34dc07ee254c4d080874ce4eda77e6fc8eee0787255", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "337f07c7-87ad-4dbc-87bc-b4c63969bfd0", "node_type": "1", "metadata": {"window": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "original_text": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. "}, "hash": "d4b3c7f30e91adc27722ab12a00d9536099bd6d8d9883bec95153d1d0d52da27", "class_name": "RelatedNodeInfo"}}, "text": "Food and Drug Administration inspections. ", "start_char_idx": 3619, "end_char_idx": 3661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "337f07c7-87ad-4dbc-87bc-b4c63969bfd0": {"__data__": {"id_": "337f07c7-87ad-4dbc-87bc-b4c63969bfd0", "embedding": null, "metadata": {"window": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "original_text": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "790dc9e7-a22b-4d23-b3c6-a54cbfb9e8a8", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "683bc852d253b49851f31da280bd2e3f68b6854bb70bb1235e7e325da17a7b40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "485a48a5-165b-4d1e-a5e9-461303dc4ac0", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. "}, "hash": "11b1137a205fd7c5733f054b56e1c5a067830adf846478b8f8793f59e911c7c1", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. ", "start_char_idx": 3661, "end_char_idx": 3776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "485a48a5-165b-4d1e-a5e9-461303dc4ac0": {"__data__": {"id_": "485a48a5-165b-4d1e-a5e9-461303dc4ac0", "embedding": null, "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "337f07c7-87ad-4dbc-87bc-b4c63969bfd0", "node_type": "1", "metadata": {"window": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "original_text": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "513fed4d7bf9151f8af9d2a54c6811cd6909d9b5156387f4eba064f892e5c7e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d5abaa4-95cc-4a19-a96f-3a842a89463a", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. ", "original_text": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. "}, "hash": "d51dd9e72d00046910bdc8fcce6d06ffe8bf3316ff28f6111683c63d3576f40a", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "start_char_idx": 3776, "end_char_idx": 3958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d5abaa4-95cc-4a19-a96f-3a842a89463a": {"__data__": {"id_": "8d5abaa4-95cc-4a19-a96f-3a842a89463a", "embedding": null, "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. ", "original_text": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "485a48a5-165b-4d1e-a5e9-461303dc4ac0", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7777b36e59a3796a950ba5de18d1994316ec3f9a094cf14554895bee2dae42f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96d6e9be-b614-4e4b-bfb5-cbb7b20f2985", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "original_text": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. "}, "hash": "da7643433aa4a847d8ce825b4b65c322b26b5d4c024db64ce60a8d5737727dde", "class_name": "RelatedNodeInfo"}}, "text": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. ", "start_char_idx": 3958, "end_char_idx": 4214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96d6e9be-b614-4e4b-bfb5-cbb7b20f2985": {"__data__": {"id_": "96d6e9be-b614-4e4b-bfb5-cbb7b20f2985", "embedding": null, "metadata": {"window": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "original_text": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d5abaa4-95cc-4a19-a96f-3a842a89463a", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. ", "original_text": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b26a654b3a327ede785fa445af6c407c40771102db343329d1d4d11edc0cf69c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19b495dc-ebed-4513-b3d4-f583a694203e", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "original_text": "District Court for the Southern District of\nNew York.\n"}, "hash": "5679a6d3bc55a1e5b693a15022ffc3164921f8854a12b359be05fe1a4f26e6ea", "class_name": "RelatedNodeInfo"}}, "text": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "start_char_idx": 4214, "end_char_idx": 4290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19b495dc-ebed-4513-b3d4-f583a694203e": {"__data__": {"id_": "19b495dc-ebed-4513-b3d4-f583a694203e", "embedding": null, "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "original_text": "District Court for the Southern District of\nNew York.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96d6e9be-b614-4e4b-bfb5-cbb7b20f2985", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "original_text": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0ed916f398a0886aa6c6944b2c24a14cd6cb53f40ffce3b409049abc9f51dd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "715943c3-63b3-4c64-b8cd-b61bdf4582fb", "node_type": "1", "metadata": {"window": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. "}, "hash": "11e833601e363295fe85ea1528b30bf6bc966d1b489670b26135bd6beb11a5dd", "class_name": "RelatedNodeInfo"}}, "text": "District Court for the Southern District of\nNew York.\n", "start_char_idx": 4290, "end_char_idx": 4344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "715943c3-63b3-4c64-b8cd-b61bdf4582fb": {"__data__": {"id_": "715943c3-63b3-4c64-b8cd-b61bdf4582fb", "embedding": null, "metadata": {"window": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19b495dc-ebed-4513-b3d4-f583a694203e", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "original_text": "District Court for the Southern District of\nNew York.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64852517b675a356957b60aa0f02d537fb697c0737a0915af3e0d45864aa2659", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28c04eda-0164-454c-b6dd-5b976363d72f", "node_type": "1", "metadata": {"window": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n"}, "hash": "fcb2992b54b97d82e1d8a6e11605f7def179192e5ed5784cb3286dac6c45a669", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. ", "start_char_idx": 4344, "end_char_idx": 4723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28c04eda-0164-454c-b6dd-5b976363d72f": {"__data__": {"id_": "28c04eda-0164-454c-b6dd-5b976363d72f", "embedding": null, "metadata": {"window": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "715943c3-63b3-4c64-b8cd-b61bdf4582fb", "node_type": "1", "metadata": {"window": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7a1bed23e55cefab28aff54721c1c6a22def01fe4aa092b786ea576f62dfbc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1e5a864-b892-48e0-b49e-2fa7cdbcafc8", "node_type": "1", "metadata": {"window": "District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. "}, "hash": "5b295fc46e66347640fb4faa0e5f33a8f80dd2e57ac64b9edce312589a3386e2", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "start_char_idx": 4723, "end_char_idx": 4819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1e5a864-b892-48e0-b49e-2fa7cdbcafc8": {"__data__": {"id_": "f1e5a864-b892-48e0-b49e-2fa7cdbcafc8", "embedding": null, "metadata": {"window": "District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28c04eda-0164-454c-b6dd-5b976363d72f", "node_type": "1", "metadata": {"window": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74ff409509b25b9d0e3ba9e33b6f7803059a418498f1d35f1a1ed3be3bda5d78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dfd1847-e97a-431e-92ad-3477f6426f30", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. "}, "hash": "060a5c4b864590af8699132e6e6e33a819f2165506ad274cb60a61259198ddbe", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "start_char_idx": 4819, "end_char_idx": 4980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dfd1847-e97a-431e-92ad-3477f6426f30": {"__data__": {"id_": "9dfd1847-e97a-431e-92ad-3477f6426f30", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1e5a864-b892-48e0-b49e-2fa7cdbcafc8", "node_type": "1", "metadata": {"window": "District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eca8edb3934ff1ac217f5de45118af0986ad057e002ee41695f3ea69b9809b31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f23913d5-1301-42bc-8faf-e0b5b32eda99", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance. "}, "hash": "47d1a9f14ca00002f14bebd835d984abda3bb8d670462e6b7db2eff01e5bcb3a", "class_name": "RelatedNodeInfo"}}, "text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "start_char_idx": 4980, "end_char_idx": 5093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f23913d5-1301-42bc-8faf-e0b5b32eda99": {"__data__": {"id_": "f23913d5-1301-42bc-8faf-e0b5b32eda99", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dfd1847-e97a-431e-92ad-3477f6426f30", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21849efd7f206c87326da58180e879971f146fcc9510cf68ede317c730bf5748", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f40efe9-5151-4ac8-a4e6-fbdfff7f62c1", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n"}, "hash": "90755b27d1e55c1c0e835bd3724a0cfa32ae4b66c7f4673147d3f466bf1a4355", "class_name": "RelatedNodeInfo"}}, "text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance. ", "start_char_idx": 5093, "end_char_idx": 5492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f40efe9-5151-4ac8-a4e6-fbdfff7f62c1": {"__data__": {"id_": "2f40efe9-5151-4ac8-a4e6-fbdfff7f62c1", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f23913d5-1301-42bc-8faf-e0b5b32eda99", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3157015ffe3ac769ffc855034a1e175ebdbd2f391daf8a677085de3a0597aab4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99c329b5-c22c-45cd-98bd-c8edec42ccff", "node_type": "1", "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "c4f5ded5c95e3de6ed7048a4e3f540858f5ec78113bee21c9d6caf4c252dab90", "class_name": "RelatedNodeInfo"}}, "text": "The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n", "start_char_idx": 5492, "end_char_idx": 5786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99c329b5-c22c-45cd-98bd-c8edec42ccff": {"__data__": {"id_": "99c329b5-c22c-45cd-98bd-c8edec42ccff", "embedding": null, "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f40efe9-5151-4ac8-a4e6-fbdfff7f62c1", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "515e9224e016443569621ff16f308860ca6566919d077184581901327adc5ed0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b609321a-3c92-4f35-a13a-f3549c28dd1a", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "4b2031568b20953417d1037674139d0d9afafcc2fc15be46c5c9fb5845423137", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 5786, "end_char_idx": 6035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b609321a-3c92-4f35-a13a-f3549c28dd1a": {"__data__": {"id_": "b609321a-3c92-4f35-a13a-f3549c28dd1a", "embedding": null, "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99c329b5-c22c-45cd-98bd-c8edec42ccff", "node_type": "1", "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d08af4a4258f6e6e76679d357f20388b7f6ebf96b8490f6bb472c72ff932441", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d51a10f5-597b-4d91-8e7b-ce9d07410c9a", "node_type": "1", "metadata": {"window": "The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring.  Management believes that this\n19", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "30f877080686cc8e8fb40f1b9405839ceaeac8b7901185b5d63ef63341f84726", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 6035, "end_char_idx": 6128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d51a10f5-597b-4d91-8e7b-ce9d07410c9a": {"__data__": {"id_": "d51a10f5-597b-4d91-8e7b-ce9d07410c9a", "embedding": null, "metadata": {"window": "The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring.  Management believes that this\n19", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b609321a-3c92-4f35-a13a-f3549c28dd1a", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of PharMEDium\nassets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b4c36ddcda14c804486a96fe8bbfd6a43151e40e646d7470a00df3ead4fb6fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b0bac72-c937-47b6-bb08-3abb4e0080b0", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring.  Management believes that this\n19", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "4ea05ca77cfce787f7eb820af3b709c4ed9c9478c23bc65c86f0b359bf9f0d48", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 6128, "end_char_idx": 6375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b0bac72-c937-47b6-bb08-3abb4e0080b0": {"__data__": {"id_": "6b0bac72-c937-47b6-bb08-3abb4e0080b0", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring.  Management believes that this\n19", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d51a10f5-597b-4d91-8e7b-ce9d07410c9a", "node_type": "1", "metadata": {"window": "The contingent consideration adjustment reflects\nan adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos\nFarmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior business\nacquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring.  Management believes that this\n19", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca7e60867a1b6e8ce13fffe504553880262fe3714f6fcade8a7e77068b76151d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35a93537-6244-4c61-b1e8-892899ef0dec", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring.  Management believes that this\n19", "original_text": "In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring. "}, "hash": "8f24e524c084c10dc51d1de068c8dc510077357808f20c4c7b4daafae4daed05", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 6375, "end_char_idx": 6580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35a93537-6244-4c61-b1e8-892899ef0dec": {"__data__": {"id_": "35a93537-6244-4c61-b1e8-892899ef0dec", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring.  Management believes that this\n19", "original_text": "In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b0bac72-c937-47b6-bb08-3abb4e0080b0", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring.  Management believes that this\n19", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecda24483a53ba6b22a99086e19cb5bea94fc7d256c9f89470e9d77684d68935", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bee99828-9cbe-4e49-b484-0b35e5519208", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring.  Management believes that this\n19", "original_text": "Management believes that this\n19"}, "hash": "be77c1c200c6a14ce6ffe22538427811b5fa5b3f9f55608558a437ea2a120613", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring. ", "start_char_idx": 6580, "end_char_idx": 6820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bee99828-9cbe-4e49-b484-0b35e5519208": {"__data__": {"id_": "bee99828-9cbe-4e49-b484-0b35e5519208", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring.  Management believes that this\n19", "original_text": "Management believes that this\n19", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9352e195-5bab-477a-bdfc-3cadefe1c595", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcf47160161c525c470271fc7920c36af10e1fc6a0eb76cc8a98507390dc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35a93537-6244-4c61-b1e8-892899ef0dec", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring.  Management believes that this\n19", "original_text": "In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8db5b17d319e1ea039d30fae4f7e32a4b77b46b316cef2b49abcd147d99841f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7899727-9ab2-485e-96a8-a576b2cb5531", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n"}, "hash": "4feb1311955c917d91af10bfd5a3697ff094ac39192fb6975098a7d81d0f8b67", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this\n19", "start_char_idx": 6820, "end_char_idx": 6852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7899727-9ab2-485e-96a8-a576b2cb5531": {"__data__": {"id_": "c7899727-9ab2-485e-96a8-a576b2cb5531", "embedding": null, "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bee99828-9cbe-4e49-b484-0b35e5519208", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020 and the gain on sale of an equity investment in fiscal 2019 are excluded from adjusted\nincome before income taxes because they were unusual, non-operating, and non-recurring.  Management believes that this\n19", "original_text": "Management believes that this\n19", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6afa5d62562583d6e725717fc9483de23e33ca6e7046999dea8c0901e82492f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72e5454e-9864-41d6-af49-48904240dd21", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. "}, "hash": "c240e760ade1cf4e3b04f3e99dcd6da04dc05307f71d4dfb9558415315d722d7", "class_name": "RelatedNodeInfo"}}, "text": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n", "start_char_idx": 0, "end_char_idx": 135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72e5454e-9864-41d6-af49-48904240dd21": {"__data__": {"id_": "72e5454e-9864-41d6-af49-48904240dd21", "embedding": null, "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7899727-9ab2-485e-96a8-a576b2cb5531", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed7a3d236020a9327d866286bc2b927abcc669b1b3c5b7f2d9a8097ff2f58298", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "082be447-20bc-4071-8a6a-5238b21d4e5a", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "fff960cbf3beb21d4dc1d65bcd8254da9a557fe0c9885fdffb5376cfe60bb6ac", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "start_char_idx": 135, "end_char_idx": 332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "082be447-20bc-4071-8a6a-5238b21d4e5a": {"__data__": {"id_": "082be447-20bc-4071-8a6a-5238b21d4e5a", "embedding": null, "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72e5454e-9864-41d6-af49-48904240dd21", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68f5a7ea56e19879e8d8313dad9992b0a5e67a0eb49b0d6a6f1a0f5305f10735", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cfe1519-ce0e-4f5d-8b71-1bdc1bb69086", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "ee9ac5b76f0fccab5ffc3479cb11834c1f951d4c9e80cc19eb30b6e7052122a7", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 332, "end_char_idx": 604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cfe1519-ce0e-4f5d-8b71-1bdc1bb69086": {"__data__": {"id_": "3cfe1519-ce0e-4f5d-8b71-1bdc1bb69086", "embedding": null, "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "082be447-20bc-4071-8a6a-5238b21d4e5a", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f8e39027393bf9a00a077a08d56a613a2d0f6273b6ad4f606c9c26b67f6a8ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ece4cae-ca5a-4649-9989-31ed3c840d55", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020. "}, "hash": "8dbe127da3b39208d5df64507ac0c83d0aa2f8f0811845a774018e8f8806f5da", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 604, "end_char_idx": 842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ece4cae-ca5a-4649-9989-31ed3c840d55": {"__data__": {"id_": "2ece4cae-ca5a-4649-9989-31ed3c840d55", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cfe1519-ce0e-4f5d-8b71-1bdc1bb69086", "node_type": "1", "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4303fdad567552d95c6bb3c76f5fb482b8df8cdc89baa08e80ef0ebcf514170", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf27b8f4-32fc-4dec-84a7-292fb48cdd57", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "In addition, the final U.S. "}, "hash": "4e7b84632d45df5ad2ac77de790501b25d8d086799835f7dd68c3eb5850fac8f", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020. ", "start_char_idx": 842, "end_char_idx": 1165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf27b8f4-32fc-4dec-84a7-292fb48cdd57": {"__data__": {"id_": "bf27b8f4-32fc-4dec-84a7-292fb48cdd57", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "In addition, the final U.S. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ece4cae-ca5a-4649-9989-31ed3c840d55", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8120f2dfa98d93c249264dfcf6366f948bacb9f3d8d93d8eda4f54a4ccadec12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67615f67-1e39-402e-8440-875db737bc7c", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n"}, "hash": "146503aa696cd0fb4f50c91e47a371396a79ad8495b9a6719bc92a55c13444dd", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the final U.S. ", "start_char_idx": 1165, "end_char_idx": 1193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67615f67-1e39-402e-8440-875db737bc7c": {"__data__": {"id_": "67615f67-1e39-402e-8440-875db737bc7c", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf27b8f4-32fc-4dec-84a7-292fb48cdd57", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "In addition, the final U.S. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bce2cc06959e1df3847df6f69a6ef40d88268f9c63c19f39a16fea10d49094bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ded1719-d446-43f8-a40c-927bc8a8d8a9", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "38364f4b983d3dd3cc76ec89c8c26ad6836f3916a83faf32ad143f06832f2780", "class_name": "RelatedNodeInfo"}}, "text": "tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n", "start_char_idx": 1193, "end_char_idx": 1445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ded1719-d446-43f8-a40c-927bc8a8d8a9": {"__data__": {"id_": "2ded1719-d446-43f8-a40c-927bc8a8d8a9", "embedding": null, "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67615f67-1e39-402e-8440-875db737bc7c", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "611b4eca735578e0e01511327ff3f7a476f611f7946226fbaca359ef4aaa5f01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a915ea01-0728-4d28-adbe-7f43e789b7fc", "node_type": "1", "metadata": {"window": "In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. "}, "hash": "a2e13f5a4d40cfb9544510c80da3429cebef4241099e58f0da7f63af139a3786", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 1445, "end_char_idx": 1689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a915ea01-0728-4d28-adbe-7f43e789b7fc": {"__data__": {"id_": "a915ea01-0728-4d28-adbe-7f43e789b7fc", "embedding": null, "metadata": {"window": "In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ded1719-d446-43f8-a40c-927bc8a8d8a9", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the nine months ended June 30, 2020.  In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ba83fb72c94817a0244c09bc00113f910e7f5737ea674b79c83fcf411deadfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f66b8e83-0b6e-4b99-bfb0-c460dd159e59", "node_type": "1", "metadata": {"window": "tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n"}, "hash": "851b157e9ec3ba32e373a54eaa73de2d4c64c563258cfe46573c38ea8dea5b58", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "start_char_idx": 1689, "end_char_idx": 1957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f66b8e83-0b6e-4b99-bfb0-c460dd159e59": {"__data__": {"id_": "f66b8e83-0b6e-4b99-bfb0-c460dd159e59", "embedding": null, "metadata": {"window": "tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a915ea01-0728-4d28-adbe-7f43e789b7fc", "node_type": "1", "metadata": {"window": "In addition, the final U.S.  tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ceae93da197dba90fde28762c61ec66fddc2eea831b0c56aa9bf6863ff76f4f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a247467a-8f6e-4bef-a810-8f78f21b4aca", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. "}, "hash": "ecf72d57456c794a4175bdb9d8cd416db428af804e7eb00ed83393ea8be9ca6a", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "start_char_idx": 1957, "end_char_idx": 2120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a247467a-8f6e-4bef-a810-8f78f21b4aca": {"__data__": {"id_": "a247467a-8f6e-4bef-a810-8f78f21b4aca", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f66b8e83-0b6e-4b99-bfb0-c460dd159e59", "node_type": "1", "metadata": {"window": "tax reform\nmeasurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits through\nDecember 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the nine months ended June 30, 2019.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8499d410ccf0d4724a1fa5fb3364d008f655ca0249bfb5b436ba72de13081483", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6e6dd81-bc21-4d09-b549-746805e9f03b", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "19d73aac0c3a69bde93cf57f4e6d75d2cbeba805b802baf260c836cfa7adcae0", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "start_char_idx": 2120, "end_char_idx": 2289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6e6dd81-bc21-4d09-b549-746805e9f03b": {"__data__": {"id_": "e6e6dd81-bc21-4d09-b549-746805e9f03b", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a247467a-8f6e-4bef-a810-8f78f21b4aca", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49695e99d92f84fcb3a004022d476b53022e10723478f558400161d76c2bda51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45f88dc7-d0bf-4928-baa8-4e2d6a016ebb", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items. "}, "hash": "20bd09bc48cad885d505e830ba65d7891b6f97faf2e1c07451c04342d8f65a30", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 2289, "end_char_idx": 2534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45f88dc7-d0bf-4928-baa8-4e2d6a016ebb": {"__data__": {"id_": "45f88dc7-d0bf-4928-baa8-4e2d6a016ebb", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6e6dd81-bc21-4d09-b549-746805e9f03b", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "680761e5c82b98cbf94618d94d59db12f09094e63658244fcf7de765021fe9e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7e08ebc-62e7-4337-a70a-acae81472307", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "original_text": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020. "}, "hash": "80b185e67f182684a8495d128bf88851f14bc5f37a9c3e14344ddbc9ea829be3", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items. ", "start_char_idx": 2534, "end_char_idx": 3170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7e08ebc-62e7-4337-a70a-acae81472307": {"__data__": {"id_": "c7e08ebc-62e7-4337-a70a-acae81472307", "embedding": null, "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "original_text": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45f88dc7-d0bf-4928-baa8-4e2d6a016ebb", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f247d34f18f20c8669a19b27f089cdd30736b7ac33948dbadd32fac42faa713", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b10c9db-6053-475b-92f0-a80970dd6c3e", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n"}, "hash": "2caea317d0faede3094442d2d96e41c87b431065ef3fa07154fd3cb278cab39c", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020. ", "start_char_idx": 3170, "end_char_idx": 3612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b10c9db-6053-475b-92f0-a80970dd6c3e": {"__data__": {"id_": "9b10c9db-6053-475b-92f0-a80970dd6c3e", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7e08ebc-62e7-4337-a70a-acae81472307", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "original_text": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cab628bdd6a991b16fcd27e1539e97dbb188d3bfd2c9df76fc6c71a8936bd5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e7bd4a3-3e70-41a3-9a36-6e8aa9c1e293", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. "}, "hash": "c4f66a2ff8017055b03032f1b84670b509e8d591fd42ecc7fe4eb8a7a934d0ac", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "start_char_idx": 3612, "end_char_idx": 3966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e7bd4a3-3e70-41a3-9a36-6e8aa9c1e293": {"__data__": {"id_": "6e7bd4a3-3e70-41a3-9a36-6e8aa9c1e293", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b10c9db-6053-475b-92f0-a80970dd6c3e", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a30693cf0c8f3ff3c1f477724a097f1404070e31277c7133c8db895b552b3d77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2ccda0e-c97e-4eec-80ae-d054e9e080d7", "node_type": "1", "metadata": {"window": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "original_text": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. "}, "hash": "91894620c2658f64f2e7f43f8a89f86c2248c6c4117a3d5ffdd8f66a421dd892", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 3966, "end_char_idx": 4417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2ccda0e-c97e-4eec-80ae-d054e9e080d7": {"__data__": {"id_": "b2ccda0e-c97e-4eec-80ae-d054e9e080d7", "embedding": null, "metadata": {"window": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "original_text": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e7bd4a3-3e70-41a3-9a36-6e8aa9c1e293", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; impairment of PharMEDium assets; a contingent consideration adjustment; loss on early retirement of\ndebt; and gain on sale of an equity investment; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3919baf877820869dee0bd909146d7dd7eae5561d0bd54907f2eb6a6a86a612", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "503269dd-99b0-4093-8847-675af3d0bf4c", "node_type": "1", "metadata": {"window": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. "}, "hash": "fa7062d9dc13d62bb31747c40dd2c0a94e7f49528c2653cb89e57e0d90a5a10c", "class_name": "RelatedNodeInfo"}}, "text": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "start_char_idx": 4417, "end_char_idx": 4497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "503269dd-99b0-4093-8847-675af3d0bf4c": {"__data__": {"id_": "503269dd-99b0-4093-8847-675af3d0bf4c", "embedding": null, "metadata": {"window": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2ccda0e-c97e-4eec-80ae-d054e9e080d7", "node_type": "1", "metadata": {"window": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe nine months ended June 30, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are\nalso excluded from adjusted diluted earnings per share for the nine months ended June 30, 2020.  Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "original_text": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57c3fe5d5a04c3ddbf832f3154406ff973f0773f0f7671d12ccfb649f4f2f8e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a247f916-2ca4-4e8a-9513-371114128f5f", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "original_text": "For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million. "}, "hash": "0636fe262e67ca373c9613d6a90ba65504c1d78fe99f1be30918cc5f21ae9ce9", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "start_char_idx": 4497, "end_char_idx": 4783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a247f916-2ca4-4e8a-9513-371114128f5f": {"__data__": {"id_": "a247f916-2ca4-4e8a-9513-371114128f5f", "embedding": null, "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "original_text": "For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "503269dd-99b0-4093-8847-675af3d0bf4c", "node_type": "1", "metadata": {"window": "Management believes that\nthis non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside\nthe control of the Company or that we consider to not be indicative of our ongoing operating performance due to their\ninherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa67aa3f7c0cc5ab145eb361958865eaf533d0e1dddae637cfd8a97a1a942d87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37d3bf0c-e23e-44ea-89c1-0e77ce8ddf5b", "node_type": "1", "metadata": {"window": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. "}, "hash": "5c69c547790b6960e4f521815d52168d2443e321beda2581aa6bc7fbb2ed2e6f", "class_name": "RelatedNodeInfo"}}, "text": "For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million. ", "start_char_idx": 4783, "end_char_idx": 5158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37d3bf0c-e23e-44ea-89c1-0e77ce8ddf5b": {"__data__": {"id_": "37d3bf0c-e23e-44ea-89c1-0e77ce8ddf5b", "embedding": null, "metadata": {"window": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a247f916-2ca4-4e8a-9513-371114128f5f", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "original_text": "For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c45e0131aa94c0fa332bddb23e0d7585798af6c2865bcc59bf055b65b6f71161", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45747be9-8796-453b-ad31-15ed1624e4f1", "node_type": "1", "metadata": {"window": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. "}, "hash": "10d1fd5d1ef7fa7a7d1f5733d9ac5c4ee53737f0ae0c8902b13f20d248ad75b1", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "start_char_idx": 5158, "end_char_idx": 5394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45747be9-8796-453b-ad31-15ed1624e4f1": {"__data__": {"id_": "45747be9-8796-453b-ad31-15ed1624e4f1", "embedding": null, "metadata": {"window": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37d3bf0c-e23e-44ea-89c1-0e77ce8ddf5b", "node_type": "1", "metadata": {"window": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9604c614d80871bd8f2dbaa63bcd52793e3e38fa3d732dbd9bbea9af681abdd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c903fbb6-afd7-4c72-8aca-aafea514cc14", "node_type": "1", "metadata": {"window": "For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20", "original_text": "Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n"}, "hash": "a0fa182b16dcf3c01f5271c9ccb982f13d1a2f65a9f2d0ebb72e9fe33467cd7d", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "start_char_idx": 5394, "end_char_idx": 5710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c903fbb6-afd7-4c72-8aca-aafea514cc14": {"__data__": {"id_": "c903fbb6-afd7-4c72-8aca-aafea514cc14", "embedding": null, "metadata": {"window": "For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20", "original_text": "Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45747be9-8796-453b-ad31-15ed1624e4f1", "node_type": "1", "metadata": {"window": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fb8b91039bc7978572eae7632d0d3ac8014cf82e214549e2f6c6b2c0583775a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "021d03d1-381e-4792-be32-f253d624aad7", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20"}, "hash": "1a6e161eeda6dd63a026dab713fef80e71a5acf916cf546e1b58856af8986b3c", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "start_char_idx": 5710, "end_char_idx": 5805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "021d03d1-381e-4792-be32-f253d624aad7": {"__data__": {"id_": "021d03d1-381e-4792-be32-f253d624aad7", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b285f77f8d05c410ae370380ae3731157d1697f53179d9b2d0678b47c337a605", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c903fbb6-afd7-4c72-8aca-aafea514cc14", "node_type": "1", "metadata": {"window": "For the nine months ended June 30, 2020 adjusted free cash flow of $714.8 million\nconsisted of net cash provided by operating activities of $907.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $251.1 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20", "original_text": "Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cd8a09c1e24a77b8d77853016b1676a6b1edb5471893d142268500df75cf55d", "class_name": "RelatedNodeInfo"}}, "text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20200805005192/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n20", "start_char_idx": 5805, "end_char_idx": 6055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"65cf5448-5f43-4262-82c8-ae4fb45cc069": {"doc_hash": "de92d6fda10a99e18ee44d2bd19b7d782ba51ea334c0b531e14ed3f4a8d7ca1f", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "7d6f6d88-24c1-4c28-827b-1f1dcbb69e45": {"doc_hash": "77bef1b152abf9ee099f9a6c967e6ccf1bd24cc4c63143e5597829c1f47acc2c", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "f43f9f0a-d150-4016-a04a-27a207abf0f3": {"doc_hash": "ebc9753be7bc1a05cb7bc4ce964b180ab2e3be164301cac6a34188695751bca4", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "a3de3e5c-4716-4a2c-9788-ae8bc87f1a14": {"doc_hash": "07da3a134c0ee7c618f7a530b87777d55d87422ae913aa723e6b3330659a7f04", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "0b8e0094-c182-4e78-b0fa-0ac0721c1281": {"doc_hash": "77d1759db4ba81f716a3b8a3c6bc92acbffd4caf607a4a9d9a2cf572e72614de", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "be2d12e1-26f7-4dec-b96f-8aa3e5d3fe98": {"doc_hash": "666829f5440a926f3f037a8ab222086b109dcfe575bc21e9e1efd74a494a3ef4", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "92986c5e-74e8-4354-ae6b-adb13da6ad54": {"doc_hash": "6122eaab9d1e11b55384c3d5c3c1d9aa45cf3e99a58c25d1de8811508268e8c5", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "9cf7f7d2-63f7-4893-9d65-c6855806b44a": {"doc_hash": "4527e03e7bab04265ef457e336373241ad4828a76562eadc6fd6e89c6fe93f51", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "9b9dd5f6-98d4-4ade-ba05-a2b175751483": {"doc_hash": "3cad07f43e4db2402d858ae8dd540a4f5e57b97735afbf163904f92505c0c4b1", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "0034bf60-6477-45e3-98f9-623168b91951": {"doc_hash": "a933b3d3be493bddb7074af53b54707d8da3c9c839d06e3d6cd6f20fa8022be3", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "4750d4fc-2788-4a51-adec-7b0f770caf59": {"doc_hash": "d1cd195f61063f99a7a54f05856c6bf2eae35fb162c7b56b872c3ed68cf05b40", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "3ca8ccc3-e5a7-4070-9fd6-d237ae957bee": {"doc_hash": "324d0ad3996f9ab1ae5aaa56a16bb6db250d11de38d352055da3304c37387d9c", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "52fb37b8-e761-43b2-9cad-eb0f16a69491": {"doc_hash": "41029a7b14f494be793abb0956a3c0b2c2ec6e7a7cd3aa4a52b755feb18b9d05", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "2f1c0d3f-f615-4d86-a3e6-63e4d989e122": {"doc_hash": "93e8b01e0214ea14c271c34baf7c9fb2ed2e47666780713a7ec1400a91f1d681", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "76e609f2-c9be-4ab9-9704-51676ff6f80b": {"doc_hash": "31f6383622e1e96f82a476da42949a9d36732958d151f089831666415c8bdba1", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "f2921b4b-04ec-4106-b38a-47980ea3667a": {"doc_hash": "97adfdce0901c9f639fed74d4b27e0e7b0deac36b4f4bbe7059e2bfcb36ac03b", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "555c8fb4-805d-4dcc-bf8c-a6471b086555": {"doc_hash": "e7bb0e599aef39e0c503703b0161dde35994ce4b4bd8f244949864c746b8dac1", "ref_doc_id": "70fbebac-ea31-4518-b251-cb6129d6e68f"}, "c61b07fc-e085-46a5-bbd9-5c868f05b95f": {"doc_hash": "38b1903f48cb32de794d2a1b413c74de81c1d484c88fa7cd1094bcfe42bf0dbe", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "2edbebf9-5b55-48d4-b7a0-142f9277a8ba": {"doc_hash": "b1da4e3e7f6bfdada522e6761d1eec4b0e5a70ddc3faf2837c2f60ae4c567f75", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "2c6a0519-3c7b-4edf-a5ff-ec2c75f65ab3": {"doc_hash": "0ef3e5298435cf3ed4d1809a1ad30b7dff29131e6b66da56c8ed15b3d0fe1af5", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "fb4cf860-3433-4096-a93e-ca96629437fe": {"doc_hash": "41fdf521d43fc979f5788bfc8771fb4b98e8f9048dcfbf91dfca36950c5ceea7", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "07886e14-7582-419a-8a5b-0fba740cd28b": {"doc_hash": "cdd307e7534aac27c6d10feddc0a32c68d96ec35c7a03c28181e76951d893ea6", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "9b347cd0-667f-4a79-9230-e23e6b78ce21": {"doc_hash": "a211f668a6d46032fdcb4884667c3cca7628b7a47e9ef8e1ff93e79bc198d943", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "70febc7e-2f9c-4741-9381-a6e192d395e8": {"doc_hash": "d129ff1b5d4165a5218bea4999da0afc2447f95898f34db7791bae1f13d8f259", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "2096a2ec-ca2d-479a-a530-fbf61d1efc21": {"doc_hash": "0e8cce02527f8b15189ec3b73a0713a9cd4778eb22bfbb89e118b75b0b3bb9f5", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "10067524-4a83-481b-8428-d60924b1b4e2": {"doc_hash": "4b04abf59506d18c34eec6260df9b91952e98f8099e369234fdf9e0e09806909", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "d36e7527-72a0-4751-a0b8-76f9e7d8b18b": {"doc_hash": "1505bdeb5fed3813bf18dc50b7e95b286b03e4a6b7d1677b0e1f33200a32f295", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "bbfd74f3-e6cb-4608-9110-850f7776f554": {"doc_hash": "3251c8833596c969837c05494a4880fff1161e634578d9df051af55fa3056333", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "f7c31c6d-ee05-42c9-bd4b-8a4239ba2f96": {"doc_hash": "1b106900bd18676c5817ac0c723d9382411394ac02423234041b52d3f8735396", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "d2f15511-665e-4dec-902c-d3359433ab00": {"doc_hash": "f06e9fee323dbd25a0f980eb0791de1abcc3a0c753f796a3876c2ef142c26958", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "60870ee5-963e-4507-a924-f1bb00ca573b": {"doc_hash": "9b82fd81f21d4e0fed26134e219df6f2c61ce8eeaf8be060f64c9ff1388e7654", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "7615bba1-4d83-46db-8753-3be042780b26": {"doc_hash": "f2f4915b553eb0d10302fce8a9fee61224a31da43e5f8c74954921f3bd3a7261", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "bcde7a54-33b6-4019-af55-5da6faca1e30": {"doc_hash": "2c0adb1862af098a5fdfd5d870dcac2fa950eac7580b7b6a89db8ac632a7f155", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "d997cf5a-719d-49cb-80f6-0bf62b31eb70": {"doc_hash": "ca1609e08fd5668b0bceae49acc7b6d6c16fd065b6d8d650216638c64d1e0a34", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "e562088d-bfb4-4f89-986e-8d532f02227c": {"doc_hash": "2e1aa15f4b9027f1ff40850ed36b110eca2ee7391880e8d93728efaeb39e7615", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "1398d408-af67-41aa-a990-5761b746b38c": {"doc_hash": "e9fe833773f983bc760dbd6e26d94db2af878a7d2c778c7769d7c9cf8e7120b1", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "52a0b661-7151-4af7-8742-0e05a3783bda": {"doc_hash": "2d85413330ae3213aa161c3653fff578600973f105e865f900a31906de313473", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "c737dfdd-6a16-45dc-b0a8-0fc674b28795": {"doc_hash": "c936d903ad6e51946a37d1a54730056acec85e8fce7ede1c944708234ccb50c8", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "d74de821-9354-40e2-bc8b-4c09101b12d8": {"doc_hash": "280d5c430efc7bc552de6abc162e0f6822217abc10fc76b578b32ba95406445a", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "7a498470-3430-4f48-bfb2-fc58d41dcd68": {"doc_hash": "05caf2d44ba2557a8f4a5867bc7d9a2bc6d1be994376ec9b69ec846b51ae9538", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "43486c2c-b2f7-40f9-8c47-9aed9ca0582c": {"doc_hash": "128e1f8ef49dbbc6b827270cba73e270453346d57aafdab445cee03cdd454744", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "8df2db55-703d-4081-89eb-135755a7455c": {"doc_hash": "025c14d7bdd2ca48c28cc687dfec5bf90fae57c3531ff9132453834d6a50046a", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "03866011-1c44-4e7c-a203-3de645853070": {"doc_hash": "0de5ef5a2203226d81bb593b9ac75c18f4957c42d2f99b1c22078b409f36c866", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "17ded132-431a-4f15-80a0-3c021c5312a6": {"doc_hash": "a55e28ba8d2f2c2eb31193a40276b3837b8282d9055032aade9945648ddb361f", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "7c4b96ef-e5c4-4cdd-8a38-d18d14a3b9aa": {"doc_hash": "87ba17408e2d4e80281a854848efd69af374da426f7be4dd74e0f160b749b310", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "68219e55-d717-42f9-9236-89f24fe8aca6": {"doc_hash": "750d25886642aff2c1fab1882fca34c6882657592d36b361bababe196570e8ae", "ref_doc_id": "c4204106-c462-4112-a022-54a77599d681"}, "2dd829af-18ca-49ab-bc5a-41852ec4039d": {"doc_hash": "c35882eae032530390d18bc496dedbff4d509062609f3a96a200ddb8b55ffb41", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "2bb8e118-5f41-4b36-8562-b5cb2093f8a4": {"doc_hash": "93ca8a2112840cee3a5219fb007920a5526e00b2147f8f7146e56a79988e18c4", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "3b20584c-1fd8-46d4-8f95-8074f9173572": {"doc_hash": "6a957fdb211aa975ba970b2fd456448d90c135628a43afc7cf024e645afe622f", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "d95cf284-192d-4136-88ba-0a196bfcbe7e": {"doc_hash": "e6326c0ff80de54f6a7872f8bc755f41569e2dbc197849498c3ef6d94c34cf40", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "f2bca132-7af7-4fa6-b525-16801b980051": {"doc_hash": "c9a7d867de30c67146e29f2275c2260e10b382d72ad24eadeb2b33eb2b6912bd", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "e870d7ed-2626-478e-8344-068fab05121c": {"doc_hash": "e353c66a7216a2e74cdb1b7a28843163a1b0ca7a0c64cb9dd936c87c562072a1", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "07160d94-78e2-451b-ae72-9610b098deba": {"doc_hash": "6e5fd220a185c3a2d43edf30a9c38297d0e1cb074dc22e3b7104e895e2c47534", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "3bc0e261-5929-4f36-a597-5805536cf65a": {"doc_hash": "f866aaf6fb3f1b0c4ea23abc775d76cc486fcba8708933d4668ac97771a60b08", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "1ed4ea10-3d63-4f11-92ff-944e50ba780b": {"doc_hash": "6ee15b837f3434ed1b6558f0884454b05c6978f991dca1a18dc28deae114d601", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "1c033763-c7fe-497c-b901-fe940d6a29f1": {"doc_hash": "70f89fa42b75b8b91bf10e9738c9114ce2790b23b936bda099d8370fd37cfb58", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "7bf23e80-efce-4844-9ecb-ffd8190f46f2": {"doc_hash": "8648775585c82d9fdc1c9affd1ef59a386c54103e5624e3ec36c196ca1067724", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "bb10e42b-97c9-436e-a179-7dafb546f876": {"doc_hash": "d58143736fbde77c84ca6a723ea6ad2f251b54b4a46d9064f20b549a66c4c300", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "63b5bf62-8b0b-4041-bbfd-733c382d4bdb": {"doc_hash": "6dbb63b5d9effbd73df14dbc747e8fb1ebb7da773f8bf1848b9a57861556d9ba", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "04642c91-5028-416a-bf53-00bf20c51836": {"doc_hash": "4402e534267023b1de7e32221461902d33b48d7ef073e9a6349ea6342c21f849", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "6811513d-cb7f-4fef-98fa-12aca72014f7": {"doc_hash": "9f2755bd5ae1f22ace196111f302a52a243cf195751fc7c0082218f05d8c3666", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "bd0e457a-04ce-4fc3-9252-836501691d12": {"doc_hash": "028180908afbe00e1a001e4fc12cdbba37fcc5ca9e5a99c9d5d347a07fc308f6", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "f81b76a2-876e-40aa-b288-711c3bf0bf5f": {"doc_hash": "54453a16a9807588f77314e227a3c22c248d4a7766499c35cf7e58dd9aff7e0e", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "bbb4de3d-c64c-4b78-b7a3-eb2cc4eddcbc": {"doc_hash": "3df1c01f6c0939cd6720dc6e2bc642a8474b6a8ba35a0de1c2092363a9f707bf", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "a85d0ad3-9925-4b24-ae2c-4df19bbdcb29": {"doc_hash": "896956fc17978e3d35ebafa760150c96c04218c75f9f4d6598343cd4c43a1646", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "c9a1e6a6-4961-477d-866d-24d684666623": {"doc_hash": "a1b680c2c3e866dbb34876cbe6aed401c2e9d8e399b36f986c09e62689eaf0b4", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "ff625ce1-47d6-4d7d-894e-ca4b5e8f7f66": {"doc_hash": "84bec078329088321c012aba91ac12b605fc22bae4c8da0aafa1eaf3e590c551", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "6e75d999-6ff5-445d-bc52-dca61a47cba1": {"doc_hash": "d0b4b5908870995b2a4da331f6fd5f9b6622362545899452a733dfa679b4e84c", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "808c28b0-e82e-4404-bb7f-1b29186eb969": {"doc_hash": "aaf2423d4bb14c69d8fd1af7dd057e3b4500b670a9270b730af49a4845e1320a", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "3e84990b-f8f5-42ec-a7b6-97002c129ee5": {"doc_hash": "e62f25594ea5ef0b224c0582b930b7d7fa4c7643d5eb863b192e3133faf7ccd5", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "8bc6c30c-a2f6-4371-a5d8-0d7cb88f9b37": {"doc_hash": "0601cf86e0e650e3e31101d5126395d8918a4cbc974eeaf8f3b626cdb2392957", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "f5befb07-a5c8-469e-b31d-485663131926": {"doc_hash": "a3f34b0a49d81deff67a565378d765ccc756701cd36661dbba93051f925cbe5c", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "c0c15b16-1c43-4ca2-aa52-24bf5fc8eb1d": {"doc_hash": "669f5345a6720b8ec596874fad851de94a2be45f5741355f849089c682f6354e", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "d1b297ad-ddf5-4437-b8ed-c276397227e3": {"doc_hash": "a98a0270fcb5c82e91e6e64cb16d0cd27bca53b4abce10338023edfdbd4a5787", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "aea15a83-6f51-4b3e-80bc-3140149d4cdb": {"doc_hash": "ec16c826309d78e4d47901ca5a11deb294e364126d04b905f79613171125c763", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "4acd4213-e5bf-46c5-ba0d-4078e84347cc": {"doc_hash": "e1ef178707254469e23d7b3c105162bdc6e011959574285cdd6588e1c3c747b0", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "bbf0dbfb-b0f2-4af1-a04b-7cefcce6c8b6": {"doc_hash": "7c56ffa0d8d6e5957b6f6270a495b5b50324f22d4ceb127f51c518ed9a20f38e", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "38a63f77-0eac-4e12-9fd1-565dcca30368": {"doc_hash": "9d75c7cc1dab256710a50a39bfb86d831d0c414907a78b9bed1cf6fd33478564", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "e99052be-0815-488e-b3b7-822cf5b1a100": {"doc_hash": "c8bc2ae8bf59e9ff23a9d74716e49e66dd1545379e2328c0dbfc25f2cb9a25d8", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "8ab5417d-0af0-4e19-8ab3-5b2c52e1fbf5": {"doc_hash": "34571ed837dd8646fa8f784ca3e679df5e7aff0748a5392422d6e58c542b47bc", "ref_doc_id": "c3e58a73-5fc6-4075-886c-8fba9b5180ce"}, "a9e5dd88-2a14-42b4-b32f-1b36551f621f": {"doc_hash": "dd0c98dd7ca803c58cdc8d61e21cef8e57ad5896f5f06e6dc1846dde935872cc", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "60431961-ac23-489e-b587-53fa02c36d62": {"doc_hash": "05c7773012f5be7aaa957cd58b26a8e858fd3ae9bd3941ab477bf8034e4b5ed9", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "058b7293-baa3-4875-a2a9-23776e73cd71": {"doc_hash": "44040eb09c5934052079518ddd1e73d1509475f429f52226a5ec70d444130405", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "49ed8040-65fa-435c-82fa-b6ae1e8d9745": {"doc_hash": "7dc0ef453eb975c37b278c235a2954039f00606450b7cf972b3929da850bde3c", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "95ff92e8-a198-44fa-bb19-212a26d4b000": {"doc_hash": "390a6f96641a04f2dac33ee748f6b96958c6cf788fcbed3a270dcad548cf0624", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "50e6c2d8-0b17-4a48-8a8c-878c8f822527": {"doc_hash": "db54878784dbb379a5a3da72e7448f556714255043bb8b8bc33d1df51196dcd8", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "3466ebfc-759a-4ef1-9d05-9b825ae4b7eb": {"doc_hash": "4caa07f525ef9179755929555e7ebc6d12c1727254a979ec4493527fa4f7ce40", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "6db64365-be1d-47bd-8732-c1ffd8041dc9": {"doc_hash": "9ae74b2fcedfe4ce2c82b7824450e3d540b19226a8cd129bc4258651f86993a6", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "fa29ce30-8b9b-4fbe-ae19-87d85a09efa8": {"doc_hash": "52418b5de58eb34f31385a2f8ff272c94b10ba5a0ca05bc09081eadb10e10e94", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "21af7843-87fe-4c07-b658-d9124465f39c": {"doc_hash": "ca41913baf6eb85e33662230b40b21a23d97c1b7146ce65b85f7224f7b68cd3d", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "904f6680-ef74-4dfb-a157-e44d4820fc47": {"doc_hash": "32cb20d65ca909c02b245d448840bf7d6c394b0124dd360a46868571fdd472e1", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "86c1be64-bc3d-4ca1-becc-afd5d160910e": {"doc_hash": "b09cb946eb45891efae5355ee385f26a135c2029e1212a635d82d0e8bc259296", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "9f00ac51-a67a-411f-b0c3-af46156d560d": {"doc_hash": "71a4f265c22dc7fadcead8533b208b57090ee43ba343935e989bcbf8dd907f72", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "fce86bc9-a518-403f-8fdc-c9ebd2e63ed0": {"doc_hash": "07b53ce7f28da6843f0b9490abc03fe3ed4d64ad6358a6392cc6b8d14c4ec623", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "a8c5bc2b-179e-4f52-8a69-86c5e3e98f71": {"doc_hash": "ab021f34d2f1985d6e6cc352d076b2a395e585a5ddbfbf91a002a549e1993d4a", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "a5bde54b-78d8-4177-9fe2-8465feee7796": {"doc_hash": "fc65ec0751771012425795fe9510c779cdadbef2fb632162363992bd8ba5fcbf", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "0458e319-7c6f-45eb-84d7-465e675d34cd": {"doc_hash": "ded00261240dab15d3ff203b6f85903ae167b7460d716eb9b2a1eccd83a35273", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "d6cbe76a-0dbc-4e04-b00d-0adcb8152852": {"doc_hash": "26264bdb38d73bb895b6077ae8a823bfd4cbb78d160b0529923fd5158be5f9a3", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "24fe7ce4-9536-4955-b92f-cce780c96465": {"doc_hash": "60b74cfe3cd1e25a45c881d8f9f81bb6d1fa2d6dfb4ee73dc7db502f1b9e81f9", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "d54feedd-f3ee-4815-b821-80370e5aa5bd": {"doc_hash": "891a471da2674796333387691aee1ae161c8afc88a73d68be800600f9165fbe7", "ref_doc_id": "e67f164e-f9f1-439d-8b06-eb90daa0892a"}, "0f50c2e9-d43b-4999-a3c9-7709abd91489": {"doc_hash": "83482ef63f7432809aa51f4b913d5faf100f0e3f367ee180de61c0c29a34ad2b", "ref_doc_id": "59500035-e69c-4271-84ef-bd94e205147b"}, "5c427d0e-d902-4857-a5a5-e589ec524299": {"doc_hash": "3316b85679f3d92a0b684cbdff1464bd16180aaa53f8ce25e75802b5b80a4995", "ref_doc_id": "180116b2-3c32-45cb-bd95-292191d67a86"}, "7e3fb727-d560-41f2-a117-8ed1383d584c": {"doc_hash": "ab034cb75db4dc7a5257316fd8275938b0897789d25aed65ccd2cac090507f7f", "ref_doc_id": "180116b2-3c32-45cb-bd95-292191d67a86"}, "4fbb6439-e309-4c88-975b-24a53dac8fbc": {"doc_hash": "811a9fa0f3681428b0541759ba6b0dc09ba90a4ac7d6bcdc437d79bb67f75ed6", "ref_doc_id": "180116b2-3c32-45cb-bd95-292191d67a86"}, "20058860-9d0e-44e2-b215-546887dfbebf": {"doc_hash": "e542baf4af994121b1d8eda8b1d637e31bb7c1238954723e575a9ee0f3e66ac3", "ref_doc_id": "180116b2-3c32-45cb-bd95-292191d67a86"}, "8c159df7-d277-4e0a-9012-706265c28ed5": {"doc_hash": "960c7d30c2d05177b88c155f9ace7409866aec4c7801a97300b5ec610b2f365e", "ref_doc_id": "180116b2-3c32-45cb-bd95-292191d67a86"}, "07b694fd-876b-46e1-a35a-20bdb2b0660f": {"doc_hash": "34fd19eeefbbcbef44a0fd66ca4c4a6d94d86c389060733965535f5a09ce100c", "ref_doc_id": "180116b2-3c32-45cb-bd95-292191d67a86"}, "b27a0407-8a21-495a-8653-1f33ce712187": {"doc_hash": "96e07018a5c0f99f50195347cbe9dd5e437e39f9bf9949755a1d7e24144a196a", "ref_doc_id": "180116b2-3c32-45cb-bd95-292191d67a86"}, "6aad0138-9cc3-4219-a7c4-90cbdd806c4f": {"doc_hash": "92774a198879f9665258354ba3b45eb2276bdcb0884418933162ab298337d068", "ref_doc_id": "a22921e2-8a35-41db-a332-2986693373ce"}, "666b43ce-d4cc-4e1d-ba9d-65baa758748e": {"doc_hash": "f183036ce8dfa9d8a3c67a95f862dccb36a21843e273c5ab7b64cc0b03fe5ff2", "ref_doc_id": "a22921e2-8a35-41db-a332-2986693373ce"}, "8d1c29d1-c8d7-4d6a-87e2-b56bce5733c8": {"doc_hash": "6f667ee2069c2472f7241782cdf34eac37d24bcdbba5546a8506f4ab7a5ee30c", "ref_doc_id": "a22921e2-8a35-41db-a332-2986693373ce"}, "707d2033-8985-4813-9649-91984dbd61d9": {"doc_hash": "fb8bd3c6496f55ae0f0cd2bd1e2da0aef866acafbf0190d5b22a64ac14342a61", "ref_doc_id": "a22921e2-8a35-41db-a332-2986693373ce"}, "bd7118f8-550d-4cb2-9d0a-21567dc8a579": {"doc_hash": "6adfdc01256e2ae4aebcb916568f57080f780e2d9562ab29d806dae33dc8e86c", "ref_doc_id": "a22921e2-8a35-41db-a332-2986693373ce"}, "2896a06c-05e2-434f-a673-ab88603153f6": {"doc_hash": "d010202987ae48d3297de09805e5f769c6ab656e9067c284ddb8b8db20d0ea68", "ref_doc_id": "a22921e2-8a35-41db-a332-2986693373ce"}, "214fd6b2-a69c-4515-93ee-6bf1cd59b4b3": {"doc_hash": "53b66d9c44121f0864c577f32536668f1a76e2ae94985a09bf930f09f788fc85", "ref_doc_id": "a22921e2-8a35-41db-a332-2986693373ce"}, "4b953c94-71f9-4a1d-afbd-6335d167b8d9": {"doc_hash": "1621580e061d4371da195a6bd4a176892d3847289aca06295ab41f82fbaa412a", "ref_doc_id": "a22921e2-8a35-41db-a332-2986693373ce"}, "31b803d2-4afe-4123-9a38-6230d9730ac4": {"doc_hash": "129478bdd26c03443e94231df9d780646851683d969c164a6b3be00f616035ce", "ref_doc_id": "a22921e2-8a35-41db-a332-2986693373ce"}, "44939be8-2b11-4e52-b9ba-8dd61a73038c": {"doc_hash": "ca191f8dfb7d58ed1a83146a73af6e720f68cebad5b7780684388f75501624e8", "ref_doc_id": "b848607e-c6c6-4df1-9963-86d9f547f5a3"}, "dd1ab706-3e10-4013-b5e1-89c1d113c7f9": {"doc_hash": "e5a12914d6906a54fd30380c596d4e943b12e62f80a1e7aa51654752a2e358ce", "ref_doc_id": "b848607e-c6c6-4df1-9963-86d9f547f5a3"}, "3ad84de5-a231-4002-8d42-63ffea721df8": {"doc_hash": "000bfbac7d8a9000271272342427e6470991b34c7d152a4375a41ab2d4846ced", "ref_doc_id": "82064b6d-623d-4086-abd7-c97481b0d37a"}, "e43c5b66-0996-447f-a490-387ccf77d556": {"doc_hash": "02f914519c346d3844145c25bd62fdcd494dc06e155bd231ceaad4769581c3de", "ref_doc_id": "82064b6d-623d-4086-abd7-c97481b0d37a"}, "77dfded4-6891-4eee-a114-d7b016812b81": {"doc_hash": "ff9875807471123ff9b8fb84a4e30351fde2faec1594f892e93d286057ce5b8c", "ref_doc_id": "82064b6d-623d-4086-abd7-c97481b0d37a"}, "ed8d293a-1959-49cb-8388-aa5c5ea59cc0": {"doc_hash": "d322427bb01181081343f3b10bf58914c18db9eabaa99101e5f70a0d046a3e5f", "ref_doc_id": "cd42e72d-411a-4d6f-acf2-179de2e96ba0"}, "2e0d6826-5cbf-4432-a0bc-1bfc58cac9ec": {"doc_hash": "954ae588168746ac342009e13cc196147b1b34d314fddcee598d702e7f59fa09", "ref_doc_id": "cd42e72d-411a-4d6f-acf2-179de2e96ba0"}, "d14e0cb7-2acf-400e-912b-73bc6c49b1fc": {"doc_hash": "338c0d904b2c94c5b592f3d65495615e7d7c11d4433a9daa4723b15e18f678ee", "ref_doc_id": "2fac4174-b67d-4b9e-8bf6-ba77db9fddc8"}, "6f66226d-e101-4790-b0fb-72ca7cf48a35": {"doc_hash": "22c7f1a93c887cf43ee9d04f0db14c1f59d52aae298cb96b47a5d248a78f0c14", "ref_doc_id": "2fac4174-b67d-4b9e-8bf6-ba77db9fddc8"}, "5f7edfa1-69f3-4eff-8ac8-8ee5720cd073": {"doc_hash": "fd2742a9b52588f3939e8e8a04b259d8b113181a2a9898310f8283cd3d29f45d", "ref_doc_id": "78dafa05-72a0-4f55-9ecf-9c84d83ac748"}, "04552432-55c9-4a63-9ed1-58a06dbf980a": {"doc_hash": "ca2990cabc698f17067f6a94380a133f1cdb18d88ddb9334bd21cb702a11fa00", "ref_doc_id": "78dafa05-72a0-4f55-9ecf-9c84d83ac748"}, "d79906c0-ed53-425c-84d6-b0e95ce9541f": {"doc_hash": "ba67d4f785c7f6bd23a8ff1b526c3b77eb60f26dcbac2dcddb75bd7068d15259", "ref_doc_id": "78dafa05-72a0-4f55-9ecf-9c84d83ac748"}, "c48b0260-3bb8-410a-a4ed-b642b9ef947d": {"doc_hash": "340f6c148a7741bfb6901e70ff1e5e5d63234064c2b36b521bcb8d950f34a5dd", "ref_doc_id": "0f13d13a-c232-4e6e-b135-f644cdeadb64"}, "89c240da-2e50-4874-95ef-6c7165cb4ac8": {"doc_hash": "e82f4affaadf10a0004c4a87e245cb327335775dbd035ecbc84921cc737adca1", "ref_doc_id": "0f13d13a-c232-4e6e-b135-f644cdeadb64"}, "a85c0113-388b-403c-b583-6289dad83352": {"doc_hash": "8375f885d0ce3692b7858e5fd00350004e19e5e096241e4809504e07e0435e52", "ref_doc_id": "0f13d13a-c232-4e6e-b135-f644cdeadb64"}, "b66ac0aa-3216-4501-9cbe-7bdce0c280b4": {"doc_hash": "d83ec7e5ac345c42cb361f728634c22997bfce7546513bba91e5aaeb0ebbde21", "ref_doc_id": "0f13d13a-c232-4e6e-b135-f644cdeadb64"}, "f8dd1933-92b1-41d9-bf6f-6b1c7e7927a2": {"doc_hash": "e8d26f16459b1651aa4bc9f14f92966b9345f57d84e1a579599709a1fb2dfb74", "ref_doc_id": "e3b9e143-b08e-4d68-aadd-e7de5f60634b"}, "a8bf31c0-8b0d-44f3-aae0-0079d5eb66be": {"doc_hash": "7ba9c0f3232a3d9c9e57ba717a7f0f5392442b0d3b7b1103f41c4a013c1c0b59", "ref_doc_id": "65bd7d66-d65b-4437-b407-bb11349b5661"}, "2e22ef0b-1020-4bc1-abb8-2ac626ed3fc2": {"doc_hash": "2344f3bee0d3a9d20a76f00b042c35218f73490b16ffe9c8b06ffa1cc6cc9699", "ref_doc_id": "65bd7d66-d65b-4437-b407-bb11349b5661"}, "28e31d3b-d6e2-43d9-9570-4827f6d81c62": {"doc_hash": "8258159b286f4407ce60d77ee8611db83a1819f880dbe7003fc6af7b4f822970", "ref_doc_id": "6544b14f-783d-42de-ac54-af861b6c02ef"}, "6850ae5f-ae50-42b1-8330-41be1b18f522": {"doc_hash": "594f6aa324f6a03192c78b80cee05cf8e03fe77908b6b0284402c8576d1e0c84", "ref_doc_id": "6544b14f-783d-42de-ac54-af861b6c02ef"}, "2ec50963-8393-410d-87f0-c07c6dc534a3": {"doc_hash": "6881c11cae757f22723c060a88c380694faa82001eec8fb797824553ce8c7ed3", "ref_doc_id": "b2b115b8-ed93-4cda-b2c7-89b8e9882f6f"}, "178fe94d-8412-4a4c-8f6d-7683665c0205": {"doc_hash": "91ff1a97f7b0545abdd4a9be4817e1d77027f4af564e10122f49b8f944b8c5ca", "ref_doc_id": "060b78bd-9e1d-4ea8-a1ad-b3aff4f72097"}, "26a4f67b-5c17-4762-af4f-9c0c30eecc7e": {"doc_hash": "d3f0fe8fa47a6f25513ec9a28358610481325dd27b47562a4652a143683376c4", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "fc51873d-b3a8-4e26-bc8e-4777492320df": {"doc_hash": "0a05d4135185b365cae577f591e392d1a8d24c34d8f0a6477a4c9549121af387", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "92c34571-edff-48bb-a596-98840875de43": {"doc_hash": "65b217f70d8dd644cc4c25352a99c34d28eed61371096aee0160e63e3fe9a867", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "bf32f49b-72d3-4557-9df8-291da68812b7": {"doc_hash": "362df9bea0cc1319eb85b4fd291e5479fac4ac230fdb5d950c685e4add4e4dbe", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "f1df983a-99ee-404a-a040-8f3d3107f03a": {"doc_hash": "f51e4f574dcad19bc19922a1c157e4c325d10fa83a216e62d032e9197d55a146", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "04331851-9731-49fb-a667-ec5a7226375e": {"doc_hash": "37292e6ff2b084260fc6fe0920c154fab6a42cfa569951c2ac957a8417f11653", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "70af933b-b328-40b4-90b4-68026826b6c4": {"doc_hash": "dd9d63832a393fc05ea241f74857b2272b01b7f2786b028008f5e403338424a6", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "a4e53a5f-9177-4317-9928-1b2854361d02": {"doc_hash": "6b080dfea2f8ddfe10a21bd7c63e6df8de35c27b33c31732160a0ea08be580ff", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "c4046d57-5ebf-4a13-849d-c423261c6463": {"doc_hash": "0b4ba9e90372057ccdc8629c6c59b06451867dc7047299aae031190de5547d68", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "9b10e31d-47e7-40b1-b5c9-29d3b4703628": {"doc_hash": "11fd60a951fc85f95f42eed4afb78a77081ee57261ef285acdcb940e147fa7b9", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "1eee06ca-34b2-4dc7-9b3a-b38541848ec5": {"doc_hash": "9be2d3c6c45f07cc50ffc06e8e408b335cc07eb7d069f3f6f3e31a630ff9d183", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "e7f6a791-e045-42f8-a28a-56bb9c351603": {"doc_hash": "fb8c641b6eca4ebaf296958774b18833fd272f69e0a8971f1734f444334e63aa", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "4ffc71c6-3022-4a8c-bb7c-3d7316fa2a30": {"doc_hash": "b592a4a96a677c0cd855ca476eadcf0d40e57cb702df204b092979600fe798e6", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "3ba64d31-f0ed-4cad-bdde-a81c5e10bc68": {"doc_hash": "f7bddb57503217b069e8c67564b90d903fc1eb31f6426cac6da3b5986ca21177", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "b03e8a4c-909a-454e-a293-f42cbfcc5f88": {"doc_hash": "285e998bb8bc07ed882ce635b109fd6773916f133de23d0202afcf36569e8463", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "719faa34-917b-46d6-9fea-d3d7ca94e5c2": {"doc_hash": "faea6463f7801bb759aee1a360d18c68b1795acf237ccd1bc9aea16556edf40e", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "383af777-f0cf-4fcf-a4d3-007c36ad3544": {"doc_hash": "4e4d507700b1aae7c34a4a894528986f827db8749f441959943e15a30ec83c07", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "c0c4d8c9-ada3-4b08-87c9-a5a07fa18905": {"doc_hash": "ef424d1ecff54061af5009773d832edcb20e76bd4793eb6821f3fbe4bb889446", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "e2e2c247-07f3-4721-893e-f7b9c14b950a": {"doc_hash": "0fd39d7073d4a1797277fc897531540461e87a57640315ecb478e3ab045945fb", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "e832e67e-0ae5-4388-b03e-4783aab99162": {"doc_hash": "cbc9e883549db1ff2a78c34dc07ee254c4d080874ce4eda77e6fc8eee0787255", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "790dc9e7-a22b-4d23-b3c6-a54cbfb9e8a8": {"doc_hash": "683bc852d253b49851f31da280bd2e3f68b6854bb70bb1235e7e325da17a7b40", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "337f07c7-87ad-4dbc-87bc-b4c63969bfd0": {"doc_hash": "513fed4d7bf9151f8af9d2a54c6811cd6909d9b5156387f4eba064f892e5c7e3", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "485a48a5-165b-4d1e-a5e9-461303dc4ac0": {"doc_hash": "7777b36e59a3796a950ba5de18d1994316ec3f9a094cf14554895bee2dae42f0", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "8d5abaa4-95cc-4a19-a96f-3a842a89463a": {"doc_hash": "b26a654b3a327ede785fa445af6c407c40771102db343329d1d4d11edc0cf69c", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "96d6e9be-b614-4e4b-bfb5-cbb7b20f2985": {"doc_hash": "b0ed916f398a0886aa6c6944b2c24a14cd6cb53f40ffce3b409049abc9f51dd1", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "19b495dc-ebed-4513-b3d4-f583a694203e": {"doc_hash": "64852517b675a356957b60aa0f02d537fb697c0737a0915af3e0d45864aa2659", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "715943c3-63b3-4c64-b8cd-b61bdf4582fb": {"doc_hash": "a7a1bed23e55cefab28aff54721c1c6a22def01fe4aa092b786ea576f62dfbc0", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "28c04eda-0164-454c-b6dd-5b976363d72f": {"doc_hash": "74ff409509b25b9d0e3ba9e33b6f7803059a418498f1d35f1a1ed3be3bda5d78", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "f1e5a864-b892-48e0-b49e-2fa7cdbcafc8": {"doc_hash": "eca8edb3934ff1ac217f5de45118af0986ad057e002ee41695f3ea69b9809b31", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "9dfd1847-e97a-431e-92ad-3477f6426f30": {"doc_hash": "21849efd7f206c87326da58180e879971f146fcc9510cf68ede317c730bf5748", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "f23913d5-1301-42bc-8faf-e0b5b32eda99": {"doc_hash": "3157015ffe3ac769ffc855034a1e175ebdbd2f391daf8a677085de3a0597aab4", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "2f40efe9-5151-4ac8-a4e6-fbdfff7f62c1": {"doc_hash": "515e9224e016443569621ff16f308860ca6566919d077184581901327adc5ed0", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "99c329b5-c22c-45cd-98bd-c8edec42ccff": {"doc_hash": "3d08af4a4258f6e6e76679d357f20388b7f6ebf96b8490f6bb472c72ff932441", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "b609321a-3c92-4f35-a13a-f3549c28dd1a": {"doc_hash": "3b4c36ddcda14c804486a96fe8bbfd6a43151e40e646d7470a00df3ead4fb6fe", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "d51a10f5-597b-4d91-8e7b-ce9d07410c9a": {"doc_hash": "ca7e60867a1b6e8ce13fffe504553880262fe3714f6fcade8a7e77068b76151d", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "6b0bac72-c937-47b6-bb08-3abb4e0080b0": {"doc_hash": "ecda24483a53ba6b22a99086e19cb5bea94fc7d256c9f89470e9d77684d68935", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "35a93537-6244-4c61-b1e8-892899ef0dec": {"doc_hash": "8db5b17d319e1ea039d30fae4f7e32a4b77b46b316cef2b49abcd147d99841f2", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "bee99828-9cbe-4e49-b484-0b35e5519208": {"doc_hash": "6afa5d62562583d6e725717fc9483de23e33ca6e7046999dea8c0901e82492f0", "ref_doc_id": "9352e195-5bab-477a-bdfc-3cadefe1c595"}, "c7899727-9ab2-485e-96a8-a576b2cb5531": {"doc_hash": "ed7a3d236020a9327d866286bc2b927abcc669b1b3c5b7f2d9a8097ff2f58298", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "72e5454e-9864-41d6-af49-48904240dd21": {"doc_hash": "68f5a7ea56e19879e8d8313dad9992b0a5e67a0eb49b0d6a6f1a0f5305f10735", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "082be447-20bc-4071-8a6a-5238b21d4e5a": {"doc_hash": "9f8e39027393bf9a00a077a08d56a613a2d0f6273b6ad4f606c9c26b67f6a8ae", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "3cfe1519-ce0e-4f5d-8b71-1bdc1bb69086": {"doc_hash": "c4303fdad567552d95c6bb3c76f5fb482b8df8cdc89baa08e80ef0ebcf514170", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "2ece4cae-ca5a-4649-9989-31ed3c840d55": {"doc_hash": "8120f2dfa98d93c249264dfcf6366f948bacb9f3d8d93d8eda4f54a4ccadec12", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "bf27b8f4-32fc-4dec-84a7-292fb48cdd57": {"doc_hash": "bce2cc06959e1df3847df6f69a6ef40d88268f9c63c19f39a16fea10d49094bd", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "67615f67-1e39-402e-8440-875db737bc7c": {"doc_hash": "611b4eca735578e0e01511327ff3f7a476f611f7946226fbaca359ef4aaa5f01", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "2ded1719-d446-43f8-a40c-927bc8a8d8a9": {"doc_hash": "2ba83fb72c94817a0244c09bc00113f910e7f5737ea674b79c83fcf411deadfd", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "a915ea01-0728-4d28-adbe-7f43e789b7fc": {"doc_hash": "ceae93da197dba90fde28762c61ec66fddc2eea831b0c56aa9bf6863ff76f4f9", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "f66b8e83-0b6e-4b99-bfb0-c460dd159e59": {"doc_hash": "8499d410ccf0d4724a1fa5fb3364d008f655ca0249bfb5b436ba72de13081483", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "a247467a-8f6e-4bef-a810-8f78f21b4aca": {"doc_hash": "49695e99d92f84fcb3a004022d476b53022e10723478f558400161d76c2bda51", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "e6e6dd81-bc21-4d09-b549-746805e9f03b": {"doc_hash": "680761e5c82b98cbf94618d94d59db12f09094e63658244fcf7de765021fe9e0", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "45f88dc7-d0bf-4928-baa8-4e2d6a016ebb": {"doc_hash": "0f247d34f18f20c8669a19b27f089cdd30736b7ac33948dbadd32fac42faa713", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "c7e08ebc-62e7-4337-a70a-acae81472307": {"doc_hash": "7cab628bdd6a991b16fcd27e1539e97dbb188d3bfd2c9df76fc6c71a8936bd5d", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "9b10c9db-6053-475b-92f0-a80970dd6c3e": {"doc_hash": "a30693cf0c8f3ff3c1f477724a097f1404070e31277c7133c8db895b552b3d77", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "6e7bd4a3-3e70-41a3-9a36-6e8aa9c1e293": {"doc_hash": "d3919baf877820869dee0bd909146d7dd7eae5561d0bd54907f2eb6a6a86a612", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "b2ccda0e-c97e-4eec-80ae-d054e9e080d7": {"doc_hash": "57c3fe5d5a04c3ddbf832f3154406ff973f0773f0f7671d12ccfb649f4f2f8e4", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "503269dd-99b0-4093-8847-675af3d0bf4c": {"doc_hash": "fa67aa3f7c0cc5ab145eb361958865eaf533d0e1dddae637cfd8a97a1a942d87", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "a247f916-2ca4-4e8a-9513-371114128f5f": {"doc_hash": "c45e0131aa94c0fa332bddb23e0d7585798af6c2865bcc59bf055b65b6f71161", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "37d3bf0c-e23e-44ea-89c1-0e77ce8ddf5b": {"doc_hash": "9604c614d80871bd8f2dbaa63bcd52793e3e38fa3d732dbd9bbea9af681abdd7", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "45747be9-8796-453b-ad31-15ed1624e4f1": {"doc_hash": "4fb8b91039bc7978572eae7632d0d3ac8014cf82e214549e2f6c6b2c0583775a", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "c903fbb6-afd7-4c72-8aca-aafea514cc14": {"doc_hash": "7cd8a09c1e24a77b8d77853016b1676a6b1edb5471893d142268500df75cf55d", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}, "021d03d1-381e-4792-be32-f253d624aad7": {"doc_hash": "600efeee8097caa9465944acd4b28385d97ff4a9ed5f036ac17737f84b74b611", "ref_doc_id": "0da1d1fe-4397-4a8a-aa11-1019da1613f9"}}, "docstore/ref_doc_info": {"70fbebac-ea31-4518-b251-cb6129d6e68f": {"node_ids": ["65cf5448-5f43-4262-82c8-ae4fb45cc069", "7d6f6d88-24c1-4c28-827b-1f1dcbb69e45", "f43f9f0a-d150-4016-a04a-27a207abf0f3", "a3de3e5c-4716-4a2c-9788-ae8bc87f1a14", "0b8e0094-c182-4e78-b0fa-0ac0721c1281", "be2d12e1-26f7-4dec-b96f-8aa3e5d3fe98", "92986c5e-74e8-4354-ae6b-adb13da6ad54", "9cf7f7d2-63f7-4893-9d65-c6855806b44a", "9b9dd5f6-98d4-4ade-ba05-a2b175751483", "0034bf60-6477-45e3-98f9-623168b91951", "4750d4fc-2788-4a51-adec-7b0f770caf59", "3ca8ccc3-e5a7-4070-9fd6-d237ae957bee", "52fb37b8-e761-43b2-9cad-eb0f16a69491", "2f1c0d3f-f615-4d86-a3e6-63e4d989e122", "76e609f2-c9be-4ab9-9704-51676ff6f80b", "f2921b4b-04ec-4106-b38a-47980ea3667a", "555c8fb4-805d-4dcc-bf8c-a6471b086555"], "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1\npercent to $1.85 in the fiscal third quarter.\n", "original_text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Thir d Quar ter Results\n8/5/2020\nRevenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year\nThird Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted EPS of $1.85\nAdjusted Diluted EPS Guidance Range Raised to $7.80 to $7.95 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third\nquarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion. ", "page_label": "1", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c4204106-c462-4112-a022-54a77599d681": {"node_ids": ["c61b07fc-e085-46a5-bbd9-5c868f05b95f", "2edbebf9-5b55-48d4-b7a0-142f9277a8ba", "2c6a0519-3c7b-4edf-a5ff-ec2c75f65ab3", "fb4cf860-3433-4096-a93e-ca96629437fe", "07886e14-7582-419a-8a5b-0fba740cd28b", "9b347cd0-667f-4a79-9230-e23e6b78ce21", "70febc7e-2f9c-4741-9381-a6e192d395e8", "2096a2ec-ca2d-479a-a530-fbf61d1efc21", "10067524-4a83-481b-8428-d60924b1b4e2", "d36e7527-72a0-4751-a0b8-76f9e7d8b18b", "bbfd74f3-e6cb-4608-9110-850f7776f554", "f7c31c6d-ee05-42c9-bd4b-8a4239ba2f96", "d2f15511-665e-4dec-902c-d3359433ab00", "60870ee5-963e-4507-a924-f1bb00ca573b", "7615bba1-4d83-46db-8753-3be042780b26", "bcde7a54-33b6-4019-af55-5da6faca1e30", "d997cf5a-719d-49cb-80f6-0bf62b31eb70", "e562088d-bfb4-4f89-986e-8d532f02227c", "1398d408-af67-41aa-a990-5761b746b38c", "52a0b661-7151-4af7-8742-0e05a3783bda", "c737dfdd-6a16-45dc-b0a8-0fc674b28795", "d74de821-9354-40e2-bc8b-4c09101b12d8", "7a498470-3430-4f48-bfb2-fc58d41dcd68", "43486c2c-b2f7-40f9-8c47-9aed9ca0582c", "8df2db55-703d-4081-89eb-135755a7455c", "03866011-1c44-4e7c-a203-3de645853070", "17ded132-431a-4f15-80a0-3c021c5312a6", "7c4b96ef-e5c4-4cdd-8a38-d18d14a3b9aa", "68219e55-d717-42f9-9236-89f24fe8aca6"], "metadata": {"window": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs.  Gross profit as a\npercentage of revenue was 2.70 percent, a decrease of 2 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2020, operating expenses were $820.9 million, compared to $824.5 million in\nthe same period last fiscal year.  The decrease in operating expenses was primarily due to lower depreciation and amortization\nexpense, offset in part by an increase in distribution, selling and administrative costs. ", "original_text": "Pharmaceutical Distribution Services and Other and lower PharMEDium remediation and shutdown costs. ", "page_label": "2", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c3e58a73-5fc6-4075-886c-8fba9b5180ce": {"node_ids": ["2dd829af-18ca-49ab-bc5a-41852ec4039d", "2bb8e118-5f41-4b36-8562-b5cb2093f8a4", "3b20584c-1fd8-46d4-8f95-8074f9173572", "d95cf284-192d-4136-88ba-0a196bfcbe7e", "f2bca132-7af7-4fa6-b525-16801b980051", "e870d7ed-2626-478e-8344-068fab05121c", "07160d94-78e2-451b-ae72-9610b098deba", "3bc0e261-5929-4f36-a597-5805536cf65a", "1ed4ea10-3d63-4f11-92ff-944e50ba780b", "1c033763-c7fe-497c-b901-fe940d6a29f1", "7bf23e80-efce-4844-9ecb-ffd8190f46f2", "bb10e42b-97c9-436e-a179-7dafb546f876", "63b5bf62-8b0b-4041-bbfd-733c382d4bdb", "04642c91-5028-416a-bf53-00bf20c51836", "6811513d-cb7f-4fef-98fa-12aca72014f7", "bd0e457a-04ce-4fc3-9252-836501691d12", "f81b76a2-876e-40aa-b288-711c3bf0bf5f", "bbb4de3d-c64c-4b78-b7a3-eb2cc4eddcbc", "a85d0ad3-9925-4b24-ae2c-4df19bbdcb29", "c9a1e6a6-4961-477d-866d-24d684666623", "ff625ce1-47d6-4d7d-894e-ca4b5e8f7f66", "6e75d999-6ff5-445d-bc52-dca61a47cba1", "808c28b0-e82e-4404-bb7f-1b29186eb969", "3e84990b-f8f5-42ec-a7b6-97002c129ee5", "8bc6c30c-a2f6-4371-a5d8-0d7cb88f9b37", "f5befb07-a5c8-469e-b31d-485663131926", "c0c15b16-1c43-4ca2-aa52-24bf5fc8eb1d", "d1b297ad-ddf5-4437-b8ed-c276397227e3", "aea15a83-6f51-4b3e-80bc-3140149d4cdb", "4acd4213-e5bf-46c5-ba0d-4078e84347cc", "bbf0dbfb-b0f2-4af1-a04b-7cefcce6c8b6", "38a63f77-0eac-4e12-9fd1-565dcca30368", "e99052be-0815-488e-b3b7-822cf5b1a100", "8ab5417d-0af0-4e19-8ab3-5b2c52e1fbf5"], "metadata": {"window": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020.  Segment operating\nincome of $426.6 million in the third quarter of fiscal 2020 was up 3.6 percent compared to the same period in the previous fiscal\nyear, due to lower operating expenses and higher gross profit.\n Other\nRevenue in Other was $1.8 billion in the third quarter of fiscal 2020, an increase of 4.4 percent compared to the same period in the\nprior fiscal year due to growth at ABCS and World Courier.  Operating income in Other decreased 12.9 percent to $82.9 million in the\nthird quarter of fiscal 2020. ", "original_text": "fiscal year primarily due to the onset of COVID-19 in March 2020, when many of our customers increased their purchases in the\nfiscal quarter ended March 31, 2020, which resulted in fewer purchases in the fiscal quarter ended June 30, 2020. ", "page_label": "3", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e67f164e-f9f1-439d-8b06-eb90daa0892a": {"node_ids": ["a9e5dd88-2a14-42b4-b32f-1b36551f621f", "60431961-ac23-489e-b587-53fa02c36d62", "058b7293-baa3-4875-a2a9-23776e73cd71", "49ed8040-65fa-435c-82fa-b6ae1e8d9745", "95ff92e8-a198-44fa-bb19-212a26d4b000", "50e6c2d8-0b17-4a48-8a8c-878c8f822527", "3466ebfc-759a-4ef1-9d05-9b825ae4b7eb", "6db64365-be1d-47bd-8732-c1ffd8041dc9", "fa29ce30-8b9b-4fbe-ae19-87d85a09efa8", "21af7843-87fe-4c07-b658-d9124465f39c", "904f6680-ef74-4dfb-a157-e44d4820fc47", "86c1be64-bc3d-4ca1-becc-afd5d160910e", "9f00ac51-a67a-411f-b0c3-af46156d560d", "fce86bc9-a518-403f-8fdc-c9ebd2e63ed0", "a8c5bc2b-179e-4f52-8a69-86c5e3e98f71", "a5bde54b-78d8-4177-9fe2-8465feee7796", "0458e319-7c6f-45eb-84d7-465e675d34cd", "d6cbe76a-0dbc-4e04-b00d-0adcb8152852", "24fe7ce4-9536-4955-b92f-cce780c96465", "d54feedd-f3ee-4815-b821-80370e5aa5bd"], "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nMorgan Stanley Annual Global Healthcare Conference, September 14-18.\n", "page_label": "4", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "59500035-e69c-4271-84ef-bd94e205147b": {"node_ids": ["0f50c2e9-d43b-4999-a3c9-7709abd91489"], "metadata": {"window": "\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a0$45,239,265 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a044,008,026 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,225,716 \u00a0\u00a02.70% \u00a01,231,239 \u00a0\u00a02.72% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0666,885 \u00a0\u00a01.47% \u00a0656,943 \u00a0\u00a01.45% \u00a01.5%\nDepreciation and amortization \u00a095,415 \u00a0\u00a00.21% \u00a0107,596 \u00a0\u00a00.24% \u00a0(11.3)%\nEmployee severance, litigation, and other 3 \u00a058,585 \u00a0\u00a0\u00a0 \u00a060,006 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0820,885 \u00a0\u00a01.81% \u00a0824,545 \u00a0\u00a01.82% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0404,831 \u00a0\u00a00.89% \u00a0406,694 \u00a0\u00a00.90% \u00a0(0.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a01,073 \u00a0\u00a0\u00a0 \u00a0(342) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a037,748 \u00a0\u00a0\u00a0 \u00a035,921 \u00a0\u00a0\u00a0 \u00a05.1%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0343,835 \u00a0\u00a00.76% \u00a0371,115 \u00a0\u00a00.82% \u00a0(7.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a056,567 \u00a0\u00a0\u00a0 \u00a069,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0287,268 \u00a0\u00a00.63% \u00a0302,002 \u00a0\u00a00.67% \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interest \u00a02,171 \u00a0\u00a0\u00a0 \u00a0(43) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$289,439 \u00a0\u00a00.64% \u00a0$301,959 \u00a0\u00a00.67% \u00a0(4.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$1.44 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0$1.43 \u00a0\u00a0\u00a0 \u00a0(1.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0203,654 \u00a0\u00a0\u00a0 \u00a0209,705 \u00a0\u00a0\u00a0 \u00a0(2.9)%\n5", "original_text": "\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of \nRevenue \u00a0Three \nMonths Ended \nJune 30, 2019 \u00a0% of \nRevenue \u00a0% \nChange\nRevenue \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a0$45,239,265 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a044,008,026 \u00a0\u00a0\u00a0 \u00a00.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,225,716 \u00a0\u00a02.70% \u00a01,231,239 \u00a0\u00a02.72% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0666,885 \u00a0\u00a01.47% \u00a0656,943 \u00a0\u00a01.45% \u00a01.5%\nDepreciation and amortization \u00a095,415 \u00a0\u00a00.21% \u00a0107,596 \u00a0\u00a00.24% \u00a0(11.3)%\nEmployee severance, litigation, and other 3 \u00a058,585 \u00a0\u00a0\u00a0 \u00a060,006 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0820,885 \u00a0\u00a01.81% \u00a0824,545 \u00a0\u00a01.82% \u00a0(0.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0404,831 \u00a0\u00a00.89% \u00a0406,694 \u00a0\u00a00.90% \u00a0(0.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net \u00a01,073 \u00a0\u00a0\u00a0 \u00a0(342) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a037,748 \u00a0\u00a0\u00a0 \u00a035,921 \u00a0\u00a0\u00a0 \u00a05.1%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0343,835 \u00a0\u00a00.76% \u00a0371,115 \u00a0\u00a00.82% \u00a0(7.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a056,567 \u00a0\u00a0\u00a0 \u00a069,113 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0287,268 \u00a0\u00a00.63% \u00a0302,002 \u00a0\u00a00.67% \u00a0(4.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interest \u00a02,171 \u00a0\u00a0\u00a0 \u00a0(43) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$289,439 \u00a0\u00a00.64% \u00a0$301,959 \u00a0\u00a00.67% \u00a0(4.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$1.44 \u00a0\u00a0\u00a0 \u00a0(1.4)%\nDiluted \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0$1.43 \u00a0\u00a0\u00a0 \u00a0(1.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0203,654 \u00a0\u00a0\u00a0 \u00a0209,705 \u00a0\u00a0\u00a0 \u00a0(2.9)%\n5", "page_label": "5", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "180116b2-3c32-45cb-bd95-292191d67a86": {"node_ids": ["5c427d0e-d902-4857-a5a5-e589ec524299", "7e3fb727-d560-41f2-a117-8ed1383d584c", "4fbb6439-e309-4c88-975b-24a53dac8fbc", "20058860-9d0e-44e2-b215-546887dfbebf", "8c159df7-d277-4e0a-9012-706265c28ed5", "07b694fd-876b-46e1-a35a-20bdb2b0660f", "b27a0407-8a21-495a-8653-1f33ce712187"], "metadata": {"window": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n Includes $11.7 million of PharMEDium remediation costs, a $9.9 million LIFO credit, and a $3.5 million gain from antitrust\nlitigation settlements in the three months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.  Includes $7.6 million of\nPharMEDium remediation costs in the three months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "Diluted \u00a0205,544 \u00a0\u00a0\u00a0 \u00a0211,161 \u00a0\u00a0\u00a0 \u00a0(2.7)%\n________________________________________\n1Includes a $6.1 million LIFO expense and $0.4 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n", "page_label": "6", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a22921e2-8a35-41db-a332-2986693373ce": {"node_ids": ["6aad0138-9cc3-4219-a7c4-90cbdd806c4f", "666b43ce-d4cc-4e1d-ba9d-65baa758748e", "8d1c29d1-c8d7-4d6a-87e2-b56bce5733c8", "707d2033-8985-4813-9649-91984dbd61d9", "bd7118f8-550d-4cb2-9d0a-21567dc8a579", "2896a06c-05e2-434f-a673-ab88603153f6", "214fd6b2-a69c-4515-93ee-6bf1cd59b4b3", "4b953c94-71f9-4a1d-afbd-6335d167b8d9", "31b803d2-4afe-4123-9a38-6230d9730ac4"], "metadata": {"window": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020.  Includes a $142.7 million gain from antitrust\nlitigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of\na prior period assessment relating to the New York State Opioid Stewardship Act in the nine months ended June 30, 2019.\n\u00a0\u00a0\n 2Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended\nJune 30, 2020.  Includes $13.8 million of PharMEDium remediation costs in the nine months ended June 30, 2019.\n\u00a0\u00a0\n", "original_text": "Interest expense, net \u00a0103,176 \u00a0\u00a0\u00a0 \u00a0121,366 \u00a0\u00a0\u00a0 \u00a0(15.0)%\nLoss on early retirement of debt \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0849,626 \u00a0\u00a00.60% \u00a0822,455 \u00a0\u00a00.61% \u00a03.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(595,321) \u00a0\u00a0\u00a0 \u00a0100,627 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,444,947 \u00a0\u00a01.03% \u00a0721,828 \u00a0\u00a00.54% \u00a0100.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interest \u00a0(7,591) \u00a0\u00a0\u00a0 \u00a0918 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,437,356 \u00a0\u00a01.02% \u00a0$722,746 \u00a0\u00a00.54% \u00a098.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.01 \u00a0\u00a0\u00a0 \u00a0$3.45 \u00a0\u00a0\u00a0 \u00a0103.2%\nDiluted \u00a0$6.95 \u00a0\u00a0\u00a0 \u00a0$3.42 \u00a0\u00a0\u00a0 \u00a0103.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,017 \u00a0\u00a0\u00a0 \u00a0209,484 \u00a0\u00a0\u00a0 \u00a0(2.1)%\nDiluted \u00a0206,714 \u00a0\u00a0\u00a0 \u00a0211,151 \u00a0\u00a0\u00a0 \u00a0(2.1)%\n\u00a0\n________________________________________\n1Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2020. ", "page_label": "7", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b848607e-c6c6-4df1-9963-86d9f547f5a3": {"node_ids": ["44939be8-2b11-4e52-b9ba-8dd61a73038c", "dd1ab706-3e10-4013-b5e1-89c1d113c7f9"], "metadata": {"window": "2019.\n\u00a0\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income \n Tax Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er Shar e\u00a0\nGAAP \u00a0$1,225,716 \u00a0\u00a0$820,885 \u00a0\u00a0$404,831 \u00a0 \u00a0$ 343,835 \u00a0 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$ 1.41 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(15) \u00a0\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u00a0\u2014 \u00a0\u00a06,061 \u00a0 \u00a06,061 \u00a0 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0432 \u00a0\u00a0(12,504) \u00a0\u00a012,936 \u00a0 \u00a012,936 \u00a0 \u00a03,264 \u00a0\u00a0\u2014 \u00a0\u00a09,672 \u00a0\u00a00.05 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,109) \u00a0\u00a025,109 \u00a0 \u00a025,109 \u00a0 \u00a06,276 \u00a0\u00a0(437) \u00a0\u00a018,396 \u00a0\u00a00.09 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(58,585) \u00a0\u00a058,585 \u00a0 \u00a058,585 \u00a0 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638) \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0 \u00a0(22) \u00a0\u00a0(1,833) \u00a0\u00a0(1,811) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n$1232209 $724687 $507522 $ 468701 $88295 $ (99) $380307 $ 185\n8", "original_text": "2019.\n\u00a0\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "82064b6d-623d-4086-abd7-c97481b0d37a": {"node_ids": ["3ad84de5-a231-4002-8d42-63ffea721df8", "e43c5b66-0996-447f-a490-387ccf77d556", "77dfded4-6891-4eee-a114-d7b016812b81"], "metadata": {"window": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a00.2 %\u00a00.3 %\u00a00.2 % \u00a0(0.5) % \u00a0(10.8) %\u00a0\u00a0 \u00a02.3 %\u00a05.1 % \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e \nIncome T axes \u00a0Income T ax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$1,231,239 \u00a0\u00a0$ 824,545 \u00a0 \u00a0$ 406,694 \u00a0\u00a0$371,115 \u00a0\u00a0$69,113 \u00a0\u00a0$ (43) \u00a0\u00a0$301,959 \u00a0\u00a0$ 1.43 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(3,480) \u00a0\u00a0\u2014 \u00a0 \u00a0(3,480) \u00a0\u00a0(3,480) \u00a0\u00a0(1,849) \u00a0\u00a0\u2014 \u00a0\u00a0(1,631) \u00a0\u00a0(0.01) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(9,913) \u00a0\u00a0\u2014 \u00a0 \u00a0(9,913) \u00a0\u00a0(9,913) \u00a0\u00a0(3,061) \u00a0\u00a0\u2014 \u00a0\u00a0(6,852) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a011,698 \u00a0\u00a0(7,646) \u00a0 \u00a019,344 \u00a0\u00a019,344 \u00a0\u00a05,301 \u00a0\u00a0\u2014 \u00a0\u00a014,043 \u00a0\u00a00.07 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "Non-GAAP \u00a0$1,232,209 \u00a0\u00a0$724,687 \u00a0\u00a0$507,522 \u00a0 \u00a0$ 468,701 \u00a0 \u00a0$88,295 \u00a0\u00a0$ (99) \u00a0\u00a0$380,307 \u00a0\u00a0$ 1.85 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "9", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cd42e72d-411a-4d6f-acf2-179de2e96ba0": {"node_ids": ["ed8d293a-1959-49cb-8388-aa5c5ea59cc0", "2e0d6826-5cbf-4432-a0bc-1bfc58cac9ec"], "metadata": {"window": "New York\nState Opioid\nStewardship\nAct \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(149) \u00a0\u00a0\u2014 \u00a0\u00a0149 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,024) \u00a0 \u00a034,024 \u00a0\u00a034,024 \u00a0\u00a09,511 \u00a0\u00a0(440) \u00a0\u00a024,073 \u00a0\u00a00.11 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(60,006) \u00a0 \u00a060,006 \u00a0\u00a060,006 \u00a0\u00a016,329 \u00a0\u00a0\u2014 \u00a0\u00a043,677 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,848 \u00a0\u00a0\u2014 \u00a0\u00a0(3,848) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(93) \u00a0\u00a0\u2014 \u00a0\u00a093 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,229,544 \u00a0\u00a0$ 722,869 \u00a0 \u00a0$ 506,675 \u00a0\u00a0$471,096 \u00a0\u00a0$98,950 \u00a0\u00a0$ (483) \u00a0\u00a0$371,663 \u00a0\u00a0$ 1.76 \u00a0 \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.72% \u00a02.72%\nOperating expenses \u00a01.82% \u00a01.60%\nOperating income \u00a00.90% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n10", "original_text": "New York\nState Opioid\nStewardship\nAct \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(149) \u00a0\u00a0\u2014 \u00a0\u00a0149 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(34,024) \u00a0 \u00a034,024 \u00a0\u00a034,024 \u00a0\u00a09,511 \u00a0\u00a0(440) \u00a0\u00a024,073 \u00a0\u00a00.11 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(60,006) \u00a0 \u00a060,006 \u00a0\u00a060,006 \u00a0\u00a016,329 \u00a0\u00a0\u2014 \u00a0\u00a043,677 \u00a0\u00a00.21 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,848 \u00a0\u00a0\u2014 \u00a0\u00a0(3,848) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(93) \u00a0\u00a0\u2014 \u00a0\u00a093 \u00a0\u00a0\u2014 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,229,544 \u00a0\u00a0$ 722,869 \u00a0 \u00a0$ 506,675 \u00a0\u00a0$471,096 \u00a0\u00a0$98,950 \u00a0\u00a0$ (483) \u00a0\u00a0$371,663 \u00a0\u00a0$ 1.76 \u00a0 \u00a0\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.72% \u00a02.72%\nOperating expenses \u00a01.82% \u00a01.60%\nOperating income \u00a00.90% \u00a01.12%\n\u00a0\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2fac4174-b67d-4b9e-8bf6-ba77db9fddc8": {"node_ids": ["d14e0cb7-2acf-400e-912b-73bc6c49b1fc", "6f66226d-e101-4790-b0fb-72ca7cf48a35"], "metadata": {"window": "\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \nInterest \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0$2,867,254 \u00a0\u00a0$977,783 \u00a0\u00a0$ 849,626 \u00a0 \u00a0$(595,321) \u00a0\u00a0$(7,591) \u00a0\u00a0$1,437,356 \u00a0\u00a0$ 6.95 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546) \u00a0\u00a0\u2014 \u00a0\u00a0(8,546) \u00a0\u00a0(8,546) \u00a0 \u00a0(2,100) \u00a0\u00a0\u2014 \u00a0\u00a0(6,446) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u2014 \u00a0\u00a043,195 \u00a0\u00a043,195 \u00a0 \u00a010,614 \u00a0\u00a0\u2014 \u00a0\u00a032,581 \u00a0\u00a00.16 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(49,015) \u00a0\u00a061,571 \u00a0\u00a061,571 \u00a0 \u00a015,128 \u00a0\u00a0\u2014 \u00a0\u00a046,443 \u00a0\u00a00.22 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(85,345) \u00a0\u00a085,345 \u00a0\u00a085,345 \u00a0 \u00a020,971 \u00a0\u00a0(1,308) \u00a0\u00a063,066 \u00a0\u00a00.31 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(165,626) \u00a0\u00a0165,626 \u00a0\u00a0165,626 \u00a0 \u00a040,697 \u00a0\u00a0\u2014 \u00a0\u00a0124,929 \u00a0\u00a00.60 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0 \u00a088,865 \u00a0\u00a0\u2014 \u00a0\u00a0272,787 \u00a0\u00a01.32 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0 \u00a0(2,987) \u00a0\u00a05,678 \u00a0\u00a0(3,488) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015) \u00a0\u00a0(3.58) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0$2,217,769 \u00a0\u00a0$1,674,473 \u00a0\u00a0$ 1,568,491 \u00a0 \u00a0$322,331 \u00a0\u00a0$(3,221) \u00a0\u00a0$1,242,939 \u00a0\u00a0$ 6.01 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a03.8 %\u00a02.9 %\u00a05.0 %\u00a06.6 % \u00a04.9 %\u00a0\u00a0 \u00a06.8 %\u00a09.1 % \u00a0\n\u00a0\n11", "original_text": "\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating Expenses \u00a0Operating Income \u00a0Income Befor e Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \nInterest \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings P er \nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0$2,867,254 \u00a0\u00a0$977,783 \u00a0\u00a0$ 849,626 \u00a0 \u00a0$(595,321) \u00a0\u00a0$(7,591) \u00a0\u00a0$1,437,356 \u00a0\u00a0$ 6.95 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546) \u00a0\u00a0\u2014 \u00a0\u00a0(8,546) \u00a0\u00a0(8,546) \u00a0 \u00a0(2,100) \u00a0\u00a0\u2014 \u00a0\u00a0(6,446) \u00a0\u00a0(0.03) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u2014 \u00a0\u00a043,195 \u00a0\u00a043,195 \u00a0 \u00a010,614 \u00a0\u00a0\u2014 \u00a0\u00a032,581 \u00a0\u00a00.16 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(49,015) \u00a0\u00a061,571 \u00a0\u00a061,571 \u00a0 \u00a015,128 \u00a0\u00a0\u2014 \u00a0\u00a046,443 \u00a0\u00a00.22 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(85,345) \u00a0\u00a085,345 \u00a0\u00a085,345 \u00a0 \u00a020,971 \u00a0\u00a0(1,308) \u00a0\u00a063,066 \u00a0\u00a00.31 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(165,626) \u00a0\u00a0165,626 \u00a0\u00a0165,626 \u00a0 \u00a040,697 \u00a0\u00a0\u2014 \u00a0\u00a0124,929 \u00a0\u00a00.60 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0 \u00a088,865 \u00a0\u00a0\u2014 \u00a0\u00a0272,787 \u00a0\u00a01.32 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0 \u00a0(2,987) \u00a0\u00a05,678 \u00a0\u00a0(3,488) \u00a0\u00a0(0.02) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0 \u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015) \u00a0\u00a0(3.58) \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0$2,217,769 \u00a0\u00a0$1,674,473 \u00a0\u00a0$ 1,568,491 \u00a0 \u00a0$322,331 \u00a0\u00a0$(3,221) \u00a0\u00a0$1,242,939 \u00a0\u00a0$ 6.01 \u00a0 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "11", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "78dafa05-72a0-4f55-9ecf-9c84d83ac748": {"node_ids": ["5f7edfa1-69f3-4eff-8ac8-8ee5720cd073", "04552432-55c9-4a63-9ed1-58a06dbf980a", "d79906c0-ed53-425c-84d6-b0e95ce9541f"], "metadata": {"window": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n Expense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interest \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed Earnings\nPer Shar e \u00a0\nGAAP \u00a0$3,953,575 \u00a0\u00a0$3,021,493 \u00a0\u00a0$932,082 \u00a0\u00a0$822,455 \u00a0\u00a0$100,627 \u00a0\u00a0$ 918 \u00a0\u00a0$722,746 \u00a0\u00a0$ 3.42 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(142,735) \u00a0\u00a0\u2014 \u00a0\u00a0(142,735) \u00a0\u00a0(142,735) \u00a0\u00a0(37,299) \u00a0\u00a0\u2014 \u00a0\u00a0(105,436) \u00a0\u00a0(0.50) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(79,747) \u00a0\u00a0\u2014 \u00a0\u00a0(79,747) \u00a0\u00a0(79,747) \u00a0\u00a0(20,839) \u00a0\u00a0\u2014 \u00a0\u00a0(58,908) \u00a0\u00a0(0.28) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a041,943 \u00a0\u00a0(13,793) \u00a0\u00a055,736 \u00a0\u00a055,736 \u00a0\u00a014,565 \u00a0\u00a0\u2014 \u00a0\u00a041,171 \u00a0\u00a00.19 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a0(22,000) \u00a0\u00a0\u2014 \u00a0\u00a0(22,000) \u00a0\u00a0(22,000) \u00a0\u00a0(5,749) \u00a0\u00a0\u2014 \u00a0\u00a0(16,251) \u00a0\u00a0(0.08) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n12", "original_text": "\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0f13d13a-c232-4e6e-b135-f644cdeadb64": {"node_ids": ["c48b0260-3bb8-410a-a4ed-b642b9ef947d", "89c240da-2e50-4874-95ef-6c7165cb4ac8", "a85c0113-388b-403c-b583-6289dad83352", "b66ac0aa-3216-4501-9cbe-7bdce0c280b4"], "metadata": {"window": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION \n13", "original_text": "Acquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(125,770) \u00a0\u00a0125,770 \u00a0\u00a0125,770 \u00a0\u00a032,866 \u00a0\u00a0(1,383) \u00a0\u00a091,521 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(156,067) \u00a0\u00a0156,067 \u00a0\u00a0156,067 \u00a0\u00a040,783 \u00a0\u00a0\u2014 \u00a0\u00a0115,284 \u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(570,000) \u00a0\u00a0570,000 \u00a0\u00a0570,000 \u00a0\u00a0148,951 \u00a0\u00a0\u2014 \u00a0\u00a0421,049 \u00a0\u00a01.99 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof an equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(13,692) \u00a0\u00a0(3,578) \u00a0\u00a0\u2014 \u00a0\u00a0(10,114) \u00a0\u00a0(0.05) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997) \u00a0\u00a0(0.18) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,751,036 \u00a0\u00a0$2,155,863 \u00a0\u00a0$1,595,173 \u00a0\u00a0$1,471,854 \u00a0\u00a0$307,324 \u00a0\u00a0$ (465) \u00a0\u00a0$1,164,065 \u00a0\u00a0$ 5.51 \u00a02\n\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.95% \u00a02.80%\nOperating expenses \u00a02.26% \u00a01.61%\nOperating income \u00a00.70% \u00a01.19%\n\u00a0\n________________________________________\n1Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\u00a0\n", "page_label": "13", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e3b9e143-b08e-4d68-aadd-e7de5f60634b": {"node_ids": ["f8dd1933-92b1-41d9-bf6f-6b1c7e7927a2"], "metadata": {"window": "SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$43,579,119 \u00a0\u00a0$43,527,552 \u00a0\u00a00.1%\nOther \u00a01,810,533 \u00a0\u00a01,734,538 \u00a0\u00a04.4%\nIntersegment eliminations \u00a0(22,875) \u00a0\u00a0(22,825) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$45,366,777 \u00a0\u00a0$45,239,265 \u00a0\u00a00.3%\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$426,643 \u00a0\u00a0$411,707 \u00a0\u00a03.6%\nOther \u00a082,875 \u00a0\u00a095,110 \u00a0\u00a0(12.9)%\nIntersegment eliminations \u00a0(1,996) \u00a0\u00a0(142) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0507,522 \u00a0\u00a0506,675 \u00a0\u00a00.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a03,480 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(6,061) \u00a0\u00a09,913 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(12,936) \u00a0\u00a0(19,344) \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,109) \u00a0\u00a0(34,024) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(58,585) \u00a0\u00a0(60,006) \u00a0\u00a0\u00a0\nOperating income \u00a0$404,831 \u00a0\u00a0$406,694 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.08% \u00a02.08% \u00a0\u00a0\nOperating expenses \u00a01.10% \u00a01.13% \u00a0\u00a0\nOperating income \u00a00.98% \u00a00.95% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.17% \u00a018.77% \u00a0\u00a0\nOperating expenses \u00a013.59% \u00a013.29% \u00a0\u00a0\nOperating income \u00a04.58% \u00a05.48% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n14", "original_text": "SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$43,579,119 \u00a0\u00a0$43,527,552 \u00a0\u00a00.1%\nOther \u00a01,810,533 \u00a0\u00a01,734,538 \u00a0\u00a04.4%\nIntersegment eliminations \u00a0(22,875) \u00a0\u00a0(22,825) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$45,366,777 \u00a0\u00a0$45,239,265 \u00a0\u00a00.3%\n\u00a0\n\u00a0 \u00a0Three months ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$426,643 \u00a0\u00a0$411,707 \u00a0\u00a03.6%\nOther \u00a082,875 \u00a0\u00a095,110 \u00a0\u00a0(12.9)%\nIntersegment eliminations \u00a0(1,996) \u00a0\u00a0(142) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0507,522 \u00a0\u00a0506,675 \u00a0\u00a00.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a03,480 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(6,061) \u00a0\u00a09,913 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(12,936) \u00a0\u00a0(19,344) \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(25,109) \u00a0\u00a0(34,024) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(58,585) \u00a0\u00a0(60,006) \u00a0\u00a0\u00a0\nOperating income \u00a0$404,831 \u00a0\u00a0$406,694 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.08% \u00a02.08% \u00a0\u00a0\nOperating expenses \u00a01.10% \u00a01.13% \u00a0\u00a0\nOperating income \u00a00.98% \u00a00.95% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.17% \u00a018.77% \u00a0\u00a0\nOperating expenses \u00a013.59% \u00a013.29% \u00a0\u00a0\nOperating income \u00a04.58% \u00a05.48% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n14", "page_label": "14", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "65bd7d66-d65b-4437-b407-bb11349b5661": {"node_ids": ["a8bf31c0-8b0d-44f3-aae0-0079d5eb66be", "2e22ef0b-1020-4bc1-abb8-2ac626ed3fc2"], "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.70% \u00a02.72% \u00a0\u00a0\nOperating expenses \u00a01.81% \u00a01.82% \u00a0\u00a0\nOperating income \u00a00.89% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72% \u00a02.72% \u00a0\u00a0\nAdjusted operating expenses \u00a01.60% \u00a01.60% \u00a0\u00a0\nAdjusted operating income \u00a01.12% \u00a01.12% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$135,178,617 \u00a0\u00a0$128,948,097 \u00a0\u00a04.8%\nOther \u00a05,534,110 \u00a0\u00a05,070,905 \u00a0\u00a09.1%\nIntersegment eliminations \u00a0(63,569) \u00a0\u00a0(67,683) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$140,649,158 \u00a0\u00a0$133,951,319 \u00a0\u00a05.0%\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02020 \u00a02019 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,381,434 \u00a0\u00a0$1,301,948 \u00a0\u00a06.1%\nOther \u00a0295,614 \u00a0\u00a0293,923 \u00a0\u00a00.6%\nIntersegment eliminations \u00a0(2,575) \u00a0\u00a0(698) \u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,674,473 \u00a0\u00a01,595,173 \u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0142,735 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(43,195) \u00a0\u00a079,747 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(61,571) \u00a0\u00a0(55,736) \u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\n15", "original_text": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.70% \u00a02.72% \u00a0\u00a0\nOperating expenses \u00a01.81% \u00a01.82% \u00a0\u00a0\nOperating income \u00a00.89% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.72% \u00a02.72% \u00a0\u00a0\nAdjusted operating expenses \u00a01.60% \u00a01.60% \u00a0\u00a0\nAdjusted operating income \u00a01.12% \u00a01.12% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6544b14f-783d-42de-ac54-af861b6c02ef": {"node_ids": ["28e31d3b-d6e2-43d9-9570-4827f6d81c62", "6850ae5f-ae50-42b1-8330-41be1b18f522"], "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(85,345) \u00a0\u00a0(125,770) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(165,626) \u00a0\u00a0(156,067) \u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652) \u00a0\u00a0(570,000) \u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$977,783 \u00a0\u00a0$932,082 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.11% \u00a02.15% \u00a0\u00a0\nOperating expenses \u00a01.09% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.02% \u00a01.01% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.78% \u00a019.27% \u00a0\u00a0\nOperating expenses \u00a013.44% \u00a013.47% \u00a0\u00a0\nOperating income \u00a05.34% \u00a05.80% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73% \u00a02.95% \u00a0\u00a0\nOperating expenses \u00a02.04% \u00a02.26% \u00a0\u00a0\nOperating income \u00a00.70% \u00a00.70% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.77% \u00a02.80% \u00a0\u00a0\nAdjusted operating expenses \u00a01.58% \u00a01.61% \u00a0\u00a0\nAdjusted operating income \u00a01.19% \u00a01.19% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n16", "original_text": "Acquisition-related intangibles amortization \u00a0(85,345) \u00a0\u00a0(125,770) \u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(165,626) \u00a0\u00a0(156,067) \u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652) \u00a0\u00a0(570,000) \u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$977,783 \u00a0\u00a0$932,082 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.11% \u00a02.15% \u00a0\u00a0\nOperating expenses \u00a01.09% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.02% \u00a01.01% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.78% \u00a019.27% \u00a0\u00a0\nOperating expenses \u00a013.44% \u00a013.47% \u00a0\u00a0\nOperating income \u00a05.34% \u00a05.80% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.73% \u00a02.95% \u00a0\u00a0\nOperating expenses \u00a02.04% \u00a02.26% \u00a0\u00a0\nOperating income \u00a00.70% \u00a00.70% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.77% \u00a02.80% \u00a0\u00a0\nAdjusted operating expenses \u00a01.58% \u00a01.61% \u00a0\u00a0\nAdjusted operating income \u00a01.19% \u00a01.19% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "16", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b2b115b8-ed93-4cda-b2c7-89b8e9882f6f": {"node_ids": ["2ec50963-8393-410d-87f0-c07c6dc534a3"], "metadata": {"window": "\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,420,272 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,548,399 \u00a0\u00a012,386,879 \u00a0\nInventories 11,849,201 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,340,935 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 596,024 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 163,741 \u00a0\u00a0157,385 \u00a0\nTotal current assets 29,918,572 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,455,008 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,615,677 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,446 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,145,149 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 966,712 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 519,710 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,631,571 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,620,641 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 268,519 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,806,260 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 494,761 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,967,951 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n17", "original_text": "\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,420,272 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,548,399 \u00a0\u00a012,386,879 \u00a0\nInventories 11,849,201 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,340,935 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 596,024 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 163,741 \u00a0\u00a0157,385 \u00a0\nTotal current assets 29,918,572 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,455,008 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,615,677 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,446 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,145,149 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 966,712 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 519,710 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,631,571 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,620,641 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 268,519 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,806,260 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 494,761 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,967,951 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $40,789,703 \u00a0\u00a0$39,171,980 \u00a0\n17", "page_label": "17", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "060b78bd-9e1d-4ea8-a1ad-b3aff4f72097": {"node_ids": ["178fe94d-8412-4a4c-8f6d-7683665c0205"], "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,444,947 \u00a0\u00a0$721,828 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1822,005 \u00a0\u00a0957,240 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (436,237) \u00a0\u00a0(672,742) \u00a0\nInventories (910,828) \u00a0\u00a0(280,148) \u00a0\nAccounts payable 824,105 \u00a0\u00a0964,667 \u00a0\nOther, net 2 (836,184) \u00a0\u00a0(19,644) \u00a0\nNet cash provided by operating activities 907,808 \u00a0\u00a01,671,201 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (251,101) \u00a0\u00a0(230,767) \u00a0\nCost of equity investments and acquired companies, net of cash acquired (34,830) \u00a0\u00a0(64,044) \u00a0\nOther, net 7,824 \u00a0\u00a0(2,222) \u00a0\nNet cash used in investing activities (278,107) \u00a0\u00a0(297,033) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (10,960) \u00a0\u00a0(130,493) \u00a0\nPayment of premium on early retirement of debt (21,448) \u00a0\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449) \u00a0\u00a0(522,778) \u00a0\nExercises of stock options 137,748 \u00a0\u00a054,860 \u00a0\nCash dividends on common stock (256,764) \u00a0\u00a0(255,064) \u00a0\nOther (11,750) \u00a0\u00a0(13,650) \u00a0\nNet cash used in financing activities (583,623) \u00a0\u00a0(867,125) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 46,078 \u00a0\u00a0507,043 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,420,272 \u00a0\u00a0$2,999,559 \u00a0\n18", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,444,947 \u00a0\u00a0$721,828 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1822,005 \u00a0\u00a0957,240 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (436,237) \u00a0\u00a0(672,742) \u00a0\nInventories (910,828) \u00a0\u00a0(280,148) \u00a0\nAccounts payable 824,105 \u00a0\u00a0964,667 \u00a0\nOther, net 2 (836,184) \u00a0\u00a0(19,644) \u00a0\nNet cash provided by operating activities 907,808 \u00a0\u00a01,671,201 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (251,101) \u00a0\u00a0(230,767) \u00a0\nCost of equity investments and acquired companies, net of cash acquired (34,830) \u00a0\u00a0(64,044) \u00a0\nOther, net 7,824 \u00a0\u00a0(2,222) \u00a0\nNet cash used in investing activities (278,107) \u00a0\u00a0(297,033) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet repayments (10,960) \u00a0\u00a0(130,493) \u00a0\nPayment of premium on early retirement of debt (21,448) \u00a0\u00a0\u2014 \u00a0\nPurchases of common stock 3 (420,449) \u00a0\u00a0(522,778) \u00a0\nExercises of stock options 137,748 \u00a0\u00a054,860 \u00a0\nCash dividends on common stock (256,764) \u00a0\u00a0(255,064) \u00a0\nOther (11,750) \u00a0\u00a0(13,650) \u00a0\nNet cash used in financing activities (583,623) \u00a0\u00a0(867,125) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 46,078 \u00a0\u00a0507,043 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,420,272 \u00a0\u00a0$2,999,559 \u00a0\n18", "page_label": "18", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9352e195-5bab-477a-bdfc-3cadefe1c595": {"node_ids": ["26a4f67b-5c17-4762-af4f-9c0c30eecc7e", "fc51873d-b3a8-4e26-bc8e-4777492320df", "92c34571-edff-48bb-a596-98840875de43", "bf32f49b-72d3-4557-9df8-291da68812b7", "f1df983a-99ee-404a-a040-8f3d3107f03a", "04331851-9731-49fb-a667-ec5a7226375e", "70af933b-b328-40b4-90b4-68026826b6c4", "a4e53a5f-9177-4317-9928-1b2854361d02", "c4046d57-5ebf-4a13-849d-c423261c6463", "9b10e31d-47e7-40b1-b5c9-29d3b4703628", "1eee06ca-34b2-4dc7-9b3a-b38541848ec5", "e7f6a791-e045-42f8-a28a-56bb9c351603", "4ffc71c6-3022-4a8c-bb7c-3d7316fa2a30", "3ba64d31-f0ed-4cad-bdde-a81c5e10bc68", "b03e8a4c-909a-454e-a293-f42cbfcc5f88", "719faa34-917b-46d6-9fea-d3d7ca94e5c2", "383af777-f0cf-4fcf-a4d3-007c36ad3544", "c0c4d8c9-ada3-4b08-87c9-a5a07fa18905", "e2e2c247-07f3-4721-893e-f7b9c14b950a", "e832e67e-0ae5-4388-b03e-4783aab99162", "790dc9e7-a22b-4d23-b3c6-a54cbfb9e8a8", "337f07c7-87ad-4dbc-87bc-b4c63969bfd0", "485a48a5-165b-4d1e-a5e9-461303dc4ac0", "8d5abaa4-95cc-4a19-a96f-3a842a89463a", "96d6e9be-b614-4e4b-bfb5-cbb7b20f2985", "19b495dc-ebed-4513-b3d4-f583a694203e", "715943c3-63b3-4c64-b8cd-b61bdf4582fb", "28c04eda-0164-454c-b6dd-5b976363d72f", "f1e5a864-b892-48e0-b49e-2fa7cdbcafc8", "9dfd1847-e97a-431e-92ad-3477f6426f30", "f23913d5-1301-42bc-8faf-e0b5b32eda99", "2f40efe9-5151-4ac8-a4e6-fbdfff7f62c1", "99c329b5-c22c-45cd-98bd-c8edec42ccff", "b609321a-3c92-4f35-a13a-f3549c28dd1a", "d51a10f5-597b-4d91-8e7b-ce9d07410c9a", "6b0bac72-c937-47b6-bb08-3abb4e0080b0", "35a93537-6244-4c61-b1e8-892899ef0dec", "bee99828-9cbe-4e49-b484-0b35e5519208"], "metadata": {"window": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020.  Includes a LIFO credit of $79.7 million and an impairment of PharMEDium assets of $570.0 million in the nine\nmonths ended June 30, 2019.\n 2Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3Purchases of common stock in the nine months ended June 30, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019. ", "original_text": "________________________________________\n1Includes a LIFO expense of $43.2 million and an impairment of PharMEDium assets of $361.7 million in the nine months ended\nJune 30, 2020. ", "page_label": "19", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0da1d1fe-4397-4a8a-aa11-1019da1613f9": {"node_ids": ["c7899727-9ab2-485e-96a8-a576b2cb5531", "72e5454e-9864-41d6-af49-48904240dd21", "082be447-20bc-4071-8a6a-5238b21d4e5a", "3cfe1519-ce0e-4f5d-8b71-1bdc1bb69086", "2ece4cae-ca5a-4649-9989-31ed3c840d55", "bf27b8f4-32fc-4dec-84a7-292fb48cdd57", "67615f67-1e39-402e-8440-875db737bc7c", "2ded1719-d446-43f8-a40c-927bc8a8d8a9", "a915ea01-0728-4d28-adbe-7f43e789b7fc", "f66b8e83-0b6e-4b99-bfb0-c460dd159e59", "a247467a-8f6e-4bef-a810-8f78f21b4aca", "e6e6dd81-bc21-4d09-b549-746805e9f03b", "45f88dc7-d0bf-4928-baa8-4e2d6a016ebb", "c7e08ebc-62e7-4337-a70a-acae81472307", "9b10c9db-6053-475b-92f0-a80970dd6c3e", "6e7bd4a3-3e70-41a3-9a36-6e8aa9c1e293", "b2ccda0e-c97e-4eec-80ae-d054e9e080d7", "503269dd-99b0-4093-8847-675af3d0bf4c", "a247f916-2ca4-4e8a-9513-371114128f5f", "37d3bf0c-e23e-44ea-89c1-0e77ce8ddf5b", "45747be9-8796-453b-ad31-15ed1624e4f1", "c903fbb6-afd7-4c72-8aca-aafea514cc14", "021d03d1-381e-4792-be32-f253d624aad7"], "metadata": {"window": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n", "page_label": "20", "file_name": "CEN-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 198188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}